




# EULAR 2025 Scientific Programme

Please note that this programme does not include our abstract presentations and is subject to change without notice.

| Session         | Date       | Time                | Room    | Session Description                                                                                                                                                                                                                                                                                                                                                            | Session Type    | Presentation title                | Start | End   | Role    | Firstname | Last name |
|-----------------|------------|---------------------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|-----------------------------------|-------|-------|---------|-----------|-----------|
| Opening Plenary | 11/06/2025 | 13:00:00 - 14:00:00 | Plenary | The EULAR 2025 Opening Plenary will ignite the Congress with an extraordinary and inspiring session. This event will feature keynote presentations and dynamic stage discussions led by experts in the field of rheumatology, offering innovative insights and forward-thinking perspectives. Join us for a compelling start to the EULAR 2025 Congress, setting the stage for | Opening Plenary | Opening by the President of EULAR | 13:00 | 14:00 | Speaker | Daniel    | Aletaha   |

|                |            |                     |     |                                                                                                                                        |                          |                                                                                                   |       |       |         |          |        |
|----------------|------------|---------------------|-----|----------------------------------------------------------------------------------------------------------------------------------------|--------------------------|---------------------------------------------------------------------------------------------------|-------|-------|---------|----------|--------|
|                |            |                     |     | impactful knowledge exchange and collaboration.                                                                                        |                          |                                                                                                   |       |       |         |          |        |
| Capillaroscopy | 11/06/2025 | 14:15:00 - 15:30:00 | 6.2 | To learn how capillaroscopy can be applied to detect very early abnormalities as well as advanced stages of connective tissue diseases | Practical Skills Lecture | Cases with capillaroscopy images                                                                  | 15:00 | 15:25 | Speaker | Vanessa  | Smith  |
|                |            |                     |     |                                                                                                                                        |                          | Introduction: Capillaroscopy findings in connective tissue diseases                               | 14:25 | 14:35 | Speaker | Vanessa  | Smith  |
|                |            |                     |     |                                                                                                                                        |                          | Discussion and closing                                                                            | 15:25 | 15:30 | Speaker | Maurizio | Cutolo |
|                |            |                     |     |                                                                                                                                        |                          | Introduction: Capillaroscopy appearance in healthy individuals and in non-inflammatory conditions | 14:15 | 14:25 | Speaker | Carina   | Mihai  |
|                |            |                     |     |                                                                                                                                        |                          | Case presentation                                                                                 | 14:35 | 15:00 | Speaker | Carina   | Mihai  |

|                                                 |                |                        |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                             |                                                                                                                                                                         |       |       |             |          |        |
|-------------------------------------------------|----------------|------------------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------------|----------|--------|
|                                                 |                |                        |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                             | s with<br>capillaroscop<br>y images                                                                                                                                     |       |       |             |          |        |
|                                                 |                |                        |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                             |                                                                                                                                                                         |       |       | Chair       | Barbara  | Ruaro  |
|                                                 |                |                        |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                             |                                                                                                                                                                         |       |       | Chair       | Maurizio | Cutolo |
| Cell<br>Therapie<br>s - CAR-<br>T and<br>Beyond | 11/06/<br>2025 | 14:15:00 -<br>15:45:00 | 6.3 | 1. To<br>understand<br>emerging<br>evidence of<br>efficacy and<br>safety of CAR-<br>T cell therapy in<br>rheumatology;2<br>. To understand<br>the potential of<br>allogeneic CAR<br>cell therapy in<br>rheumatology;3<br>. To understand<br>the potential of<br>antigen-specific<br>regulatory cell<br>therapy in<br>rheumatology;4<br>. To understand<br>the potential<br>regulatory<br>hurdles for<br>approval of cell<br>therapies in<br>rheumatology. | From<br>Bench to<br>Bedside | Regulatory<br>approval of<br>cellular<br>therapies in<br>rheumatolog<br>y                                                                                               | 15:15 | 15:30 | Spea<br>ker |          |        |
|                                                 |                |                        |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                             | Allogeneic<br>CARs: CAR-<br>T, CAR-NK,<br>etc - how do<br>they differ<br>from<br>autologous<br>CAR-T in<br>their<br>production<br>function and<br>clinical<br>potential | 14:36 | 14:51 | Spea<br>ker | tbc      | tbc    |
|                                                 |                |                        |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                             | Oral Abstract<br>Presentation                                                                                                                                           | 15:35 | 15:45 | Spea<br>ker |          |        |
|                                                 |                |                        |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                             | Antigen<br>specific T<br>reg therapies<br>for SLE and<br>beyond                                                                                                         | 15:10 | 15:15 | Spea<br>ker | Joshua   | Ooi    |
|                                                 |                |                        |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                             | Antigen<br>specific T<br>reg therapies                                                                                                                                  | 14:56 | 15:10 | Spea<br>ker | Joshua   | Ooi    |

|                                                         |                |                        |    |                                                                                                                                                                                                                                                                         |                                 |                                                                  |       |       |         |          |             |
|---------------------------------------------------------|----------------|------------------------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|------------------------------------------------------------------|-------|-------|---------|----------|-------------|
|                                                         |                |                        |    |                                                                                                                                                                                                                                                                         |                                 | for SLE and beyond                                               |       |       |         |          |             |
|                                                         |                |                        |    |                                                                                                                                                                                                                                                                         |                                 | CAR-T in Rheumatology - what is the latest?                      | 14:31 | 14:36 | Speaker | Georg    | Schett      |
|                                                         |                |                        |    |                                                                                                                                                                                                                                                                         |                                 | Introduction                                                     | 14:15 | 14:16 | Speaker | Thomas   | Dörner      |
|                                                         |                |                        |    |                                                                                                                                                                                                                                                                         |                                 | CAR-T in Rheumatology - what is the latest?                      | 14:16 | 14:31 | Speaker | Georg    | Schett      |
|                                                         |                |                        |    |                                                                                                                                                                                                                                                                         |                                 |                                                                  |       |       | Chair   | Thomas   | Dörner      |
|                                                         |                |                        |    |                                                                                                                                                                                                                                                                         |                                 |                                                                  |       |       | Chair   | Bohdana  | Doskaliuk   |
| Difficult-to-<br>Manage<br>Antiphospholipid<br>syndrome | 11/06/<br>2025 | 14:15:00 -<br>15:30:00 | B2 | The speakers will present 2 difficult clinical cases of APS providing useful information about the proper management of these patients regarding: 1. To discuss potential challenges in treating chronic Antiphospholipid Syndrome (APS) nephropathy; 2. To learn about | Challenges in Clinical Practice | Case presentation by junior 1                                    | 14:15 | 14:30 | Speaker |          |             |
|                                                         |                |                        |    |                                                                                                                                                                                                                                                                         |                                 | Case presentation by junior 2                                    | 14:50 | 15:05 | Speaker |          |             |
|                                                         |                |                        |    |                                                                                                                                                                                                                                                                         |                                 | Q&A and Closing                                                  | 15:25 | 15:30 | Speaker | Antonis  | Fanouriakis |
|                                                         |                |                        |    |                                                                                                                                                                                                                                                                         |                                 | Diagnosis and treatment of Antiphospholipid Syndrome nephropathy | 15:05 | 15:25 | Speaker | Laura    | Andreoli    |
|                                                         |                |                        |    |                                                                                                                                                                                                                                                                         |                                 | Managing catastrophic Antiphospholipid Syndrome                  | 14:30 | 14:50 | Speaker | Ljudmila | Stojanovich |

|                                    |            |                     |    |                                                                                                                                                                                                                                                                                 |                                            |                                                                                                                            |       |       |         |         |             |
|------------------------------------|------------|---------------------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|-------|-------|---------|---------|-------------|
|                                    |            |                     |    | the emergency management of catastrophic APS; 3. To learn how to prevent and recognise APS complications.                                                                                                                                                                       |                                            |                                                                                                                            |       |       | Chair   | Antonis | Fanouriakis |
|                                    |            |                     |    |                                                                                                                                                                                                                                                                                 |                                            |                                                                                                                            |       |       | Chair   | Zahir   | Amoura      |
| EULAR HPR: A welcoming environment | 11/06/2025 | 14:15:00 - 15:15:00 | C1 | Participants will:1. Learn more about environmental factors that affect people's health and discover ways to influence them;2. Identify new networks to engage in different HPR activities;3. Become familiar with the congress programme offered by the different communities. | Health Professionals in Rheumatology (HPR) | Keynote: Art, history and innovation - integrating environmental health into HPR practice for the healthcare of the future | 14:20 | 14:35 | Speaker | tbc     | tbc         |
|                                    |            |                     |    |                                                                                                                                                                                                                                                                                 |                                            | Keynote: Art, history and innovation - integrating environmental health into HPR practice for the healthcare of the future | 14:35 | 14:40 | Speaker | tbc     | tbc         |
|                                    |            |                     |    |                                                                                                                                                                                                                                                                                 |                                            | What's on the menu? How to get the                                                                                         | 14:55 | 15:05 | Speaker | Erika   | Mosor       |

|  |  |  |  |  |  |                                                                               |       |       |         |              |        |
|--|--|--|--|--|--|-------------------------------------------------------------------------------|-------|-------|---------|--------------|--------|
|  |  |  |  |  |  | most from this year's Congress programme.                                     |       |       |         |              |        |
|  |  |  |  |  |  | What's on the menu? How to get the most from this year's Congress programme.  | 15:05 | 15:10 | Speaker | Erika        | Mosor  |
|  |  |  |  |  |  | Closing                                                                       | 15:10 | 15:15 | Speaker | Kirsten      | Hoeper |
|  |  |  |  |  |  | What is what we are trying to move forward - insights into our EULAR HPR work | 14:50 | 14:55 | Speaker | Rikke Helene | Moe    |
|  |  |  |  |  |  | What is what we are trying to move forward - insights into our EULAR HPR work | 14:40 | 14:50 | Speaker | Rikke Helene | Moe    |
|  |  |  |  |  |  | Introduction to the session                                                   | 14:15 | 14:20 | Speaker | Mwidimi      | Ndosi  |
|  |  |  |  |  |  |                                                                               |       |       | Chair   | Mwidimi      | Ndosi  |
|  |  |  |  |  |  |                                                                               |       |       | Chair   | Kirsten      | Hoeper |

|                                                          |            |                     |            |                                                                                                                                                                                                                    |                   |                                                                              |       |       |         |              |             |
|----------------------------------------------------------|------------|---------------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|------------------------------------------------------------------------------|-------|-------|---------|--------------|-------------|
| Fast ultrasound protocols in Rheumatology: Point of Care | 11/06/2025 | 14:15:00 - 15:30:00 | Hands-On 2 | 1. How to perform fast ultrasonography scans in daily clinical practice;2. Using handheld portable ultrasound devices;3. Examples in different anatomical areas and pathologies using portable ultrasound devices. | Hands-on Sessions | Point of Care vessel scan in suspected vasculitis                            | 14:30 | 14:35 | Speaker | Christina    | Duftner     |
|                                                          |            |                     |            |                                                                                                                                                                                                                    |                   | Hands-on stations                                                            | 14:40 | 15:30 | Speaker | Christina    | Duftner     |
|                                                          |            |                     |            |                                                                                                                                                                                                                    |                   | Point of Care salivary gland scan in suspected sjögren's                     | 14:20 | 14:25 | Speaker | Baptiste     | Quere       |
|                                                          |            |                     |            |                                                                                                                                                                                                                    |                   | Point of Care joint scan in suspected arthritis                              | 14:25 | 14:30 | Speaker | Marina       | Backhaus    |
|                                                          |            |                     |            |                                                                                                                                                                                                                    |                   | Point of Care lung scan in patients with suspected interstitial lung disease | 14:15 | 14:20 | Speaker | Andrea       | Delle Sedie |
|                                                          |            |                     |            |                                                                                                                                                                                                                    |                   | Discussion on presentations                                                  | 14:35 | 14:40 | Speaker | Marion       | Kortekaas   |
|                                                          |            |                     |            |                                                                                                                                                                                                                    |                   |                                                                              |       |       | Chair   | Marion       | Kortekaas   |
|                                                          |            |                     |            |                                                                                                                                                                                                                    |                   |                                                                              |       |       | Chair   | Hilde Berner | Hammer      |

|                                                                                    |                |                        |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |  |  |  |  |             |  |  |
|------------------------------------------------------------------------------------|----------------|------------------------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--|--|--|--|-------------|--|--|
| Fishbowl<br>- How to<br>drug<br>prices<br>influence<br>treatment<br>decisions<br>? | 11/06/<br>2025 | 14:15:00 -<br>15:30:00 | A1 | To discuss in a<br>fishbowl format<br>how and why<br>price and<br>market could<br>influence our<br>therapeutic<br>decisions- what<br>influences the<br>priced in<br>different<br>countries?-<br>does that<br>impact on the<br>way we<br>prescribe and<br>on guidelines?-<br>does it make a<br>difference for<br>patients?Fishb<br>owl is a format<br>involving the<br>public into a<br>podium<br>discussion. The<br>literally empty<br>seat in the<br>round is to be<br>taken by<br>anybody who<br>feels a need to<br>contribute.<br>being it with<br>own | Innovation |  |  |  |  | Spea<br>ker |  |  |
|------------------------------------------------------------------------------------|----------------|------------------------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--|--|--|--|-------------|--|--|

|                                                       |            |                     |            |                                                                                                                                                                                                                                   |                   |                                                      |       |       |         |                 |            |
|-------------------------------------------------------|------------|---------------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|------------------------------------------------------|-------|-------|---------|-----------------|------------|
|                                                       |            |                     |            | experiences, an opinion, a question - for as long as no one else wants that seat. In that moment the person is free to finish the sentence and then has to liberate the seat for the next. This should lead to a vivid discussion |                   |                                                      |       |       |         |                 |            |
| How to evaluate larger joints: the shoulder and elbow | 11/06/2025 | 14:15:00 - 15:30:00 | Hands-On 1 | 1. Assessment of the shoulder and elbow joints by physical examination; 2. Assessment of the shoulder and elbow joints by ultrasound; 3. How to integrate and correlate clinical and ultrasonography findings.                    | Hands-on Sessions | How to access the elbow: ultrasonography examination | 14:20 | 14:25 | Speaker | Lene            | Terslev    |
|                                                       |            |                     |            |                                                                                                                                                                                                                                   |                   | Discussion on presentations                          | 14:35 | 14:40 | Speaker | David           | Kane       |
|                                                       |            |                     |            |                                                                                                                                                                                                                                   |                   | How to access the shoulder: clinical examination     | 14:25 | 14:30 | Speaker | Edoardo         | Cipolletta |
|                                                       |            |                     |            |                                                                                                                                                                                                                                   |                   | How to access the                                    | 14:15 | 14:20 | Speaker | Florentin Ananu | Vreju      |

|                                                                                                                                              |                |                        |     |                                                                                                                                                                                                                                                                                                                 |                             |                                                                                                 |       |       |             |                    |                       |
|----------------------------------------------------------------------------------------------------------------------------------------------|----------------|------------------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-------------------------------------------------------------------------------------------------|-------|-------|-------------|--------------------|-----------------------|
|                                                                                                                                              |                |                        |     |                                                                                                                                                                                                                                                                                                                 |                             | elbow:<br>clinical<br>examination                                                               |       |       |             |                    |                       |
|                                                                                                                                              |                |                        |     |                                                                                                                                                                                                                                                                                                                 |                             | Hands-on<br>stations                                                                            | 14:40 | 15:30 | Spea<br>ker | Florentin<br>Ananu | Vreju                 |
|                                                                                                                                              |                |                        |     |                                                                                                                                                                                                                                                                                                                 |                             | How to<br>access the<br>shoulder:<br>ultrasonogra<br>phy<br>examination                         | 14:30 | 14:35 | Spea<br>ker | Giorgio            | Tamborrini-<br>Schütz |
|                                                                                                                                              |                |                        |     |                                                                                                                                                                                                                                                                                                                 |                             |                                                                                                 |       |       | Chair       | David              | Kane                  |
|                                                                                                                                              |                |                        |     |                                                                                                                                                                                                                                                                                                                 |                             |                                                                                                 |       |       | Chair       | Petra              | Hanova                |
| Hyperuric<br>emia and<br>gout:<br>bridging<br>basic<br>science<br>with<br>clinical<br>practice<br>and new<br>targetabl<br>e<br>mechanis<br>m | 11/06/<br>2025 | 14:15:00 -<br>15:30:00 | 6.1 | 1. To learn<br>about new<br>genetic<br>polymorphisms<br>predisposing to<br>gout; 2. To<br>learn how<br>functional<br>genomics helps<br>understanding<br>inflammatory<br>reprogramming<br>of the innate<br>immune system<br>in gout<br>patients; 3. To<br>understand<br>how novel<br>biomarkers can<br>influence | From<br>Bench to<br>Bedside | Novel<br>biomarkers<br>and<br>therapeutic<br>strategies in<br>gout                              | 15:05 | 15:30 | Spea<br>ker | Pascal             | Richette              |
|                                                                                                                                              |                |                        |     |                                                                                                                                                                                                                                                                                                                 |                             | Investigating<br>innate<br>immune<br>memory in<br>gout using<br>functional<br>genomics          | 14:40 | 15:05 | Spea<br>ker | Tania              | Crisan                |
|                                                                                                                                              |                |                        |     |                                                                                                                                                                                                                                                                                                                 |                             | Largest<br>GWAS<br>cohort of and<br>novel<br>insights in<br>the<br>etiopathogen<br>esis of gout | 14:15 | 14:40 | Spea<br>ker | Tony               | Merriman              |

|                                                                  |            |                     |    |                                                                                                                                                                                                                                                                                                                                               |                   |                                                               |       |       |         |            |           |
|------------------------------------------------------------------|------------|---------------------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|---------------------------------------------------------------|-------|-------|---------|------------|-----------|
|                                                                  |            |                     |    | therapeutic strategies                                                                                                                                                                                                                                                                                                                        |                   |                                                               |       |       | Chair   | Tuhina     | Neogi     |
|                                                                  |            |                     |    |                                                                                                                                                                                                                                                                                                                                               |                   |                                                               |       |       | Chair   | Hang Korng | Ea        |
| Mastering Research Writing and Publishing in 2025: from AI to IF | 11/06/2025 | 14:15:00 - 15:30:00 | B4 | Which are the essential skills a young researcher should develop alongside their research skills?1. Successful grant and fellowship writing;2. How to turn networking opportunities to research collaborations;3 . How to implement artificial intelligence;4. How to understand impact factors and how are they influencing your publishing. | EMEUNE T Presents | Impact Factor and its Influence on Scientific Writing         | 14:45 | 14:50 | Speaker | Gerd R.    | Burmester |
|                                                                  |            |                     |    |                                                                                                                                                                                                                                                                                                                                               |                   | Impact Factor and its Influence on Scientific Writing         | 14:30 | 14:45 | Speaker | Gerd R.    | Burmester |
|                                                                  |            |                     |    |                                                                                                                                                                                                                                                                                                                                               |                   | Should we include AI in our writing?                          | 14:50 | 15:05 | Speaker | Diego      | Benavent  |
|                                                                  |            |                     |    |                                                                                                                                                                                                                                                                                                                                               |                   | Should we include AI in our writing?                          | 15:05 | 15:10 | Speaker | Diego      | Benavent  |
|                                                                  |            |                     |    |                                                                                                                                                                                                                                                                                                                                               |                   | From Manuscript to Journal: A Guide to Successful Publication | 15:10 | 15:25 | Speaker | Pedro      | Machado   |
|                                                                  |            |                     |    |                                                                                                                                                                                                                                                                                                                                               |                   | How to write a successful research paper ?                    | 14:15 | 14:30 | Speaker | Meghna     | Jani      |
|                                                                  |            |                     |    |                                                                                                                                                                                                                                                                                                                                               |                   | From Manuscript to Journal: A Guide to                        | 15:25 | 15:30 | Speaker | Pedro      | Machado   |

|                                                                                           |            |                     |    |                                                                                                                                                                                                                                                                                                                                                              |                |                                                                                                                                                                  |       |       |         |             |             |
|-------------------------------------------------------------------------------------------|------------|---------------------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|---------|-------------|-------------|
|                                                                                           |            |                     |    |                                                                                                                                                                                                                                                                                                                                                              |                | Successful Publication                                                                                                                                           |       |       |         |             |             |
|                                                                                           |            |                     |    |                                                                                                                                                                                                                                                                                                                                                              |                |                                                                                                                                                                  |       |       | Chair   | Anastasia   | Madenidou   |
|                                                                                           |            |                     |    |                                                                                                                                                                                                                                                                                                                                                              |                |                                                                                                                                                                  |       |       | Chair   | Caludia     | Cobilinschi |
| Navigating between the calm seas of disease remission and stormy waters of flares in RMDs | 11/06/2025 | 14:15:00 - 15:30:00 | B1 | 1. To understand the immunological basis of flares and disease persistence in ANCA-associated vasculitis 2. To learn about predictive markers and mechanisms of sustained drug-free remission in rheumatoid arthritis 3. To report on the cellular and molecular mechanisms and predictors of flare in rheumatoid arthritis Keep up to date with FOREUM here | EULAR Projects | Dissecting the cellular and molecular atlas of Rheumatoid Arthritis (RA) in sustained remission to identify pathways maintaining Remission and Triggering Flares | 15:00 | 15:20 | Speaker | Stefano     | Alivernini  |
|                                                                                           |            |                     |    |                                                                                                                                                                                                                                                                                                                                                              |                | Debate and Closing                                                                                                                                               | 15:20 | 15:30 | Speaker | Rik         | Lories      |
|                                                                                           |            |                     |    |                                                                                                                                                                                                                                                                                                                                                              |                | Signs of danger: extrafollicular, auto-reactive B cell responses as drivers of disease flares in AAV                                                             | 14:40 | 15:00 | Speaker | Hans Ulrich | Scherer     |
|                                                                                           |            |                     |    |                                                                                                                                                                                                                                                                                                                                                              |                | Introduction                                                                                                                                                     | 14:15 | 14:20 | Speaker | Oliver      | Distler     |

|                                                                           |            |                     |    |                                                                                                                                                                                                                                                                                                                            |                         |                                                                                               |       |       |         |            |            |
|---------------------------------------------------------------------------|------------|---------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|-----------------------------------------------------------------------------------------------|-------|-------|---------|------------|------------|
|                                                                           |            |                     |    |                                                                                                                                                                                                                                                                                                                            |                         | Sustained drug-free remission in rheumatoid arthritis: immunological and patient perspectives | 14:20 | 14:40 | Speaker | Kenneth F  | Baker      |
|                                                                           |            |                     |    |                                                                                                                                                                                                                                                                                                                            |                         |                                                                                               |       |       | Chair   | Rik        | Lories     |
|                                                                           |            |                     |    |                                                                                                                                                                                                                                                                                                                            |                         |                                                                                               |       |       | Chair   | Oliver     | Distler    |
| Not all about B cells: myeloid-related inflammation in lupus pathogenesis | 11/06/2025 | 14:15:00 - 15:30:00 | A3 | Participants will<br>1. understand the role of myeloid cells in the pathogenesis of systemic lupus; 2. explore the mechanisms by which type I interferons and IL-1 $\beta$ contribute to inflammation in lupus monocytes and their impact on disease progression; 3. gain insights into the involvement of intraglomerular | Basic and Translational | Type I IFN requirement for IL-1 $\beta$ secretion in lupus monocytes                          | 15:00 | 15:05 | Speaker | Virginia   | Pascual    |
|                                                                           |            |                     |    |                                                                                                                                                                                                                                                                                                                            |                         | Inflammatory skin education of myeloid cells in lupus pathogenesis                            | 14:35 | 14:40 | Speaker | J Michelle | Kahlenberg |
|                                                                           |            |                     |    |                                                                                                                                                                                                                                                                                                                            |                         | Intraglomerular Myeloid Cells in Lupus Nephritis                                              | 15:25 | 15:30 | Speaker | Andrea     | Fava       |
|                                                                           |            |                     |    |                                                                                                                                                                                                                                                                                                                            |                         | Intraglomerular Myeloid Cells in Lupus Nephritis                                              | 15:05 | 15:25 | Speaker | Andrea     | Fava       |

|                                                                                                                |            |                     |    |                                                                                                                                                                                                                      |       |                                                                                               |       |       |         |            |            |
|----------------------------------------------------------------------------------------------------------------|------------|---------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-----------------------------------------------------------------------------------------------|-------|-------|---------|------------|------------|
|                                                                                                                |            |                     |    | myeloid cells in lupus nephritis and how they affect renal outcomes                                                                                                                                                  |       | Type I IFN requirement for IL-1 $\beta$ secretion in lupus monocytes                          | 14:40 | 15:00 | Speaker | Virginia   | Pascual    |
|                                                                                                                |            |                     |    |                                                                                                                                                                                                                      |       | Inflammatory skin education of myeloid cells in lupus pathogenesis                            | 14:15 | 14:35 | Speaker | J Michelle | Kahlenberg |
|                                                                                                                |            |                     |    |                                                                                                                                                                                                                      |       |                                                                                               |       |       | Chair   | Nisha      | Limaye     |
|                                                                                                                |            |                     |    |                                                                                                                                                                                                                      |       |                                                                                               |       |       | Chair   | Alessia    | Alunno     |
| Nutrition, Microbiome & Immune System: The inseparable link for the prevention and cure of autoimmune diseases | 11/06/2025 | 14:15:00 - 15:30:00 | F3 | 1. Learn how the microbiome influences the immune system;2. Learn how microbiome interventions can change the outcome of RMDs;3. Learn about the role of nutrition for the prevention and management of inflammatory | Joint | Clinical evidence for the role of the microbiome in the evolution of immune-mediated diseases | 14:15 | 14:35 | Speaker | Alexander  | Moschen    |
|                                                                                                                |            |                     |    |                                                                                                                                                                                                                      |       | Clinical evidence for the role of the microbiome in the evolution of immune-                  | 14:35 | 14:40 | Speaker | Alexander  | Moschen    |

|  |  |  |  |                     |  |                                                                                                                       |       |       |         |        |                |
|--|--|--|--|---------------------|--|-----------------------------------------------------------------------------------------------------------------------|-------|-------|---------|--------|----------------|
|  |  |  |  | rheumatic diseases. |  | mediated diseases                                                                                                     |       |       |         |        |                |
|  |  |  |  |                     |  | Nutrition in the prevention and management of inflammatory rheumatic diseases                                         | 15:05 | 15:25 | Speaker | Elena  | Philippou      |
|  |  |  |  |                     |  | Nutrition in the prevention and management of inflammatory rheumatic diseases                                         | 15:25 | 15:30 | Speaker | Elena  | Philippou      |
|  |  |  |  |                     |  | Targeted microbiome interventions and their impact on treatment response and prognosis - examples beyond rheumatology | 14:40 | 15:00 | Speaker | Claire | Immediato Daen |

|                                                          |            |                     |    |                                                                                                                                                                                                                                   |                  |                                                                                                                       |       |       |         |          |                      |
|----------------------------------------------------------|------------|---------------------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|-----------------------------------------------------------------------------------------------------------------------|-------|-------|---------|----------|----------------------|
|                                                          |            |                     |    |                                                                                                                                                                                                                                   |                  | Targeted microbiome interventions and their impact on treatment response and prognosis - examples beyond rheumatology | 15:00 | 15:05 | Speaker | Claire   | Immediato Daien      |
|                                                          |            |                     |    |                                                                                                                                                                                                                                   |                  |                                                                                                                       |       |       | Chair   | Jasminka | Milas Ahic           |
|                                                          |            |                     |    |                                                                                                                                                                                                                                   |                  |                                                                                                                       |       |       | Chair   | Daniela  | Marasović Krstulović |
| Rheumatology meets hematology: Unveiling Shared Pathways | 11/06/2025 | 14:15:00 - 15:30:00 | A2 | Session on overlap between rheumatology and another specialty involving experts from the respective field.1. Learn about the multidisciplinary approaches in diagnosing and managing diseases at the intersection of rheumatology | Clinical Science | What Should Rheumatologists Know About Hypereosinophilic Syndrome?                                                    | 14:40 | 15:00 | Speaker | tbc      | tbc                  |
|                                                          |            |                     |    |                                                                                                                                                                                                                                   |                  | Immune Cytopenias: Understanding the Spectrum and Mechanisms                                                          | 14:15 | 14:35 | Speaker | tbc      | tbc                  |
|                                                          |            |                     |    |                                                                                                                                                                                                                                   |                  | What Should Rheumatologists Know About                                                                                | 15:00 | 15:05 | Speaker | tbc      | tbc                  |

|  |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                              |  |                                                                                                 |       |       |         |                |          |
|--|--|--|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|-------------------------------------------------------------------------------------------------|-------|-------|---------|----------------|----------|
|  |  |  |  | and hematology;2. Explore the underlying mechanisms and pathophysiology of hypereosinophilic syndrome;3. Understand the diagnostic challenges and commonalities between rheumatologic and hematologic conditions;4. Discuss shared treatment strategies and drug repurposing approaches bridging hematology and rheumatology;5 . Re-evaluate and redefine clinical boundaries and diagnostic |  | Hypereosinophilic Syndrome?                                                                     |       |       |         |                |          |
|  |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                              |  | Immune Cytopenias: Understanding the Spectrum and Mechanisms                                    | 14:35 | 14:40 | Speaker | tbc            | tbc      |
|  |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                              |  | When Rheumatology Crosses into Hematology: Diagnosis, Treatment Approaches and Drug repurposing | 15:25 | 15:30 | Speaker | tbc            | tbc      |
|  |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                              |  | When Rheumatology Crosses into Hematology: Diagnosis, Treatment Approaches and Drug repurposing | 15:05 | 15:25 | Speaker | tbc            | tbc      |
|  |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                              |  |                                                                                                 |       |       | Chair   | Ertugrul Cagri | Bolek    |
|  |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                              |  |                                                                                                 |       |       | Chair   | Gözde Kübra    | Yardımcı |

|                                                |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                                                                             |                       |                                                                                                               |       |       |         |            |          |
|------------------------------------------------|------------|---------------------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|---------------------------------------------------------------------------------------------------------------|-------|-------|---------|------------|----------|
|                                                |            |                     |    | criteria for these overlapping disorders.                                                                                                                                                                                                                                                                                                                                                                                   |                       |                                                                                                               |       |       |         |            |          |
| Rheumatology: its not rocket science or is it? | 11/06/2025 | 14:15:00 - 15:30:00 | F1 | To learn about the link between air and space medicine and the challenges of space flying in the context of what can we transfer to rheumatology:1. to understand resilience and its impact on wellbeing even in the face of pending or existing stress;2. to understand the impact of microgravity on bone loss and the relation to the effects seen in chronic immobility and inflammation;3. to understand the impact of | From Bench to Bedside | Houston, we have a problem: resilience in the face of potential disaster - what can we learn for rheumatology | 14:20 | 14:40 | Speaker | tbc        | tbc      |
|                                                |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                                                                             |                       | Immunology and space traveling: what do we still have to learn before we get to Mars?                         | 15:00 | 15:20 | Speaker | tbc        | tbc      |
|                                                |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                                                                             |                       | Debate and Closing                                                                                            | 15:20 | 15:30 | Speaker | Bimba      | Hoyer    |
|                                                |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                                                                             |                       | Losing bone mass - what happens in space does not stay in space                                               | 14:40 | 15:00 | Speaker | Anna-Maria | Liphardt |
|                                                |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                                                                             |                       | Introduction                                                                                                  | 14:15 | 14:20 | Speaker | Marta      | Mosca    |
|                                                |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                                                                             |                       |                                                                                                               |       |       | Chair   | Bimba      | Hoyer    |

|                                        |            |                     |         |                                                                                                                                                                                                                                                     |                   |                                 |       |       |         |           |          |
|----------------------------------------|------------|---------------------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|---------------------------------|-------|-------|---------|-----------|----------|
|                                        |            |                     |         | stress and other environmental factors on the immune system - do we know already what we need to know and what can space medicine learn from rheumatology and vice versa.                                                                           |                   |                                 |       |       | Chair   | Marta     | Mosca    |
| Still's disease in children and adults | 11/06/2025 | 14:15:00 - 15:00:00 | Plenary | To learn about the evidence supporting a disease continuum of Still's disease across ages; To discuss dysregulated immune pathways that can be new targets for therapies; To understand the potential mechanisms leading to different phenotypes of | What is New (WIN) | What is new in Still's disease? | 14:15 | 15:00 | Speaker | Peter     | Nigrovic |
|                                        |            |                     |         |                                                                                                                                                                                                                                                     |                   |                                 |       |       | Chair   | Lorenzo   | Dagna    |
|                                        |            |                     |         |                                                                                                                                                                                                                                                     |                   |                                 |       |       | Chair   | Charlotte | Girard   |

|                                                                             |            |                     |    |                                                                                                                                                                                                                                     |                  |                                                 |       |       |         |            |               |
|-----------------------------------------------------------------------------|------------|---------------------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|-------------------------------------------------|-------|-------|---------|------------|---------------|
|                                                                             |            |                     |    | the disease; To learn how to manage complications such as Macrophage Activation Syndrome (MAS) or lung disease.                                                                                                                     |                  |                                                 |       |       |         |            |               |
| Systemic sclerosis - how to manage difficult cases of common manifestations | 11/06/2025 | 14:15:00 - 15:30:00 | D1 | 1. Learn how to manage systemic sclerosis patients with refractory anemia;2. Learn how to fight small intestinal bacterial overgrowth in systemic sclerosis;3. Learn how to manage critical digital ischemia in systemic sclerosis. | Clinical Science | Oral Abstract Presentation                      | 15:15 | 15:25 | Speaker |            |               |
|                                                                             |            |                     |    |                                                                                                                                                                                                                                     |                  | Refractory Anemia in Systemic Sclerosis         | 14:55 | 15:10 | Speaker | Yannick    | Allanore      |
|                                                                             |            |                     |    |                                                                                                                                                                                                                                     |                  | Refractory Anemia in Systemic Sclerosis         | 15:10 | 15:15 | Speaker | Yannick    | Allanore      |
|                                                                             |            |                     |    |                                                                                                                                                                                                                                     |                  | Small bowel involvement in Systemic Sclerosis   | 14:30 | 14:35 | Speaker | Anna-Maria | Hoffmann-Vold |
|                                                                             |            |                     |    |                                                                                                                                                                                                                                     |                  | Small bowel involvement in Systemic Sclerosis   | 14:15 | 14:30 | Speaker | Anna-Maria | Hoffmann-Vold |
|                                                                             |            |                     |    |                                                                                                                                                                                                                                     |                  | Critical digital ischemia in Systemic Sclerosis | 14:35 | 14:50 | Speaker | Ariane L.  | Herrick       |

|                                                      |            |                     |    |                                                                                                                                                                                                                                                                                  |      |                                                                     |       |       |         |           |               |
|------------------------------------------------------|------------|---------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|---------------------------------------------------------------------|-------|-------|---------|-----------|---------------|
|                                                      |            |                     |    |                                                                                                                                                                                                                                                                                  |      | Critical digital ischemia in Systemic Sclerorsis                    | 14:50 | 14:55 | Speaker | Ariane L. | Herrick       |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                                                  |      |                                                                     |       |       | Chair   | Alexandra | Balbir-Gurman |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                                                  |      |                                                                     |       |       | Chair   | Ulf       | Müller-Ladner |
| Transforming Healthcare: Navigating New Technologies | 11/06/2025 | 14:15:00 - 15:30:00 | C3 | 1. To highlight challenges and solutions in developing information for patients using digital technologies;2. To discuss how are the healthcare sector and its users dealing with digital health innovation;3. To brainstorm on how can accessibility and usability be improved. | PARE | Oral Abstract Presentation                                          | 15:00 | 15:10 | Speaker |           |               |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                                                  |      | Oral Abstract Presentation                                          | 15:10 | 15:20 | Speaker |           |               |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                                                  |      | Developing new AI resources: Lupus 100 and Lupus GPT                | 14:30 | 14:45 | Speaker | Jeanette  | Andersen      |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                                                  |      | Challenges in using AI generated patient information                | 14:45 | 15:00 | Speaker | Peter     | Böhm          |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                                                  |      | Debate and closing                                                  | 15:20 | 15:30 | Speaker | Kyriaki   | Spanidou      |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                                                  |      | One size does not fit all: experiences on digital health innovation | 14:15 | 14:30 | Speaker | Frances   | Mair          |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                                                  |      |                                                                     |       |       | Chair   | Diederik  | De Cock       |

|                                  |                |                        |     |                                                                                                                                                                                                                                                                                                                              |                             |                                                                                             |       |       |             |                  |                     |
|----------------------------------|----------------|------------------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------------------------------------------------------------------------------|-------|-------|-------------|------------------|---------------------|
|                                  |                |                        |     |                                                                                                                                                                                                                                                                                                                              |                             |                                                                                             |       |       | Chair       | Kyriaki          | Spanidou            |
| Type 1<br>interferon<br>opathies | 11/06/<br>2025 | 14:15:00 -<br>15:30:00 | 6.4 | In this session,<br>delegates<br>will:1.<br>Understand the<br>pathogenesis<br>and genetic<br>causes of type<br>1<br>interferonopathi<br>es;2.<br>Recognise the<br>clinical<br>presentations<br>of these<br>conditions;3.<br>Identify<br>diagnostic tools<br>and<br>management<br>strategies for<br>improved<br>patient care. | From<br>Bench to<br>Bedside | Genetic<br>Insights into<br>the<br>Pathogenesi<br>s of Type I<br>Interferonop<br>athies     | 14:15 | 14:35 | Spea<br>ker | Marie-<br>Louise | Frémond             |
|                                  |                |                        |     |                                                                                                                                                                                                                                                                                                                              |                             | Genetic<br>Insights into<br>the<br>Pathogenesi<br>s of Type I<br>Interferonop<br>athies     | 14:35 | 14:40 | Spea<br>ker | Marie-<br>Louise | Frémond             |
|                                  |                |                        |     |                                                                                                                                                                                                                                                                                                                              |                             | Clinical<br>Heterogeneit<br>y in the<br>Presentation<br>of Type I<br>Interferonop<br>athies | 15:00 | 15:05 | Spea<br>ker | Marco            | Gattorno            |
|                                  |                |                        |     |                                                                                                                                                                                                                                                                                                                              |                             | Clinical<br>Heterogeneit<br>y in the<br>Presentation<br>of Type I<br>Interferonop<br>athies | 14:40 | 15:00 | Spea<br>ker | Marco            | Gattorno            |
|                                  |                |                        |     |                                                                                                                                                                                                                                                                                                                              |                             | The<br>treatment of<br>Type I<br>Interferonop<br>athies                                     | 15:25 | 15:30 | Spea<br>ker | Raphaela         | Goldbach-<br>Mansky |

|                                                                                            |            |                     |         |                                                                                                                                                                                                                                                                                                                   |                    |                                                                            |       |       |         |           |                 |
|--------------------------------------------------------------------------------------------|------------|---------------------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------------------------------------------------------------|-------|-------|---------|-----------|-----------------|
|                                                                                            |            |                     |         |                                                                                                                                                                                                                                                                                                                   |                    | The treatment of Type I Interferonopathies                                 | 15:05 | 15:25 | Speaker | Raphaela  | Goldbach-Mansky |
|                                                                                            |            |                     |         |                                                                                                                                                                                                                                                                                                                   |                    |                                                                            |       |       | Chair   | Edward M. | Vital           |
|                                                                                            |            |                     |         |                                                                                                                                                                                                                                                                                                                   |                    |                                                                            |       |       | Chair   | Stephanie | Shoop-Worrall   |
| Bridging Gaps, Innovating Care: Advancing Juvenile Idiopathic Arthritis Treatment Globally | 11/06/2025 | 15:00:00 - 15:45:00 | Plenary | 1. Present the latest advancements in biologic therapies, personalized medicine, and emerging technologies for managing Juvenile Idiopathic Arthritis, applicable across diverse healthcare settings;2. Discuss scalable strategies to implement effective JIA treatments in low-resource environments, including | How to Treat (HOT) | Closing the Care Divide: Advancing Juvenile Idiopathic Arthritis Treatment | 15:00 | 15:45 | Speaker | Wafa      | Hamdi           |
|                                                                                            |            |                     |         |                                                                                                                                                                                                                                                                                                                   |                    |                                                                            |       |       | Chair   | tbc       | tbc             |
|                                                                                            |            |                     |         |                                                                                                                                                                                                                                                                                                                   |                    |                                                                            |       |       | Chair   | tbc       | tbc             |

|  |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |  |  |  |  |  |  |  |  |
|--|--|--|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|--|--|--|--|--|
|  |  |  |  | telemedicine, task-shifting, and affordable diagnostic tools; 3. Highlight the importance of collaborative care involving rheumatologists, pediatricians, physical therapists, and mental health professionals to ensure holistic management of JIA; 4. Identify key challenges and solutions to minimize healthcare inequities in JIA treatment across the globe, focusing on policy development, advocacy, and community-based interventions; 5. Showcase strategies that |  |  |  |  |  |  |  |  |
|--|--|--|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|--|--|--|--|--|

|                                     |            |                     |    |                                                                                                                                                                                                                                      |                                            |                               |       |       |         |           |           |
|-------------------------------------|------------|---------------------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|-------------------------------|-------|-------|---------|-----------|-----------|
|                                     |            |                     |    | align with the goals of universal healthcare by integrating innovative care delivery models and sustainable healthcare financing mechanisms for managing JIA in both high- and low-income countries.                                 |                                            |                               |       |       |         |           |           |
| WIN - Foot and ankle Osteoarthritis | 11/06/2025 | 15:15:00 - 16:00:00 | C1 | 1. Introduce delegates to the rationale for providing joint specific guidance in OA;2. Provide an update on what is new in our understanding of the pathophysiology and risk factors for foot and ankle OA;3. Provide a state of the | Health Professionals in Rheumatology (HPR) | Foot and ankle Osteoarthritis | 15:15 | 16:00 | Speaker | Hylton    | Menz      |
|                                     |            |                     |    |                                                                                                                                                                                                                                      |                                            |                               |       |       | Chair   | Philip G. | Conaghan  |
|                                     |            |                     |    |                                                                                                                                                                                                                                      |                                            |                               |       |       | Chair   | Elisabeth | Mulrooney |

|                                                               |            |                     |                   |                                                                                                                                                                                                                                  |                       |                                                               |       |       |         |          |           |
|---------------------------------------------------------------|------------|---------------------|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|---------------------------------------------------------------|-------|-------|---------|----------|-----------|
|                                                               |            |                     |                   | art update on current evidence for the treatment of foot and ankle OA.                                                                                                                                                           |                       |                                                               |       |       |         |          |           |
| Challenges associated with the management of Kawasaki Disease | 11/06/2025 | 15:45:00 - 16:15:00 | Meet the Expert 2 | 1. Deepen Knowledge on Pathophysiology and Diagnosis of Kawasaki Disease; 2. Examine Evolving Management Strategies in Kawasaki Disease; 3. Address Geographic and Resource-Based Disparities in Management of Kawasaki Disease. | Meet the EULAR Expert | Challenges associated with the management of Kawasaki Disease | 15:45 | 16:15 | Speaker | Isabelle | Koné-Paut |

|                                                                                               |            |                     |                   |                                                                                                                                                                                                                                                                                                                                                    |                       |                                                                                              |       |       |         |        |         |
|-----------------------------------------------------------------------------------------------|------------|---------------------|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|----------------------------------------------------------------------------------------------|-------|-------|---------|--------|---------|
| Conventional DMARDs in Rheumatoid Arthritis: rational combinations and appropriate follow-up, | 11/06/2025 | 15:45:00 - 16:15:00 | Meet the Expert 3 | 1. To discuss the evidence behind combinations of conventional DMARDs for treatment of RA2. To learn about the rationale behind (the frequency of) follow-up investigation in patients treated with conventional DMARDs3. To discuss the frequency and severity of adverse events of conventional DMARDs when used as mono- or combination therapy | Meet the EULAR Expert | Conventional DMARDs in Rheumatoid Arthritis: rational combinations and appropriate follow-up | 15:45 | 16:15 | Speaker | Jon    | Lampa   |
| Cutting edge autoimmune serology: How to make the                                             | 11/06/2025 | 15:45:00 - 16:15:00 | Meet the Expert 4 | 1. To learn about likelihood ratios as a means to interpret autoantibody results;2. To                                                                                                                                                                                                                                                             | Meet the EULAR Expert | Cutting edge autoimmune serology: How to make the most of autoantibody results               | 15:45 | 16:15 | Speaker | Xavier | Bossuyt |

|                                                                     |            |                     |                   |                                                                                                                                                                                                                                                         |                                            |                                                                       |       |       |         |          |              |
|---------------------------------------------------------------------|------------|---------------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|-----------------------------------------------------------------------|-------|-------|---------|----------|--------------|
| most of autoantibody results                                        |            |                     |                   | understand the value of standardised autoantibody analyses in clinical decision-making.                                                                                                                                                                 |                                            |                                                                       |       |       |         |          |              |
| When to think about Immunodeficiency in a patient with autoimmunity | 11/06/2025 | 15:45:00 - 16:15:00 | Meet the Expert 1 | Immunodeficiency can present or can be associated with autoimmunity. 1. The objective is to learn about the typology of patients presenting with symptoms of autoimmunity and carrying Mendelian or acquired mutations associated with immunodeficiency | Meet the EULAR Expert                      | When to think about Immunodeficiency in a patient with autoimmunity ? | 15:45 | 16:15 | Speaker | Frédéric | Rieux-Laucat |
| Co-designing new non-pharmacological                                | 11/06/2025 | 16:30:00 - 17:45:00 | C1                | This session aims to help delegates to: 1. Get inspiration from different                                                                                                                                                                               | Health Professionals in Rheumatology (HPR) | Using participatory design in the development of new digital          | 16:50 | 17:05 | Speaker | tbc      | tbc          |

|                                                                                   |  |  |  |                                                                                                                                                                                                    |  |                                                                                                         |       |       |         |             |          |
|-----------------------------------------------------------------------------------|--|--|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|---------------------------------------------------------------------------------------------------------|-------|-------|---------|-------------|----------|
| interventions: how to best involve people living with RMDs and other stakeholders |  |  |  | frameworks for the development of new non-pharmacological interventions with involvement of relevant stakeholders;2. Discuss how to overcome social inequity in non-pharmacological interventions. |  | support for strength and physical activity                                                              |       |       |         |             |          |
|                                                                                   |  |  |  |                                                                                                                                                                                                    |  | Oral Abstract Presentation                                                                              | 17:30 | 17:40 | Speaker |             |          |
|                                                                                   |  |  |  |                                                                                                                                                                                                    |  | Using participatory design in the development of new digital support for strength and physical activity | 17:05 | 17:10 | Speaker | tbc         | tbc      |
|                                                                                   |  |  |  |                                                                                                                                                                                                    |  | Development of non-pharmacological complex interventions - opportunities and pitfalls                   | 16:45 | 16:50 | Speaker | Bente Appel | Esbensen |
|                                                                                   |  |  |  |                                                                                                                                                                                                    |  | Development of non-pharmacological complex interventions - opportunities and pitfalls                   | 16:30 | 16:45 | Speaker | Bente Appel | Esbensen |
|                                                                                   |  |  |  |                                                                                                                                                                                                    |  | Designing interventions to optimise                                                                     | 17:25 | 17:30 | Speaker | Sónia       | Dias     |

|                                                             |            |                     |    |                                                                                                                                                                                                                 |      |                                                                               |       |       |         |                        |               |
|-------------------------------------------------------------|------------|---------------------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-------------------------------------------------------------------------------|-------|-------|---------|------------------------|---------------|
|                                                             |            |                     |    |                                                                                                                                                                                                                 |      | health literacy in vulnerable populations                                     |       |       |         |                        |               |
|                                                             |            |                     |    |                                                                                                                                                                                                                 |      | Designing interventions to optimise health literacy in vulnerable populations | 17:10 | 17:25 | Speaker | Sónia                  | Dias          |
|                                                             |            |                     |    |                                                                                                                                                                                                                 |      |                                                                               |       |       | Chair   | Christina Merete Tvede | Madsen        |
|                                                             |            |                     |    |                                                                                                                                                                                                                 |      |                                                                               |       |       | Chair   | Rafael                 | Prieto Moreno |
| From exclusion to empowerment: Engaging marginalised groups | 11/06/2025 | 16:30:00 - 17:45:00 | A1 | 1. To highlight the vulnerabilities of some groups of people with RMD 2. To address the impact on access to care and self-management 3. To identify unmet needs regarding access, quality of care and research. | PARE | Health Inequities in LGBT People                                              | 17:06 | 17:24 | Speaker | tbc                    | tbc           |
|                                                             |            |                     |    |                                                                                                                                                                                                                 |      | The LGBTQIA+ Community in Rheumatology Research                               | 17:24 | 17:42 | Speaker | tbc                    | tbc           |
|                                                             |            |                     |    |                                                                                                                                                                                                                 |      | Challenges of Inflammatory rheumatic diseases in migrants                     | 16:48 | 17:06 | Speaker | Martin                 | Krusche       |
|                                                             |            |                     |    |                                                                                                                                                                                                                 |      | The impact of Income-                                                         | 16:30 | 16:48 | Speaker | Simone                 | Battista      |

|                                                          |            |                     |                   |                                                                                                                                                                                                                                                                                                                         |                       |                                                          |       |       |         |         |         |
|----------------------------------------------------------|------------|---------------------|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|----------------------------------------------------------|-------|-------|---------|---------|---------|
|                                                          |            |                     |                   |                                                                                                                                                                                                                                                                                                                         |                       | Related Inequalities                                     |       |       |         |         |         |
|                                                          |            |                     |                   |                                                                                                                                                                                                                                                                                                                         |                       | Closing                                                  | 17:42 | 17:45 | Speaker | Simon   | Stones  |
|                                                          |            |                     |                   |                                                                                                                                                                                                                                                                                                                         |                       |                                                          |       |       | Chair   | Simon   | Stones  |
| Case discussion: Difficult to treat Rheumatoid Arthritis | 12/06/2025 | 09:45:00 - 10:15:00 | Meet the Expert 1 | Several factors may make Rheumatoid arthritis (RA) difficult to treat (D2T). This session will provide a state-of-the art overview of D2T RA, including: 1. contributing factors; 2. burden of the disease and management options. Practical guidance will be provided for the classification and management of D2T RA. | Meet the EULAR Expert | Case discussion: Difficult to treat Rheumatoid Arthritis | 09:45 | 10:15 | Speaker | Iain B. | McInnes |

|                                                                                                            |            |                     |                   |                                                                                                                                                                                                                                                         |                       |                                                                                                            |       |       |         |         |            |
|------------------------------------------------------------------------------------------------------------|------------|---------------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|------------------------------------------------------------------------------------------------------------|-------|-------|---------|---------|------------|
| Challenges associated with the management of interstitial lung disease in patients with systemic sclerosis | 12/06/2025 | 09:45:00 - 10:15:00 | Meet the Expert 2 | 1. To highlight the unmet needs regarding the management of systemic sclerosis-related interstitial lung disease;2. To learn about diagnosis, clinical relevance and definition of progression;3. To know about the most modern therapeutic strategies. | Meet the EULAR Expert | Challenges associated with the management of interstitial lung disease in patients with systemic sclerosis | 09:45 | 10:15 | Speaker | Roberto | Giacomelli |
| Challenges associated with the management of Lupus Nephritis                                               | 12/06/2025 | 09:45:00 - 10:15:00 | Meet the Expert 3 | 1. To discuss the definition difficult to manage Lupus nephritis2. To discuss the optimal treatment selection in different cases with lupus nephritis3. To discuss the                                                                                  | Meet the EULAR Expert | Challenges associated with the management of Lupus Nephritis                                               | 09:45 | 10:15 | Speaker | Anisur  | Rahman     |

|                              |            |                     |                   |                                                                                                                                                                                   |                       |                              |       |       |         |           |          |
|------------------------------|------------|---------------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|------------------------------|-------|-------|---------|-----------|----------|
|                              |            |                     |                   | relevance of repeat biopsy in patients with lupus nephritis                                                                                                                       |                       |                              |       |       |         |           |          |
| Future of AI in Rheumatology | 12/06/2025 | 09:45:00 - 10:15:00 | Meet the Expert 4 | Speakers will delve into the potential and challenges of integrating AI in rheumatology, critically assessing its impact on clinical practice and the authenticity of research.   | Meet the EULAR Expert | Future of AI in Rheumatology | 09:45 | 10:15 | Speaker | Thomas    | Hügler   |
| Behcet's disease             | 12/06/2025 | 10:30:00 - 11:15:00 | Plenary           | 1. Explore recent findings in the pathophysiology of Behçet's disease, highlighting the influence of genetic and immune factors on disease progression. 2. Receive updates on the | What is New (WIN)     | Behcet's Disease             | 10:30 | 11:15 | Speaker | Matteo    | Piga     |
|                              |            |                     |                   |                                                                                                                                                                                   |                       |                              |       |       | Chair   | Gerard    | Espinosa |
|                              |            |                     |                   |                                                                                                                                                                                   |                       |                              |       |       | Chair   | Petros P. | Sfikakis |

|                                                        |            |                     |    |                                                                                                                                                                                                                               |      |                                                                           |       |       |         |          |                 |
|--------------------------------------------------------|------------|---------------------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|---------------------------------------------------------------------------|-------|-------|---------|----------|-----------------|
|                                                        |            |                     |    | latest advancements in diagnostic techniques for the disease. 3. Review cutting-edge treatment options, with a focus on novel biologics and their practical applications to enhance patient outcomes.                         |      |                                                                           |       |       |         |          |                 |
| Breaking the silence on mental health and inflammation | 12/06/2025 | 10:30:00 - 11:45:00 | C3 | 1. To highlight the interplay between inflammation and mental disease;2. To raise awareness on the importance of preventing mental disease in people with RMD;3. To explore strategies to address loneliness and isolation in | PARE | Oral Abstract Presentation                                                | 11:30 | 11:40 | Speaker |          |                 |
|                                                        |            |                     |    |                                                                                                                                                                                                                               |      | Navigating Chronic Pain: Insights into Brain Impact and Coping Strategies | 10:45 | 11:00 | Speaker | Lars     | Arendt-Nielsen  |
|                                                        |            |                     |    |                                                                                                                                                                                                                               |      | Q&A and Closing                                                           | 11:40 | 11:45 | Speaker | Jeanette | Andersen        |
|                                                        |            |                     |    |                                                                                                                                                                                                                               |      | Fighting loneliness with a rheumatic disease                              | 11:15 | 11:30 | Speaker | Corinna  | Elling-Audersch |
|                                                        |            |                     |    |                                                                                                                                                                                                                               |      | GRASP and tRi: support to the RMD                                         | 11:00 | 11:15 | Speaker | Franklin | Hiagbe          |

|                                                 |            |                     |            |                                                                                                                                                                                   |                   |                                                         |       |       |         |              |            |
|-------------------------------------------------|------------|---------------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|---------------------------------------------------------|-------|-------|---------|--------------|------------|
|                                                 |            |                     |            | people with RMD.                                                                                                                                                                  |                   | community in Ghana                                      |       |       |         |              |            |
|                                                 |            |                     |            |                                                                                                                                                                                   |                   | Connecting the Dots: Inflammation and Mental Health     | 10:30 | 10:45 | Speaker | Vasco        | Medeiros   |
|                                                 |            |                     |            |                                                                                                                                                                                   |                   |                                                         |       |       | Chair   | Peter        | Böhm       |
|                                                 |            |                     |            |                                                                                                                                                                                   |                   |                                                         |       |       | Chair   | Jeanette     | Andersen   |
| Crystal identification, synovial fluid analysis | 12/06/2025 | 10:30:00 - 11:45:00 | Hands-On 2 | This session will help delegates to know: 1. When to perform a synovial fluid analysis;2. How to perform a synovial fluid analysis;3. How to interpret a synovial fluid analysis. | Hands-on Sessions | Crystal characteristics and detection in synovial fluid | 10:30 | 10:45 | Speaker | Anne-Kathrin | Tausche    |
|                                                 |            |                     |            |                                                                                                                                                                                   |                   | Hands-on stations                                       | 11:05 | 11:45 | Speaker | Anne-Kathrin | Tausche    |
|                                                 |            |                     |            |                                                                                                                                                                                   |                   | When is Synovial Fluid analysis recommended?            | 10:45 | 11:00 | Speaker | Francisca    | Sivera     |
|                                                 |            |                     |            |                                                                                                                                                                                   |                   | Discussion on presentations                             | 11:00 | 11:05 | Speaker | Abhishek     | Abhishek   |
|                                                 |            |                     |            |                                                                                                                                                                                   |                   |                                                         |       |       | Chair   | Abhishek     | Abhishek   |
|                                                 |            |                     |            |                                                                                                                                                                                   |                   |                                                         |       |       | Chair   | Thomas       | Schneidert |
| How to evaluate larger joints: the              | 12/06/2025 | 10:30:00 - 11:45:00 | Hands-On 1 | 1. Assessment of ankle and the knee joints by physical                                                                                                                            | Hands-on Sessions | Discussion on presentations                             | 10:50 | 10:55 | Speaker |              |            |

|                             |            |                     |         |                                                                                                                                                   |                    |                                                                        |       |       |         |              |           |
|-----------------------------|------------|---------------------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------------------------------------------------------------------|-------|-------|---------|--------------|-----------|
| ankle and knee              |            |                     |         | examination;2. Assessment of the ankle and the knee joints by ultrasound;3. How to integrate and correlate clinical and ultrasonography findings. |                    | How to access the knee: clinical examination                           | 10:40 | 10:45 | Speaker | Rusmir       | Husic     |
|                             |            |                     |         |                                                                                                                                                   |                    | How to access the ankle: clinical examination                          | 10:30 | 10:35 | Speaker | Giasna       | Giokic    |
|                             |            |                     |         |                                                                                                                                                   |                    | Hands-on Session                                                       | 10:55 | 11:45 | Speaker | Giasna       | Giokic    |
|                             |            |                     |         |                                                                                                                                                   |                    | How to access the knee: ultrasonography examination                    | 10:45 | 10:50 | Speaker | Daniela      | Fodor     |
|                             |            |                     |         |                                                                                                                                                   |                    | How to access the ankle: ultrasonography examination                   | 10:35 | 10:40 | Speaker | Esperanza    | Naredo    |
|                             |            |                     |         |                                                                                                                                                   |                    |                                                                        |       |       | Chair   | Zunaid       | Karim     |
|                             |            |                     |         |                                                                                                                                                   |                    |                                                                        |       |       | Chair   | David Andrew | Bong      |
| Erosive hand osteoarthritis | 12/06/2025 | 11:15:00 - 12:00:00 | Plenary | This session will concentrate on the best practices for managing erosive hand osteoarthritis, including:1.                                        | How to Treat (HOT) | Innovative strategies in the management of erosive hand osteoarthritis | 11:15 | 12:00 | Speaker | Cosimo       | De Bari   |
|                             |            |                     |         |                                                                                                                                                   |                    |                                                                        |       |       | Chair   | Zoltán       | Szekanecz |

|                                                                        |            |                     |                   |                                                                                                                                                                                                                                                                                                                                                                        |                       |                                                                        |       |       |         |          |              |
|------------------------------------------------------------------------|------------|---------------------|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|------------------------------------------------------------------------|-------|-------|---------|----------|--------------|
|                                                                        |            |                     |                   | Accurate disease diagnosis <sup>2</sup> . Appropriate application of systemic treatment options                                                                                                                                                                                                                                                                        |                       |                                                                        |       |       | Chair   | Margreet | Kloppenburg  |
| Fertility, pregnancy and lactation in patients with rheumatic diseases | 12/06/2025 | 13:15:00 - 13:45:00 | Meet the Expert 3 | To understand the challenges associated with conception/fertility, pregnancy and lactation in patients with RMDs:1. To understand the most critical points in fertility and pregnancy counseling;2. to understand the most critical points in patient management around delivery;3. to understand where patients with RMDs might face problems in the lactation phase. | Meet the EULAR Expert | Fertility, pregnancy and lactation in patients with rheumatic diseases | 13:15 | 13:45 | Speaker | Rebecca  | Fischer-Betz |

|                                                  |            |                     |                   |                                                                                                                                                                                                                                                  |                       |                                                  |       |       |         |       |                 |
|--------------------------------------------------|------------|---------------------|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|--------------------------------------------------|-------|-------|---------|-------|-----------------|
| Management of Uveitis in childhood               | 12/06/2025 | 13:15:00 - 13:45:00 | Meet the Expert 1 | 1. Understanding the presentation and management of uveitis 2. What are the challenges in Children 3. How to ensure tight monitoring 4. What outcome measures are available 5. Drug Choices                                                      | Meet the EULAR Expert | Management of Uveitis in childhood               | 13:15 | 13:45 | Speaker | Lola  | Solebo          |
| Management of vasculopathy in Systemic Sclerosis | 12/06/2025 | 13:15:00 - 13:45:00 | Meet the Expert 2 | 1. To describe the different clinical features of the vascular involvement in systemic sclerosis 2. To provide clues and pearls for an early diagnosis 3. To explain the treatment of the different vascular complications in systemic sclerosis | Meet the EULAR Expert | Management of vasculopathy in systemic sclerosis | 13:15 | 13:45 | Speaker | Marco | Matucci-Cerinic |

|                                                         |            |                     |                   |                                                                                                                                                                                                                                                                                                                                          |                       |                                                         |       |       |         |              |         |
|---------------------------------------------------------|------------|---------------------|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|---------------------------------------------------------|-------|-------|---------|--------------|---------|
| Use of Biologics in patients with chronic liver disease | 12/06/2025 | 13:15:00 - 13:45:00 | Meet the Expert 4 | Learn about the interaction and overlap with rheumatological disease and what to expect (IBD, chronic hepatitis, autoimmune hepatitis)1. what to consider in pat with chronic liver disease and a newly diagnosed RMD;2. what to do if in a patient with RMD liver values start to rise;3. what to do as screening in patients with RMD. | Meet the EULAR Expert | Use of Biologics in patients with chronic liver disease | 13:15 | 13:45 | Speaker | tbc          | tbc     |
| Crystal identification, synovial fluid analysis         | 12/06/2025 | 13:30:00 - 14:45:00 | Hands-On 2        | This session will help delegates to know:1. When to perform a synovial fluid analysis;2. How                                                                                                                                                                                                                                             | Hands-on Sessions     | Crystal characteristics and detection in synovial fluid | 13:30 | 13:45 | Speaker | Anne-Kathrin | Tausche |
|                                                         |            |                     |                   |                                                                                                                                                                                                                                                                                                                                          |                       | Hands-on stations                                       | 14:05 | 14:45 | Speaker | Anne-Kathrin | Tausche |

|                                                    |            |                     |    |                                                                                                                                                                                                                                                     |                         |                                                  |       |       |         |           |            |
|----------------------------------------------------|------------|---------------------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|--------------------------------------------------|-------|-------|---------|-----------|------------|
|                                                    |            |                     |    | to perform a synovial fluid analysis;3. How to interpret a synovial fluid analysis.                                                                                                                                                                 |                         | When is Synovial Fluid analysis recommended?     | 13:45 | 14:00 | Speaker | Francisca | Sivera     |
|                                                    |            |                     |    |                                                                                                                                                                                                                                                     |                         | Discussion on presentations                      | 14:00 | 14:05 | Speaker | Abhishek  | Abhishek   |
|                                                    |            |                     |    |                                                                                                                                                                                                                                                     |                         |                                                  |       |       | Chair   | Abhishek  | Abhishek   |
|                                                    |            |                     |    |                                                                                                                                                                                                                                                     |                         |                                                  |       |       | Chair   | Thomas    | Schneidert |
| Dendritic Cells - orchestrators of tissue immunity | 12/06/2025 | 13:30:00 - 14:45:00 | A3 | 1. To hear about physiological functions and pathological changes of dendritic cells2. To learn about specific subtypes of dendritic cells and their specialised functions3. To learn how dendritic cell functions can be exploited therapeutically | Basic and Translational | Oral Abstract Presentation                       | 14:30 | 14:40 | Speaker |           |            |
|                                                    |            |                     |    |                                                                                                                                                                                                                                                     |                         | Dendritic cells and tolerizing immunotherapy     | 14:25 | 14:30 | Speaker | Ranjeny   | Thomas     |
|                                                    |            |                     |    |                                                                                                                                                                                                                                                     |                         | Dendritic cells and tolerizing immunotherapy     | 14:10 | 14:25 | Speaker | Ranjeny   | Thomas     |
|                                                    |            |                     |    |                                                                                                                                                                                                                                                     |                         | Changes in dendritic cell function during ageing | 13:30 | 13:45 | Speaker | Stefanie  | Wculek     |
|                                                    |            |                     |    |                                                                                                                                                                                                                                                     |                         | Changes in dendritic cell function               | 13:45 | 13:50 | Speaker | Stefanie  | Wculek     |
|                                                    |            |                     |    |                                                                                                                                                                                                                                                     |                         |                                                  |       |       |         |           |            |

|                                                                              |            |                     |     |                                                                                                                                                                                                                          |                       |                                                         |       |       |         |           |                    |
|------------------------------------------------------------------------------|------------|---------------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|---------------------------------------------------------|-------|-------|---------|-----------|--------------------|
|                                                                              |            |                     |     |                                                                                                                                                                                                                          |                       | during ageing                                           |       |       |         |           |                    |
|                                                                              |            |                     |     |                                                                                                                                                                                                                          |                       | Dendritic cells in Rheumatoid Arthritis synovial tissue | 13:50 | 14:05 | Speaker | Mariola   | Kurowska-Stolarska |
|                                                                              |            |                     |     |                                                                                                                                                                                                                          |                       | Dendritic cells in Rheumatoid Arthritis synovial tissue | 14:05 | 14:10 | Speaker | Mariola   | Kurowska-Stolarska |
|                                                                              |            |                     |     |                                                                                                                                                                                                                          |                       |                                                         |       |       | Chair   | Mary      | Canavan            |
|                                                                              |            |                     |     |                                                                                                                                                                                                                          |                       |                                                         |       |       | Chair   | Stephan   | Blüml              |
| Ehlers-Danlos Syndrome and hypermobility - from patients to bench to bedside | 12/06/2025 | 13:30:00 - 14:50:00 | 6.4 | 1. To hear about missing needs in Ehlers-Danlos research;2. To learn about pathogenic pathways in Ehlers-Danlos-Syndrome;3. To learn about the needs and clinical management of people with Ehlers-Danlos-Syndrome;4. To | From Bench to Bedside | Pathogenic pathways of Ehlers-Danlos-Syndrome           | 13:50 | 13:55 | Speaker | Fransiska | Malfait            |
|                                                                              |            |                     |     |                                                                                                                                                                                                                          |                       | Pathogenic pathways of Ehlers-Danlos-Syndrome           | 13:35 | 13:50 | Speaker | Fransiska | Malfait            |
|                                                                              |            |                     |     |                                                                                                                                                                                                                          |                       | Introduction                                            | 13:30 | 13:35 | Speaker | Karina    | Sturm              |
|                                                                              |            |                     |     |                                                                                                                                                                                                                          |                       | Diagnostics, therapies and co-morbidities in Ehlers-    | 14:35 | 14:40 | Speaker | Aylin     | Canbek             |

|                                                |            |                     |    |                                                                                                               |                       |                                                                          |       |       |         |              |          |
|------------------------------------------------|------------|---------------------|----|---------------------------------------------------------------------------------------------------------------|-----------------------|--------------------------------------------------------------------------|-------|-------|---------|--------------|----------|
|                                                |            |                     |    | be informed about red flags and typical signs of Ehlers-Danlos-Syndrome to look out for in clinical practice. |                       | Danlos-Syndrome                                                          |       |       |         |              |          |
|                                                |            |                     |    |                                                                                                               |                       | Diagnostics, therapies and co-morbidities in Ehlers-Danlos-Syndrome      | 14:15 | 14:35 | Speaker | Aylin        | Canbek   |
|                                                |            |                     |    |                                                                                                               |                       | Closing                                                                  | 14:40 | 14:45 | Speaker | Alan         | Hakim    |
|                                                |            |                     |    |                                                                                                               |                       | Mast cell activation and hypermobile syndromes: How do they go together? | 14:10 | 14:15 | Speaker | Anne         | Maitland |
|                                                |            |                     |    |                                                                                                               |                       | Mast cell activation and hypermobile syndromes: How do they go together? | 13:55 | 14:10 | Speaker | Anne         | Maitland |
|                                                |            |                     |    |                                                                                                               |                       |                                                                          |       |       | Chair   | Karina       | Sturm    |
|                                                |            |                     |    |                                                                                                               |                       |                                                                          |       |       | Chair   | Alan         | Hakim    |
| Enthesitis in PsA, from disease development to | 12/06/2025 | 13:30:00 - 14:45:00 | F3 | 1. To learn what are the initial triggers of enthesitis in PsA; 2. To understand                              | From Bench to Bedside | Oral Abstract Presentation                                               | 14:30 | 14:40 | Speaker |              |          |
|                                                |            |                     |    |                                                                                                               |                       | Novel therapeutic target in PsA enthesitis                               | 14:25 | 14:30 | Speaker | Maria Simona | Stoenoiu |

|                              |  |  |  |                                                                                                                                       |  |                                                                                                           |       |       |         |              |          |
|------------------------------|--|--|--|---------------------------------------------------------------------------------------------------------------------------------------|--|-----------------------------------------------------------------------------------------------------------|-------|-------|---------|--------------|----------|
| specific therapeutic targets |  |  |  | how inflammation in PsA involved other structures beyond entheses;3. To learn about novel treatment approaches for enthesitis in PsA. |  | Novel therapeutic target in PsA enthesitis                                                                | 14:10 | 14:25 | Speaker | Maria Simona | Stoenoiu |
|                              |  |  |  |                                                                                                                                       |  | Perpetuation and extension of enthesitic inflammation towards other structures in PsA                     | 14:05 | 14:10 | Speaker | Andreas      | Ramming  |
|                              |  |  |  |                                                                                                                                       |  | Perpetuation and extension of enthesitic inflammation towards other structures in PsA                     | 13:50 | 14:05 | Speaker | Andreas      | Ramming  |
|                              |  |  |  |                                                                                                                                       |  | The transition from normal to inflammation , triggers and mechanistic steps in PsA enthesitis development | 13:45 | 13:50 | Speaker | Francesco    | Ciccia   |

|                                                                                            |            |                     |     |                                                                                                                                                                                                                                                    |                  |                                                                                                           |       |       |         |           |              |
|--------------------------------------------------------------------------------------------|------------|---------------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|-----------------------------------------------------------------------------------------------------------|-------|-------|---------|-----------|--------------|
|                                                                                            |            |                     |     |                                                                                                                                                                                                                                                    |                  | The transition from normal to inflammation , triggers and mechanistic steps in PsA enthesitis development | 13:30 | 13:45 | Speaker | Francesco | Ciccia       |
|                                                                                            |            |                     |     |                                                                                                                                                                                                                                                    |                  | Closing                                                                                                   | 14:40 | 14:45 | Speaker | Dennis    | McGonagle    |
|                                                                                            |            |                     |     |                                                                                                                                                                                                                                                    |                  |                                                                                                           |       |       | Chair   | Dennis    | McGonagle    |
|                                                                                            |            |                     |     |                                                                                                                                                                                                                                                    |                  |                                                                                                           |       |       | Chair   | Merete    | Lund Hetland |
| Gaslighting and Unconscious Bias in Rheumatology: An Inter- and intra-professional problem | 12/06/2025 | 13:30:00 - 14:45:00 | 6.2 | Gaslighting is a form of psychological influence where a person causes someone to question their perception of reality. People who experience gaslighting may feel confused, anxious, or unable to trust themselves. This can happen to healthcare | Clinical Science | Cultural prejudices in healthcare in Europe                                                               | 13:50 | 14:10 | Speaker | tbc       | tbc          |
|                                                                                            |            |                     |     |                                                                                                                                                                                                                                                    |                  | Discussion and Closing                                                                                    | 14:30 | 14:45 | Speaker | Eric      | Morand       |
|                                                                                            |            |                     |     |                                                                                                                                                                                                                                                    |                  | Imposter syndrome, race, and gender                                                                       | 13:30 | 13:50 | Speaker | Puja      | Mehta        |
|                                                                                            |            |                     |     |                                                                                                                                                                                                                                                    |                  | Gaslighting the patient: are we culpable?                                                                 | 14:10 | 14:30 | Speaker | Caitjan   | Gainty       |
|                                                                                            |            |                     |     |                                                                                                                                                                                                                                                    |                  |                                                                                                           |       |       | Chair   | Eric      | Morand       |
|                                                                                            |            |                     |     |                                                                                                                                                                                                                                                    |                  |                                                                                                           |       |       | Chair   | Grainne   | O Leary      |

|  |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                                        |  |  |  |  |  |  |  |
|--|--|--|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|--|--|--|--|
|  |  |  |  | <p>professionals as well as patients, especially due to unconscious bias. 1. Imposter syndrome is the state of feeling one is insufficiently qualified for the task you are doing. Understand how this common perception can be the effect of external factors;2. Cultural prejudices are common in society, and medicine is no exception. Understand how these can impact on the self and careers; 3. Gaslighting of patients can</p> |  |  |  |  |  |  |  |
|--|--|--|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|--|--|--|--|

|                                                   |            |                     |            |                                                                                                                                                                                                                                                             |                   |                                               |       |       |         |        |        |
|---------------------------------------------------|------------|---------------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-----------------------------------------------|-------|-------|---------|--------|--------|
|                                                   |            |                     |            | happen when their beliefs are dismissed, resulting in a loss of trust. This needs to be better understood by healthcare professionals in order to be minimised; 4. Understand how unconscious bias impact on the work and lives of clinicians and patients. |                   |                                               |       |       |         |        |        |
| How to evaluate larger joints: the ankle and knee | 12/06/2025 | 13:30:00 - 14:45:00 | Hands-On 1 | 1. Assessment of ankle and the knee joints by physical examination; 2. Assessment of the ankle and the knee joints by ultrasound; 3. How to integrate and correlate                                                                                         | Hands-on Sessions | Discussion on presentations                   | 13:50 | 13:55 | Speaker |        |        |
|                                                   |            |                     |            |                                                                                                                                                                                                                                                             |                   | How to access the knee: clinical examination  | 13:40 | 13:45 | Speaker | Rusmir | Husic  |
|                                                   |            |                     |            |                                                                                                                                                                                                                                                             |                   | How to access the ankle: clinical examination | 13:30 | 13:35 | Speaker | Giasna | Giokic |

|                                                |            |                     |    |                                                                                                                                                                                                                                 |                  |                                                       |       |       |         |              |            |
|------------------------------------------------|------------|---------------------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|-------------------------------------------------------|-------|-------|---------|--------------|------------|
|                                                |            |                     |    | clinical and ultrasonography findings.                                                                                                                                                                                          |                  | Hands-on stations                                     | 13:55 | 14:45 | Speaker | Giasna       | Giokic     |
|                                                |            |                     |    |                                                                                                                                                                                                                                 |                  | How to access the knee: ultrasonography examination   | 13:45 | 13:50 | Speaker | Daniela      | Fodor      |
|                                                |            |                     |    |                                                                                                                                                                                                                                 |                  | How to access the ankle: ultrasonography examination  | 13:35 | 13:40 | Speaker | Esperanza    | Naredo     |
|                                                |            |                     |    |                                                                                                                                                                                                                                 |                  |                                                       |       |       | Chair   | Zunaid       | Karim      |
|                                                |            |                     |    |                                                                                                                                                                                                                                 |                  |                                                       |       |       | Chair   | David Andrew | Bong       |
| JAK it out! New perspectives on JAK inhibitors | 12/06/2025 | 13:30:00 - 14:45:00 | D1 | 1. To learn about novel indications of JAK inhibitors beyond arthritis;2. To learn about the safety of JAK inhibitors with regard to infections and malignancy;3. To discuss the future role of JAK inhibitors in rheumatology. | Clinical Science | Oral Abstract Presentation                            | 14:35 | 14:45 | Speaker |              |            |
|                                                |            |                     |    |                                                                                                                                                                                                                                 |                  | JAKs and infections - better or worse than biologics? | 14:30 | 14:35 | Speaker | David        | Liew       |
|                                                |            |                     |    |                                                                                                                                                                                                                                 |                  | JAKs and infections - better or worse than biologics? | 14:15 | 14:30 | Speaker | David        | Liew       |
|                                                |            |                     |    |                                                                                                                                                                                                                                 |                  | JAKs - new hope for treatment of RMD beyond arthritis | 13:30 | 13:50 | Speaker | Andreas      | Kerschbaum |

|                                                            |            |                     |    |                                                                                                                                                                                                                                                            |                          |                                                                       |       |       |         |         |               |
|------------------------------------------------------------|------------|---------------------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|-----------------------------------------------------------------------|-------|-------|---------|---------|---------------|
|                                                            |            |                     |    |                                                                                                                                                                                                                                                            |                          | JAKs - new hope for treatment of RMD beyond arthritis                 | 13:50 | 13:55 | Speaker | Andreas | Kerschbauer   |
|                                                            |            |                     |    |                                                                                                                                                                                                                                                            |                          | JAKs and malignancy - is it really a big deal?                        | 14:10 | 14:15 | Speaker | Kim     | Lauper        |
|                                                            |            |                     |    |                                                                                                                                                                                                                                                            |                          | JAKs and malignancy - is it really a big deal?                        | 13:55 | 14:10 | Speaker | Kim     | Lauper        |
|                                                            |            |                     |    |                                                                                                                                                                                                                                                            |                          |                                                                       |       |       | Chair   | Rudresh | Shukla        |
|                                                            |            |                     |    |                                                                                                                                                                                                                                                            |                          |                                                                       |       |       | Chair   | Roba    | Ghossan       |
| Kidney biopsy in connective tissue diseases and vasculitis | 12/06/2025 | 13:30:00 - 14:45:00 | B4 | By the end of this session, participants will: 1. explore the role and findings of kidney biopsy in connective tissue diseases; 2. assess the diagnostic value of kidney biopsy in the management of vasculitis; 3. gain practical experience and insights | Practical Skills Lecture | Kidney biopsy in vasculitis                                           | 13:45 | 13:55 | Speaker | Beatriz | Sanchez-Alamo |
|                                                            |            |                     |    |                                                                                                                                                                                                                                                            |                          | Kidney biopsy in vasculitis                                           | 13:55 | 14:00 | Speaker | Beatriz | Sanchez-Alamo |
|                                                            |            |                     |    |                                                                                                                                                                                                                                                            |                          | Kidney biopsy in lupus nephritis and other connective tissue diseases | 13:30 | 13:40 | Speaker | Myrto   | Kostopoulou   |
|                                                            |            |                     |    |                                                                                                                                                                                                                                                            |                          | Kidney biopsy in lupus nephritis and other                            | 13:40 | 13:45 | Speaker | Myrto   | Kostopoulou   |

|                                                      |            |                     |    |                                                                                                                                                                                                                                                            |      |                                                           |       |       |         |               |          |  |
|------------------------------------------------------|------------|---------------------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------------------------------------------------------|-------|-------|---------|---------------|----------|--|
|                                                      |            |                     |    | through hands-off practice with kidney biopsy specimens.                                                                                                                                                                                                   |      | connective tissue diseases                                |       |       |         |               |          |  |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                            |      | Hands-off practice based on 10 kidney biopsy specimens    | 14:00 | 14:45 | Speaker | Ingeborg      | Bajema   |  |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                            |      |                                                           |       |       | Chair   | Gabriella     | Moroni   |  |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                            |      |                                                           |       |       | Chair   | Ioannis       | Parodis  |  |
| Let's talk about relationships – conception to birth | 12/06/2025 | 13:30:00 - 14:45:00 | C3 | 1. The session will showcase the issues affecting those with RMDs at every stage of their relationship. 2. Speakers will discuss disclosure, sexual relationships and family planning. 3. Delegates will learn how to discuss and handle these challenges. | PARE | Oral Abstract Presentation                                | 14:15 | 14:25 | Speaker |               |          |  |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                            |      | Oral Abstract Presentation                                | 14:25 | 14:35 | Speaker |               |          |  |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                            |      | Debate and Closing                                        | 14:35 | 14:45 | Speaker | Jeanette      | Andersen |  |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                            |      | Medical Treatment and Psychology during Pregnancy         | 14:00 | 14:15 | Speaker | Louise        | Moore    |  |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                            |      | Embracing Intimacy: Men's Perspective on Living with RMDs | 13:30 | 13:45 | Speaker | Luis Fernando | Perez    |  |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                            |      | From Struggle to Strength: Insights on Pregnancy          | 13:45 | 14:00 | Speaker | Silvia        | Aguilera |  |

|                                      |                |                        |     |                                                                                                                                                                                                                                                                                                                                       |                             |                                                                                                        |       |       |             |          |                      |
|--------------------------------------|----------------|------------------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|--------------------------------------------------------------------------------------------------------|-------|-------|-------------|----------|----------------------|
|                                      |                |                        |     |                                                                                                                                                                                                                                                                                                                                       |                             | and Relationship<br>s with an<br>RMD                                                                   |       |       |             |          |                      |
|                                      |                |                        |     |                                                                                                                                                                                                                                                                                                                                       |                             |                                                                                                        |       |       | Chair       | Peter    | Boyd                 |
|                                      |                |                        |     |                                                                                                                                                                                                                                                                                                                                       |                             |                                                                                                        |       |       | Chair       | Jeanette | Andersen             |
| Macrophage<br>activation<br>syndrome | 12/06/<br>2025 | 13:30:00 -<br>14:45:00 | 6.3 | 1. To highlight<br>the latest<br>advances in<br>pathogenic<br>mechanisms of<br>disease;2. To<br>provide the<br>basis to<br>discuss clinical<br>features,<br>including the<br>difficulties of<br>differential<br>diagnoses;3. To<br>know the most<br>modern<br>therapeutic<br>strategies in<br>the<br>management of<br>these patients. | From<br>Bench to<br>Bedside | Differential<br>diagnoses<br>and<br>macrophage<br>activation<br>syndrome-<br>like clinical<br>picture  | 13:55 | 14:15 | Spea<br>ker | Sophie   | Georgin-<br>Lavialle |
|                                      |                |                        |     |                                                                                                                                                                                                                                                                                                                                       |                             | Differential<br>diagnoses<br>and<br>macrophage<br>activation<br>syndrome-<br>like clinical<br>picture  | 14:15 | 14:20 | Spea<br>ker | Sophie   | Georgin-<br>Lavialle |
|                                      |                |                        |     |                                                                                                                                                                                                                                                                                                                                       |                             | Advances in<br>the<br>understandin<br>g of<br>macrophage<br>activation<br>syndrome<br>pathogenesi<br>s | 13:50 | 13:55 | Spea<br>ker | Fabrizio | De<br>Benedetti      |
|                                      |                |                        |     |                                                                                                                                                                                                                                                                                                                                       |                             | Advances in<br>the<br>understandin                                                                     | 13:30 | 13:50 | Spea<br>ker | Fabrizio | De<br>Benedetti      |

|                                                                                        |                |                        |    |                                                                                                                                                 |                                           |                                                                            |       |       |             |         |         |
|----------------------------------------------------------------------------------------|----------------|------------------------|----|-------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|----------------------------------------------------------------------------|-------|-------|-------------|---------|---------|
|                                                                                        |                |                        |    |                                                                                                                                                 |                                           | g of<br>macrophage<br>activation<br>syndrome<br>pathogenesi<br>s           |       |       |             |         |         |
|                                                                                        |                |                        |    |                                                                                                                                                 |                                           | Advances in<br>the<br>treatment of<br>macrophage<br>activation<br>syndrome | 14:20 | 14:40 | Spea<br>ker | Jessica | Manson  |
|                                                                                        |                |                        |    |                                                                                                                                                 |                                           | Advances in<br>the<br>treatment of<br>macrophage<br>activation<br>syndrome | 14:40 | 14:45 | Spea<br>ker | Jessica | Manson  |
|                                                                                        |                |                        |    |                                                                                                                                                 |                                           |                                                                            |       |       | Chair       | Tadej   | Avcin   |
|                                                                                        |                |                        |    |                                                                                                                                                 |                                           |                                                                            |       |       | Chair       | Cem     | Gabay   |
| Managing<br>life-<br>threateni<br>ng<br>manifesta<br>tions in<br>systemic<br>sclerosis | 12/06/<br>2025 | 13:30:00 -<br>14:45:00 | A2 | 1. Learn how to<br>diagnose and<br>treat<br>Scleroderma<br>cardiac crisis;2.<br>Learn how to<br>manage<br>Scleroderma<br>renal crisis<br>(SRC). | Challenge<br>s in<br>Clinical<br>Practice | Scleroderma<br>renal crisis<br>(case<br>presentation)                      | 14:05 | 14:15 | Spea<br>ker |         |         |
|                                                                                        |                |                        |    |                                                                                                                                                 |                                           | Scleroderma<br>cardiac crisis<br>(case<br>presentation)                    | 13:30 | 13:40 | Spea<br>ker |         |         |
|                                                                                        |                |                        |    |                                                                                                                                                 |                                           | How to<br>diagnose<br>and treat<br>Scleroderma<br>cardiac crisis           | 13:40 | 14:00 | Spea<br>ker | Luc     | Mouthon |

|                                                                                            |            |                     |    |                                                                                                                                                                                     |                                            |                                                                                |       |       |         |         |                |
|--------------------------------------------------------------------------------------------|------------|---------------------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|--------------------------------------------------------------------------------|-------|-------|---------|---------|----------------|
|                                                                                            |            |                     |    |                                                                                                                                                                                     |                                            | How to diagnose and treat Scleroderma cardiac crisis                           | 14:00 | 14:05 | Speaker | Luc     | Mouthon        |
|                                                                                            |            |                     |    |                                                                                                                                                                                     |                                            | How to diagnose and treat Scleroderma renal crisis                             | 14:35 | 14:40 | Speaker | Madelon | Vonk           |
|                                                                                            |            |                     |    |                                                                                                                                                                                     |                                            | Debate and Closing                                                             | 14:40 | 14:45 | Speaker | Julia   | Spierings      |
|                                                                                            |            |                     |    |                                                                                                                                                                                     |                                            | How to diagnose and treat Scleroderma renal crisis                             | 14:15 | 14:35 | Speaker | Madelon | Vonk           |
|                                                                                            |            |                     |    |                                                                                                                                                                                     |                                            |                                                                                |       |       | Chair   | Otylia  | Kowal Bielecka |
|                                                                                            |            |                     |    |                                                                                                                                                                                     |                                            |                                                                                |       |       | Chair   | Julia   | Spierings      |
| Navigating the field of osteoarthritis: American and European interprofessional approaches | 12/06/2025 | 13:30:00 - 14:45:00 | C1 | 1. To recall the current burden of osteoarthritis (OA), including risk factors for hand, back, knee, hip, and foot problems; 2. To describe current interventions being utilised in | Health Professionals in Rheumatology (HPR) | Oral Abstract Presentation                                                     | 14:20 | 14:30 | Speaker |         |                |
|                                                                                            |            |                     |    |                                                                                                                                                                                     |                                            | Q&A and Closing                                                                | 14:30 | 14:45 | Speaker | Erika   | Mosor          |
|                                                                                            |            |                     |    |                                                                                                                                                                                     |                                            | Introduction                                                                   | 13:30 | 13:35 | Speaker | Erika   | Mosor          |
|                                                                                            |            |                     |    |                                                                                                                                                                                     |                                            | New paths and potential game changers for the future osteoarthritis management | 14:05 | 14:20 | Speaker | Ali     | Mobasheri      |

|                                                                           |            |                     |    |                                                                                                                                                                                                    |                       |                                                                                                        |       |       |         |           |           |
|---------------------------------------------------------------------------|------------|---------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|--------------------------------------------------------------------------------------------------------|-------|-------|---------|-----------|-----------|
|                                                                           |            |                     |    | America and Europe to mitigate the burden of OA;3. To discuss what we can learn from each other and ideas on how the future field of OA may look.                                                  |                       | and treatment                                                                                          |       |       |         |           |           |
|                                                                           |            |                     |    |                                                                                                                                                                                                    |                       | The right care at the right time                                                                       | 13:50 | 14:05 | Speaker | Nina      | Østerås   |
|                                                                           |            |                     |    |                                                                                                                                                                                                    |                       | How to prevent the development and progression of osteoarthritis and decrease the burden in daily life | 13:35 | 13:50 | Speaker | Aileen    | Ledingham |
|                                                                           |            |                     |    |                                                                                                                                                                                                    |                       |                                                                                                        |       |       | Chair   | Erika     | Mosor     |
|                                                                           |            |                     |    |                                                                                                                                                                                                    |                       |                                                                                                        |       |       | Chair   | Ingrid    | de Groot  |
| Obesity and it's impact on pathophysiology, clinic, and treatment of RMDs | 12/06/2025 | 13:30:00 - 14:45:00 | F1 | 1. To learn about the role of adipose tissue in inflammation;2. To understand how adipose tissue may impact disease processes in rheumatic diseases;3. To learn about the influence of obesity and | From Bench to Bedside | Adipose tissue as an inflammatory organ                                                                | 13:30 | 13:45 | Speaker | tbc       | tbc       |
|                                                                           |            |                     |    |                                                                                                                                                                                                    |                       | Oral Abstract Presentation                                                                             | 14:15 | 14:25 | Speaker |           |           |
|                                                                           |            |                     |    |                                                                                                                                                                                                    |                       | The impact of body weight (and weight-loss) on treatment outcomes                                      | 14:00 | 14:15 | Speaker | George E. | Fragoulis |
|                                                                           |            |                     |    |                                                                                                                                                                                                    |                       | Mechanistic links between                                                                              | 13:45 | 14:00 | Speaker | Cristina  | Maglio    |

|                                               |            |                     |    |                                                                                                                                                                                                                                                                                                                |                         |                                                                                                         |       |       |         |                |           |
|-----------------------------------------------|------------|---------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|---------------------------------------------------------------------------------------------------------|-------|-------|---------|----------------|-----------|
|                                               |            |                     |    | weight-loss treatment on outcomes in rheumatic diseases.                                                                                                                                                                                                                                                       |                         | adipose tissue and pathophysiology of rheumatic diseases                                                |       |       |         |                |           |
|                                               |            |                     |    |                                                                                                                                                                                                                                                                                                                |                         | Q&A and Closing                                                                                         | 14:25 | 14:40 | Speaker | William        | Tillett   |
|                                               |            |                     |    |                                                                                                                                                                                                                                                                                                                |                         |                                                                                                         |       |       | Chair   | William        | Tillett   |
|                                               |            |                     |    |                                                                                                                                                                                                                                                                                                                |                         |                                                                                                         |       |       | Chair   | Elena          | Neumann   |
| Precision Medicine in RA: let's use Genetics! | 12/06/2025 | 13:30:00 - 14:45:00 | A1 | This session will focus on the applications of polygenic risk scores (PRS) as clinical tools to support diagnostic and prognostic procedures. Specifically you will learn about: 1. disease stratification based on genetics; 2. the role of genetics in evaluating disease risk; 3. what genetics can tell us | Basic and Translational | Genetics to improve disease stratification in rheumatology                                              | 13:30 | 13:45 | Speaker | Rachel         | Knevel    |
|                                               |            |                     |    |                                                                                                                                                                                                                                                                                                                |                         | Genetics of osteoarthritis : towards clinical applications                                              | 14:00 | 14:15 | Speaker | Joyce          | Van Meurs |
|                                               |            |                     |    |                                                                                                                                                                                                                                                                                                                |                         | Polygenic risk scores to predict complications in juvenile idiopathic arthritis and psoriatic arthritis | 13:45 | 14:00 | Speaker | John           | Bowes     |
|                                               |            |                     |    |                                                                                                                                                                                                                                                                                                                |                         | Mendelian randomisation to provide                                                                      | 14:15 | 14:30 | Speaker | Sizheng Steven | Zhao      |

|                                        |            |                     |    |                                                                                                                                                                                                                                                               |                   |                                                                          |       |       |         |                 |                 |
|----------------------------------------|------------|---------------------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|--------------------------------------------------------------------------|-------|-------|---------|-----------------|-----------------|
|                                        |            |                     |    | about drug safety                                                                                                                                                                                                                                             |                   | insight into drug safety and repurposing in rheumatic diseases           |       |       |         |                 |                 |
|                                        |            |                     |    |                                                                                                                                                                                                                                                               |                   | Debate and Closing                                                       | 14:30 | 14:45 | Speaker | Sebastien       | Viatte          |
|                                        |            |                     |    |                                                                                                                                                                                                                                                               |                   |                                                                          |       |       | Chair   | Sytske Anne     | Bergstra        |
|                                        |            |                     |    |                                                                                                                                                                                                                                                               |                   |                                                                          |       |       | Chair   | Sebastien       | Viatte          |
| Rheumatology training around the Globe | 12/06/2025 | 13:30:00 - 14:45:00 | B1 | The “Rheumatology around the Globe” session aims to provide a comprehensive understanding of rheumatology training and the activities of young societies across various continents, including the US, South/Middle America, Africa, Asia Pacific, and Europe. | EMEUNE T Presents | Rheumatology training in the PanAmerican region and role of PANLAR Joven | 14:05 | 14:20 | Speaker | Wilson          | Bautista-Molano |
|                                        |            |                     |    |                                                                                                                                                                                                                                                               |                   | Rheumatology training in Africa and forming a young AFLAR network        | 14:20 | 14:35 | Speaker | Dzifa           | Dey             |
|                                        |            |                     |    |                                                                                                                                                                                                                                                               |                   | Roundtable and closing                                                   | 14:35 | 14:45 | Speaker | Alexandros      | Panagiotopoulos |
|                                        |            |                     |    |                                                                                                                                                                                                                                                               |                   | Rheumatology training in the Asia Pacific region and role of             | 13:50 | 14:05 | Speaker | Sunith Himantha | Atukorale       |

|                                                                                      |            |                     |    |                                                                                                                                                                                                                                    |            |                                                                                      |       |       |         |            |                 |
|--------------------------------------------------------------------------------------|------------|---------------------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------------------------------------------------------------------------|-------|-------|---------|------------|-----------------|
|                                                                                      |            |                     |    |                                                                                                                                                                                                                                    |            | APLAR Association of Young Rheumatologists (AYR)                                     |       |       |         |            |                 |
|                                                                                      |            |                     |    |                                                                                                                                                                                                                                    |            | Introduction                                                                         | 13:30 | 13:35 | Speaker | Latika     | Gupta           |
|                                                                                      |            |                     |    |                                                                                                                                                                                                                                    |            | Rheumatology training in the US and role of ACR Fellows in Training                  | 13:35 | 13:50 | Speaker | Ibtissam   | Gad             |
|                                                                                      |            |                     |    |                                                                                                                                                                                                                                    |            |                                                                                      |       |       | Chair   | Latika     | Gupta           |
|                                                                                      |            |                     |    |                                                                                                                                                                                                                                    |            |                                                                                      |       |       | Chair   | Alexandros | Panagiotopoulos |
| Spotlight consultation: Difficult decisions in patients with small vessel vasculitis | 12/06/2025 | 13:30:00 - 14:45:00 | B2 | Difficult cases with several critical decisions will be discussed by three experts on the stage and the audience. The experts will not be aware of the cases and express their recommendations spontaneously based on evidence and | Innovation | Discussion on difficult decisions in patients with small vessel vasculitis           | 14:15 | 14:45 | Speaker | Michael    | Walsh           |
|                                                                                      |            |                     |    |                                                                                                                                                                                                                                    |            | Spotlight consultation: Difficult decisions in patients with small vessel vasculitis | 13:35 | 14:15 | Speaker | Milena     | Bond            |
|                                                                                      |            |                     |    |                                                                                                                                                                                                                                    |            | Introduction                                                                         | 13:30 | 13:35 | Speaker | Georgina   | Espigol-Frigole |
|                                                                                      |            |                     |    |                                                                                                                                                                                                                                    |            |                                                                                      |       |       | Chair   | Georgina   | Espigol-Frigole |
|                                                                                      |            |                     |    |                                                                                                                                                                                                                                    |            |                                                                                      |       |       | Chair   | Maria      | Sandovici       |

|                                       |            |                     |         |                                                                                                                                                                                                                                                                                                               |                   |                                                                |       |       |         |                 |               |
|---------------------------------------|------------|---------------------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|----------------------------------------------------------------|-------|-------|---------|-----------------|---------------|
|                                       |            |                     |         | clinical experience.                                                                                                                                                                                                                                                                                          |                   |                                                                |       |       |         |                 |               |
| Uniting forces to manage fibromyalgia | 12/06/2025 | 13:30:00 - 14:45:00 | 6.1     | 1. To understand key theoretical models related to fibromyalgia;2. To evaluate the efficacy of innovative therapies;3. To update the evidence for physical exercise (the first line treatment in fibromyalgia);4. To recognise the importance of advocacy and promote collaboration between key stakeholders. | Joint             | Lets tackle this together: the importance of advocacy          | 13:30 | 13:45 | Speaker | Souzi           | Makri         |
|                                       |            |                     |         |                                                                                                                                                                                                                                                                                                               |                   | Fibromyalgia : Imbalance of Threat and Soothing Systems model  | 13:45 | 14:00 | Speaker | José Antonio P. | da Silva      |
|                                       |            |                     |         |                                                                                                                                                                                                                                                                                                               |                   | Self-guided digital behavioural therapy: a RCT                 | 14:00 | 14:15 | Speaker | Juan            | Luciano       |
|                                       |            |                     |         |                                                                                                                                                                                                                                                                                                               |                   | Physical exercise in the management of fibromyalgia: an update | 14:15 | 14:30 | Speaker | Eva             | Kosek         |
|                                       |            |                     |         |                                                                                                                                                                                                                                                                                                               |                   | Q&A and Closing                                                | 14:30 | 14:45 | Speaker | Fernando        | Estevez-Lopez |
|                                       |            |                     |         |                                                                                                                                                                                                                                                                                                               |                   |                                                                |       |       | Chair   | Fernando        | Estevez-Lopez |
|                                       |            |                     |         |                                                                                                                                                                                                                                                                                                               |                   |                                                                |       |       | Chair   | Rinie           | Geenen        |
| VEXAS syndrome and other              | 12/06/2025 | 13:30:00 - 14:15:00 | Plenary | Explore the role of somatic mutations in                                                                                                                                                                                                                                                                      | What is New (WIN) | VEXAS syndrome and other                                       | 13:30 | 14:15 | Speaker | Sinisa          | Savic         |

|                                        |            |                     |         |                                                                                                                                                                                                                                                                                                                                              |                    |                                                      |       |       |         |             |          |
|----------------------------------------|------------|---------------------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------------------------------------------------|-------|-------|---------|-------------|----------|
| RMDs caused by somatic mutations       |            |                     |         | different rheumatic diseases including VEXAS ;1. to understand the pathophysiology of diseases caused by somatic mutations ;2. to recognise the clinical manifestations of VEXAS and other diseases caused by somatic mutations; 3. to learn to incorporate genetic testing in clinical practice and discuss emerging therapeutic approaches |                    | somatic mutations: what rheumatologists need to know |       |       |         |             |          |
|                                        |            |                     |         |                                                                                                                                                                                                                                                                                                                                              |                    |                                                      |       |       |         |             |          |
|                                        |            |                     |         |                                                                                                                                                                                                                                                                                                                                              |                    |                                                      |       |       |         |             |          |
| IgG4 related disease and histiocytosis | 12/06/2025 | 14:15:00 - 15:00:00 | Plenary | 1. To learn about the pathogenesis and clinical manifestations of IgG4 related                                                                                                                                                                                                                                                               | How to Treat (HOT) | IgG4 related disease and histiocytosis               | 14:15 | 15:00 | Speaker | Augusto     | Vaglio   |
|                                        |            |                     |         |                                                                                                                                                                                                                                                                                                                                              |                    |                                                      |       |       | Chair   | Gözde Kübra | Yardımcı |
|                                        |            |                     |         |                                                                                                                                                                                                                                                                                                                                              |                    |                                                      |       |       | Chair   | tbc         | tbc      |

|                                                                            |            |                     |                   |                                                                                                                                                                                                                                            |                       |                                                                           |       |       |         |           |         |
|----------------------------------------------------------------------------|------------|---------------------|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|---------------------------------------------------------------------------|-------|-------|---------|-----------|---------|
|                                                                            |            |                     |                   | disease and histiocytosis;2. to learn about the diagnosis and differential diagnosis of these diseases;3. to learn about the management of IgG4 related disease and histiocytosis.                                                         |                       |                                                                           |       |       |         |           |         |
| Collaborative Research : Insights From Researchers on Patient Partnerships | 12/06/2025 | 15:00:00 - 15:30:00 | Meet the Expert 1 | 1. To provide an understanding of collaborative research and patient partnership;2. To share best practices from the researcher's experiences;3. To learn how to effectively engage patient research partners within the research project. | Meet the EULAR Expert | Collaborative Research: Insights from researchers on patient partnerships | 15:00 | 15:30 | Speaker | Martin J. | Stevens |

|                                                                         |            |                     |                   |                                                                                                                                                                                                                                       |                       |                                                                         |       |       |         |           |                   |
|-------------------------------------------------------------------------|------------|---------------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|-------------------------------------------------------------------------|-------|-------|---------|-----------|-------------------|
| Is there a bone safe dose of Glucocorticoids in the management of RMDs? | 12/06/2025 | 15:00:00 - 15:30:00 | Meet the Expert 2 | 1. To learn the main implications of glucocorticoid-induced osteoporosis; 2. To know how to limit the glucocorticoid-induced osteoporosis; 3. To discuss the existence of a safe bone dose for the administration of glucocorticoids. | Meet the EULAR Expert | Is there a bone safe dose of Glucocorticoids in the management of RMDs? | 15:00 | 15:30 | Speaker | Natasha   | Appelman-Dijkstra |
| Polymyalgia rheumatica – when to use glucocorticoid sparing agents      | 12/06/2025 | 15:00:00 - 15:30:00 | Meet the Expert 3 | 1. To discuss the potential burden of long-term glucocorticoids in patients with PMR; 2. To discuss potential risk factors for relapses and glucocorticoid-related adverse events; 3. To discuss recent trials on                     | Meet the EULAR Expert | Polymyalgia rheumatica – when to use glucocorticoid sparing agents      | 15:00 | 15:30 | Speaker | Elisabeth | Brouwer           |

|                                                                                          |            |                     |                   |                                                                                                                                                                                                                                                                                                                  |                       |                                                                                          |       |       |         |      |       |
|------------------------------------------------------------------------------------------|------------|---------------------|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|------------------------------------------------------------------------------------------|-------|-------|---------|------|-------|
|                                                                                          |            |                     |                   | glucocorticoid sparing agents in PMR.                                                                                                                                                                                                                                                                            |                       |                                                                                          |       |       |         |      |       |
| Should we use Methotrexate or Biologics as first-line treatment of Rheumatoid Arthritis? | 12/06/2025 | 15:00:00 - 15:30:00 | Meet the Expert 4 | 1. To discuss the evidence behind methotrexate versus biological agents (biosimilars) as first-line treatment in RA2. To discuss price developments of biologics and its possible influence on drug choice3. To discuss drug safety when using methotrexate as compared to biological agents as first-line agent | Meet the EULAR Expert | Should we use Methotrexate or Biologics as first-line treatment of Rheumatoid Arthritis? | 15:00 | 15:30 | Speaker | Paul | Emery |
| All about Paget's Disease:                                                               | 12/06/2025 | 15:45:00 - 17:00:00 | F1                | 1. To better understand the pathophysiology                                                                                                                                                                                                                                                                      | Clinical Science      | Current treatment of Paget's                                                             | 16:25 | 16:40 | Speaker | tbc  | tbc   |

|                                                 |  |  |  |                                                                                                                                                                                             |  |                                                                                |       |       |         |          |               |
|-------------------------------------------------|--|--|--|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--------------------------------------------------------------------------------|-------|-------|---------|----------|---------------|
| from pathophysiology to diagnosis and treatment |  |  |  | y of Paget's disease of bone; 2. to learn about the clinical and imaging presentations; 3. To learn about how to diagnose the disease; 4. To discuss currently available treatment options. |  | disease of bone                                                                |       |       |         |          |               |
|                                                 |  |  |  |                                                                                                                                                                                             |  | Closing                                                                        | 16:55 | 17:00 | Speaker |          |               |
|                                                 |  |  |  |                                                                                                                                                                                             |  | Oral Abstract Presentation                                                     | 16:45 | 16:55 | Speaker |          |               |
|                                                 |  |  |  |                                                                                                                                                                                             |  | Current treatment of Paget's disease of bone                                   | 16:40 | 16:45 | Speaker | tbc      | tbc           |
|                                                 |  |  |  |                                                                                                                                                                                             |  | Pathophysiology of Paget's disease of bone: what we know so far                | 16:00 | 16:05 | Speaker | Fernando | Gianfrancesco |
|                                                 |  |  |  |                                                                                                                                                                                             |  | Pathophysiology of Paget's disease of bone: what we know so far                | 15:45 | 16:00 | Speaker | Fernando | Gianfrancesco |
|                                                 |  |  |  |                                                                                                                                                                                             |  | Clinical and imaging presentations of Paget's disease of bone: how to diagnose | 16:05 | 16:20 | Speaker | Stuart   | Ralston       |
|                                                 |  |  |  |                                                                                                                                                                                             |  | Clinical and imaging                                                           | 16:20 | 16:25 | Speaker | Stuart   | Ralston       |

|                                                                                                                                   |                |                        |    |                                                                                                                                                                                                                                                                                                                                              |                 |                                                                                                          |       |       |             |                 |                      |
|-----------------------------------------------------------------------------------------------------------------------------------|----------------|------------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|----------------------------------------------------------------------------------------------------------|-------|-------|-------------|-----------------|----------------------|
|                                                                                                                                   |                |                        |    |                                                                                                                                                                                                                                                                                                                                              |                 | presentation<br>s of Paget's<br>disease of<br>bone: how to<br>diagnose                                   |       |       |             |                 |                      |
|                                                                                                                                   |                |                        |    |                                                                                                                                                                                                                                                                                                                                              |                 |                                                                                                          |       |       | Chair       | Stuart          | Ralston              |
|                                                                                                                                   |                |                        |    |                                                                                                                                                                                                                                                                                                                                              |                 |                                                                                                          |       |       | Chair       | João            | Madruga<br>Dias      |
| Are<br>cannabis<br>and<br>cannabin<br>oids a<br>valid<br>treatment<br>option in<br>patients<br>with<br>rheumatic<br>diseases<br>? | 12/06/<br>2025 | 15:45:00 -<br>17:00:00 | F3 | 1. To learn<br>about potential<br>anti-<br>inflammatory<br>aspects of<br>cannabis; 2. To<br>learn about a<br>potential role of<br>cannabis in<br>pain treatment;<br>3. To learn the<br>difference<br>between<br>synthetic and<br>herbal<br>cannabis<br>preparations; 4.<br>To learn about<br>potential safety<br>aspects of<br>cannabis use. | EULAR<br>Debate | Cannabis - a<br>drug with<br>underestimat<br>ed value in<br>the<br>treatment of<br>rheumatic<br>diseases | 16:05 | 16:25 | Spea<br>ker | tbc             | tbc                  |
|                                                                                                                                   |                |                        |    |                                                                                                                                                                                                                                                                                                                                              |                 | Audience<br>Voting                                                                                       | 15:45 | 15:45 | Spea<br>ker |                 |                      |
|                                                                                                                                   |                |                        |    |                                                                                                                                                                                                                                                                                                                                              |                 | Cannabis - a<br>drug with<br>underestimat<br>ed value in<br>the<br>treatment of<br>rheumatic<br>diseases | 16:35 | 16:45 | Spea<br>ker | tbc             | tbc                  |
|                                                                                                                                   |                |                        |    |                                                                                                                                                                                                                                                                                                                                              |                 | Debate and<br>closing                                                                                    | 16:45 | 17:00 | Spea<br>ker | Neil            | Basu                 |
|                                                                                                                                   |                |                        |    |                                                                                                                                                                                                                                                                                                                                              |                 | Cannabis -<br>good for<br>parties but<br>not for our<br>patients                                         | 16:25 | 16:35 | Spea<br>ker | Nebojsa<br>Nick | Knezevic,<br>MD, PhD |

|                                                                                 |            |                     |    |                                                                                                                                                                                                                                                                                                                                                         |                  |                                                                                |       |       |         |              |                   |
|---------------------------------------------------------------------------------|------------|---------------------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|--------------------------------------------------------------------------------|-------|-------|---------|--------------|-------------------|
|                                                                                 |            |                     |    |                                                                                                                                                                                                                                                                                                                                                         |                  | Cannabis - good for parties but not for our patients                           | 15:45 | 16:05 | Speaker | Nebojsa Nick | Knezevic, MD, PhD |
|                                                                                 |            |                     |    |                                                                                                                                                                                                                                                                                                                                                         |                  |                                                                                |       |       | Chair   | Silvia       | Hayer             |
|                                                                                 |            |                     |    |                                                                                                                                                                                                                                                                                                                                                         |                  |                                                                                |       |       | Chair   | Neil         | Basu              |
| Beyond the Joints: Managing Extra-Articular Manifestations in Spondyloarthritis | 12/06/2025 | 15:45:00 - 17:00:00 | D1 | This session will cover the intersection of spondyloarthritis (SpA) and extramusculoskeletal manifestations (EMMs), appealing to rheumatologists managing these conditions. 1. Learn about the ocular manifestations of SpA; 2. Learn about GI implications and manifestations of SpA; 3. Learn about skin manifestations of SpA; 4. Learn about the CV | Clinical Science | Gastrointestinal Involvement in SpA: From IBD to Microbiome                    | 16:00 | 16:15 | Speaker | Gaëlle       | Varkas            |
|                                                                                 |            |                     |    |                                                                                                                                                                                                                                                                                                                                                         |                  | Cardiovascular Risks in Spondyloarthritis Patients: Recognition and Management | 16:30 | 16:45 | Speaker | Anna         | Moltó             |
|                                                                                 |            |                     |    |                                                                                                                                                                                                                                                                                                                                                         |                  | Eyes on Uveitis: Understanding Its Role in SpA                                 | 15:45 | 16:00 | Speaker | Martin       | Rudwaleit         |
|                                                                                 |            |                     |    |                                                                                                                                                                                                                                                                                                                                                         |                  | Dermatological Manifestations of Spondyloarthritis: Psoriasis and Beyond       | 16:15 | 16:30 | Speaker | Maria Sole   | Chimenti          |

|                                                                                                 |            |                     |     |                                                                                                                                                                                                                                                                                                                      |       |                                                                                                   |       |       |         |            |              |
|-------------------------------------------------------------------------------------------------|------------|---------------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|---------------------------------------------------------------------------------------------------|-------|-------|---------|------------|--------------|
|                                                                                                 |            |                     |     | comorbidities of SpA.                                                                                                                                                                                                                                                                                                |       | Q&A and Closing                                                                                   | 16:45 | 17:00 | Speaker | Clementina | López-Medina |
|                                                                                                 |            |                     |     |                                                                                                                                                                                                                                                                                                                      |       |                                                                                                   |       |       | Chair   | Dirk       | Elewaut      |
|                                                                                                 |            |                     |     |                                                                                                                                                                                                                                                                                                                      |       |                                                                                                   |       |       | Chair   | Clementina | López-Medina |
| Brush your arthritis away - the importance of oral health in patients with rheumatoid arthritis | 12/06/2025 | 15:45:00 - 17:00:00 | 6.2 | Delegates will be able to: 1: Understand how rheumatoid arthritis, periodontitis, citrullination and bacteria p. gingivalis are related;2: Identify and know how to treat periodontitis non-surgically in individuals with rheumatoid arthritis in clinical practice;3: Discuss the importance for further research. | Joint | Oral Abstract Presentation                                                                        | 16:45 | 16:55 | Speaker |            |              |
|                                                                                                 |            |                     |     |                                                                                                                                                                                                                                                                                                                      |       | Periodontitis and the mechanism behind periodontitis and disease activity in rheumatoid arthritis | 15:45 | 16:00 | Speaker | Rafael     | de Molon     |
|                                                                                                 |            |                     |     |                                                                                                                                                                                                                                                                                                                      |       | Periodontitis and the mechanism behind periodontitis and disease activity in rheumatoid arthritis | 16:00 | 16:05 | Speaker | Rafael     | de Molon     |
|                                                                                                 |            |                     |     |                                                                                                                                                                                                                                                                                                                      |       | What is non-surgical treatment for periodontitis and is it effective?                             | 16:20 | 16:25 | Speaker | Michelle   | Scott        |
|                                                                                                 |            |                     |     |                                                                                                                                                                                                                                                                                                                      |       | What is non-surgical treatment for                                                                | 16:05 | 16:20 | Speaker | Michelle   | Scott        |

|                                                                                      |            |                     |     |                                                                                                                                                                     |            |                                                                                                    |       |       |         |                  |             |
|--------------------------------------------------------------------------------------|------------|---------------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------------------------------------------------------------------------|-------|-------|---------|------------------|-------------|
|                                                                                      |            |                     |     |                                                                                                                                                                     |            | periodontitis and is it effective?                                                                 |       |       |         |                  |             |
|                                                                                      |            |                     |     |                                                                                                                                                                     |            | Feasibility of periodontal therapy in patients with rheumatoid arthritis - experiences from an RCT | 16:25 | 16:40 | Speaker | Paola            | de Pablo    |
|                                                                                      |            |                     |     |                                                                                                                                                                     |            | Feasibility of periodontal therapy in patients with rheumatoid arthritis - experiences from an RCT | 16:40 | 16:45 | Speaker | Paola            | de Pablo    |
|                                                                                      |            |                     |     |                                                                                                                                                                     |            |                                                                                                    |       |       | Chair   | tbc              | tbc         |
|                                                                                      |            |                     |     |                                                                                                                                                                     |            |                                                                                                    |       |       | Chair   | Charlotte Werdal | Hansen      |
| Clinical implications of basic immunology: from off label treatment to understanding | 12/06/2025 | 15:45:00 - 17:00:00 | 6.4 | Where do ideas for off label therapies come from and what can they teach us on the pathophysiology of a disease?<br>1. understanding the mechanism of action of off | Innovation | Vasculitis - why do complement inhibitors actually work?                                           | 16:35 | 16:55 | Speaker | Andreas          | Kronbichler |
|                                                                                      |            |                     |     |                                                                                                                                                                     |            | Vasculitis - why do complement inhibitors actually work?                                           | 16:55 | 17:00 | Speaker | Andreas          | Kronbichler |

|                 |  |  |  |                                                                                          |  |                                                                                           |       |       |         |        |          |
|-----------------|--|--|--|------------------------------------------------------------------------------------------|--|-------------------------------------------------------------------------------------------|-------|-------|---------|--------|----------|
| pathophysiology |  |  |  | and in label therapies starting from a clinical case and going back into pathophysiology |  | Lupus immunology - what do CARs teach us about lupus pathophysiology?                     | 16:20 | 16:25 | Speaker | Thomas | Dörner   |
|                 |  |  |  |                                                                                          |  | Case Presentation : Lupus immunology - what do CARs teach us about lupus pathophysiology? | 15:50 | 16:00 | Speaker | Jule   | Taubmann |
|                 |  |  |  |                                                                                          |  | Lupus immunology - what do CARs teach us about lupus pathophysiology?                     | 16:00 | 16:20 | Speaker | Thomas | Dörner   |
|                 |  |  |  |                                                                                          |  | Introduction                                                                              | 15:45 | 15:50 | Speaker | Bimba  | Hoyer    |
|                 |  |  |  |                                                                                          |  | Case Presentation : Vasculitis - why do complement inhibitors                             | 16:25 | 16:35 | Speaker | Milena | Bond     |

|                                                                     |            |                     |            |                                                                                                                                                                                                                                                                                         |                          |                                                             |       |       |         |         |            |  |
|---------------------------------------------------------------------|------------|---------------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|-------------------------------------------------------------|-------|-------|---------|---------|------------|--|
|                                                                     |            |                     |            |                                                                                                                                                                                                                                                                                         |                          | actually work?                                              |       |       |         |         |            |  |
|                                                                     |            |                     |            |                                                                                                                                                                                                                                                                                         |                          |                                                             |       |       | Chair   | Bimba   | Hoyer      |  |
|                                                                     |            |                     |            |                                                                                                                                                                                                                                                                                         |                          |                                                             |       |       | Chair   | Marta   | Mosca      |  |
| Histopathology of synovial tissue - know your scores and pathotypes | 12/06/2025 | 15:45:00 - 17:00:00 | B1         | 1. Learn about the typical histological features of synovial tissue<br>2. Learn which pathological features of synovial tissues are assessed with which stainings and scores<br>3. Learn how to discriminate a lympho-myeloid, from a myeloid and a pauci-immune histological pathotype | Practical Skills Lecture | Defining histological pathotypes in the synovium            | 16:25 | 16:50 | Speaker | Frances | Humby      |  |
|                                                                     |            |                     |            |                                                                                                                                                                                                                                                                                         |                          | Introduction                                                | 15:45 | 15:50 | Speaker | Felice  | Rivellese  |  |
|                                                                     |            |                     |            |                                                                                                                                                                                                                                                                                         |                          | Defining histological pathotypes in the synovium            | 16:50 | 17:00 | Speaker | Frances | Humby      |  |
|                                                                     |            |                     |            |                                                                                                                                                                                                                                                                                         |                          | How to assess synovial pathology in inflammatory arthritis? | 16:15 | 16:25 | Speaker | Ellen   | Gravallese |  |
|                                                                     |            |                     |            |                                                                                                                                                                                                                                                                                         |                          | How to assess synovial pathology in inflammatory arthritis? | 15:50 | 16:15 | Speaker | Ellen   | Gravallese |  |
|                                                                     |            |                     |            |                                                                                                                                                                                                                                                                                         |                          |                                                             |       |       | Chair   | Andrew  | Filer      |  |
|                                                                     |            |                     |            |                                                                                                                                                                                                                                                                                         |                          |                                                             |       |       | Chair   | Felice  | Rivellese  |  |
| How to evaluate larger joints: the                                  | 12/06/2025 | 15:45:00 - 17:00:00 | Hands-On 1 | 1. Assessment of the shoulder and elbow joints by                                                                                                                                                                                                                                       | Hands-on Sessions        | How to access the elbow: ultrasonogra                       | 15:50 | 15:55 | Speaker | Lene    | Terslev    |  |

|                                                    |            |                     |            |                                                                                                                                                            |                   |                                                         |       |       |         |                 |                   |
|----------------------------------------------------|------------|---------------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|---------------------------------------------------------|-------|-------|---------|-----------------|-------------------|
| shoulder and elbow                                 |            |                     |            | physical examination;2. Assessment of the shoulder and elbow joints by ultrasound;3. How to integrate and correlate clinical and ultrasonography findings. |                   | phy examination                                         |       |       |         |                 |                   |
|                                                    |            |                     |            |                                                                                                                                                            |                   | Discussion on presentations                             | 16:05 | 16:10 | Speaker | David           | Kane              |
|                                                    |            |                     |            |                                                                                                                                                            |                   | How to access the shoulder: clinical examination        | 15:55 | 16:00 | Speaker | Edoardo         | Cipolletta        |
|                                                    |            |                     |            |                                                                                                                                                            |                   | How to access the elbow: clinical examination           | 15:45 | 15:50 | Speaker | Florentin Ananu | Vreju             |
|                                                    |            |                     |            |                                                                                                                                                            |                   | Hands-on stations                                       | 16:10 | 17:00 | Speaker | Florentin Ananu | Vreju             |
|                                                    |            |                     |            |                                                                                                                                                            |                   | How to access the shoulder: ultrasonography examination | 16:00 | 16:05 | Speaker | Giorgio         | Tamborrini-Schütz |
|                                                    |            |                     |            |                                                                                                                                                            |                   |                                                         |       |       | Chair   | David           | Kane              |
|                                                    |            |                     |            |                                                                                                                                                            |                   |                                                         |       |       | Chair   | Petra           | Hanova            |
| How to evaluate small joints: hand, wrist and foot | 12/06/2025 | 15:45:00 - 17:00:00 | Hands-On 2 | 1. Assessment of hand, wrist and foot joints by physical examination;2. Assessment of the hand, wrist and foot joints                                      | Hands-on Sessions | Discussion on presentations                             | 16:05 | 16:10 | Speaker | Miroslav        | Mayer             |
|                                                    |            |                     |            |                                                                                                                                                            |                   | How to access the wrist and hand:                       | 15:50 | 15:55 | Speaker | Sarah           | Ohrndorf          |

|                                                |            |                     |     |                                                                                                                                                             |                       |                                                          |       |       |         |          |                 |
|------------------------------------------------|------------|---------------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|----------------------------------------------------------|-------|-------|---------|----------|-----------------|
|                                                |            |                     |     | by ultrasound;3. How to integrate and correlate clinical and ultrasonography findings.                                                                      |                       | ultrasonography examination                              |       |       |         |          |                 |
|                                                |            |                     |     |                                                                                                                                                             |                       | How to access the foot: ultrasonography examination      | 16:00 | 16:05 | Speaker | Emilio   | Filippucci      |
|                                                |            |                     |     |                                                                                                                                                             |                       | How to access the foot: clinical examination             | 15:55 | 16:00 | Speaker | Carlo    | Perricone       |
|                                                |            |                     |     |                                                                                                                                                             |                       | How to access the wrist and hand: clinical examination   | 15:45 | 15:50 | Speaker | Luis     | Coronel         |
|                                                |            |                     |     |                                                                                                                                                             |                       | Hands-on stations                                        | 16:10 | 17:00 | Speaker | Luis     | Coronel         |
|                                                |            |                     |     |                                                                                                                                                             |                       |                                                          |       |       | Chair   | Miroslav | Mayer           |
|                                                |            |                     |     |                                                                                                                                                             |                       |                                                          |       |       | Chair   | Ingrid   | Möller          |
| Microbiome and autoimmunity: what is the link? | 12/06/2025 | 15:45:00 - 17:00:00 | 6.3 | 1. Normal and pathological host-microbe interplay at different sites throughout the body except for the gastrointestinal tract;2. How microbiome-associated | From Bench to Bedside | Oral Abstract Presentation                               | 16:45 | 16:55 | Speaker |          |                 |
|                                                |            |                     |     |                                                                                                                                                             |                       | Closing                                                  | 16:55 | 17:00 | Speaker | Claire   | Immediato Daien |
|                                                |            |                     |     |                                                                                                                                                             |                       | Host-microbiome interplay at different sites of the body | 15:45 | 16:05 | Speaker | Martin   | Kriegel         |
|                                                |            |                     |     |                                                                                                                                                             |                       | Microbial influence on                                   | 16:25 | 16:45 | Speaker | Kulveer  | Mankia          |

|                                                            |            |                     |     |                                                                                                                                                                                                                                 |                   |                                                               |       |       |         |                |                 |
|------------------------------------------------------------|------------|---------------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|---------------------------------------------------------------|-------|-------|---------|----------------|-----------------|
|                                                            |            |                     |     | events may trigger autoimmune responses and rheumatic disease;3. Understand the clinical evidence of a link between microbiome and arthritis, including the therapeutic implications.                                           |                   | arthritis - clinical evidence and therapeutic implications    |       |       |         |                |                 |
|                                                            |            |                     |     |                                                                                                                                                                                                                                 |                   | How the microbiome may trigger autoimmunity                   | 16:05 | 16:25 | Speaker | Kristine A.    | Kuhn            |
|                                                            |            |                     |     |                                                                                                                                                                                                                                 |                   |                                                               |       |       | Chair   | Claire         | Immediato Daien |
|                                                            |            |                     |     |                                                                                                                                                                                                                                 |                   |                                                               |       |       | Chair   | Francesco      | Ciccia          |
| Rheuma Vision, the rheumatology knowledge transfer contest | 12/06/2025 | 15:45:00 - 17:02:00 | 6.1 | Join the RheumaVision Final Round. Here, you will see presentations from winners of the RheumaVision virtual semifinals. You will learn rheumatology from young peers. There will also be a focus on presentation skills with a | EMEUNE T Presents | RheumaVision Talks                                            | 15:45 | 16:37 | Speaker |                |                 |
|                                                            |            |                     |     |                                                                                                                                                                                                                                 |                   | Discussion and Closing                                        | 16:47 | 17:02 | Speaker | Cristiana      | Sieiro Santos   |
|                                                            |            |                     |     |                                                                                                                                                                                                                                 |                   | How to win RheumaVision (how to give an effective flash talk) | 16:37 | 16:47 | Speaker | Iain B.        | McInnes         |
|                                                            |            |                     |     |                                                                                                                                                                                                                                 |                   |                                                               |       |       | Chair   | Jean-Guillaume | Letarouilly     |
|                                                            |            |                     |     |                                                                                                                                                                                                                                 |                   |                                                               |       |       | Chair   | Cristiana      | Sieiro Santos   |

|                                            |            |                     |         |                                                                                                                                                                                                                                        |                   |                                                                        |       |       |         |          |               |
|--------------------------------------------|------------|---------------------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|------------------------------------------------------------------------|-------|-------|---------|----------|---------------|
|                                            |            |                     |         | closing by RheumaVision jury (EULAR faculty).                                                                                                                                                                                          |                   |                                                                        |       |       |         |          |               |
| Shining a light on Rare Rheumatic Diseases | 12/06/2025 | 15:45:00 - 17:00:00 | C3      | 1. This session will highlight the rarer diseases that perhaps don't get as much exposure. 2. Delegates will get a personal insight living with a rare RMDs.3. Delegates will learn how rare RMDs are diagnosed and managed in Africa. | PARE              | Oral Abstract Presentation                                             | 16:30 | 16:40 | Speaker |          |               |
|                                            |            |                     |         |                                                                                                                                                                                                                                        |                   | Oral Abstract Presentation                                             | 16:40 | 16:50 | Speaker |          |               |
|                                            |            |                     |         |                                                                                                                                                                                                                                        |                   | Diagnosis and Treatment of rare RMDs in Africa: A Clinical Perspective | 16:15 | 16:30 | Speaker | Dzifa    | Dey           |
|                                            |            |                     |         |                                                                                                                                                                                                                                        |                   | Focus on Mixed Connective Tissue Diseases and other rare RMDs          | 15:45 | 16:00 | Speaker | Rosaria  | Talarico      |
|                                            |            |                     |         |                                                                                                                                                                                                                                        |                   | Living with Myositis - A Personal Perspective                          | 16:00 | 16:15 | Speaker | Ingrid   | de Groot      |
|                                            |            |                     |         |                                                                                                                                                                                                                                        |                   | Q&A and Closing                                                        | 16:50 | 17:00 | Speaker | Silvia   | Aguilera      |
|                                            |            |                     |         |                                                                                                                                                                                                                                        |                   |                                                                        |       |       | Chair   | Silvia   | Aguilera      |
|                                            |            |                     |         |                                                                                                                                                                                                                                        |                   |                                                                        |       |       | Chair   | Gonzalo  | Tobar Carrizo |
| Sjögren's Syndrome                         | 12/06/2025 | 15:45:00 - 16:30:00 | Plenary | To learn about new pathophysiologic                                                                                                                                                                                                    | What is New (WIN) | Sjögren's Syndrome                                                     | 15:45 | 16:30 | Speaker | Gaetane  | Nocturne      |
|                                            |            |                     |         |                                                                                                                                                                                                                                        |                   |                                                                        |       |       | Chair   | ALOJZIJA | HOCEVAR       |

|                                                |            |                     |    |                                                                                                                                                                                                                                                                              |                         |                                                                             |       |       |         |           |           |
|------------------------------------------------|------------|---------------------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|-----------------------------------------------------------------------------|-------|-------|---------|-----------|-----------|
|                                                |            |                     |    | al pathways found in the disease with focus on cross-talk between epithelial cells and immune cellsTo discover the first positive clinical trials in the disease                                                                                                             |                         |                                                                             |       |       | Chair   | Elena     | Pontarini |
| SLE pathophysiology: From genes to environment | 12/06/2025 | 15:45:00 - 17:00:00 | B2 | 1. To give an overview of different genetic variants and involved pathways contributing to Lupus; 2. To understand how genetic mutations lead to altered B-Cell reactions to viral triggers in Lupus;3. To learn what is the impact of the environment on Lupus phenotype in | Basic and Translational | Lupus aetiology: how much is it in the genes?                               | 15:45 | 16:05 | Speaker | alexandre | belot     |
|                                                |            |                     |    |                                                                                                                                                                                                                                                                              |                         | Lupus aetiology: how much is it in the genes?                               | 16:05 | 16:10 | Speaker | alexandre | belot     |
|                                                |            |                     |    |                                                                                                                                                                                                                                                                              |                         | Genetic variations leading to altered innate virus sensing in Lupus B-Cells | 16:10 | 16:30 | Speaker | Carola    | Vinuesa   |
|                                                |            |                     |    |                                                                                                                                                                                                                                                                              |                         | Genetic variations leading to altered                                       | 16:30 | 16:35 | Speaker | Carola    | Vinuesa   |

|                                                               |            |                     |    |                                                                                                          |                                            |                                                                          |       |       |         |        |                    |
|---------------------------------------------------------------|------------|---------------------|----|----------------------------------------------------------------------------------------------------------|--------------------------------------------|--------------------------------------------------------------------------|-------|-------|---------|--------|--------------------|
|                                                               |            |                     |    | different parts of the world?                                                                            |                                            | innate virus sensing in Lupus B-Cells                                    |       |       |         |        |                    |
|                                                               |            |                     |    |                                                                                                          |                                            | Can the same mutations lead to diverse lupus phenotypes across the globe | 16:55 | 17:00 | Speaker | Laura  | Lewandowski        |
|                                                               |            |                     |    |                                                                                                          |                                            | Can the same mutations lead to diverse lupus phenotypes across the globe | 16:35 | 16:55 | Speaker | Laura  | Lewandowski        |
|                                                               |            |                     |    |                                                                                                          |                                            |                                                                          |       |       | Chair   | Raquel | Campanilho-Marques |
|                                                               |            |                     |    |                                                                                                          |                                            |                                                                          |       |       | Chair   | Jordi  | Anton              |
| Stop smoking, eat healthier and move more: Primary prevention | 12/06/2025 | 15:45:00 - 17:00:00 | C1 | Delegates will achieve an understanding of: 1. Preclinical phases of RA and how far we are in preventing | Health Professionals in Rheumatology (HPR) | Oral Abstract Presentation                                               | 16:45 | 16:55 | Speaker |        |                    |
|                                                               |            |                     |    |                                                                                                          |                                            | Primary prevention of osteoarthritis - challenges and opportunities      | 16:20 | 16:25 | Speaker | Ewa M. | Roos               |

|           |  |  |  |                                                                                                                                                                                     |  |                                                                                                    |       |       |         |               |           |
|-----------|--|--|--|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|----------------------------------------------------------------------------------------------------|-------|-------|---------|---------------|-----------|
| n of RMDs |  |  |  | RA;2. Predictive factors and preventive strategies for the development of osteoarthritis;3. Overview of the evidence regarding lifestyle of importance for the progression of RMDs. |  | Primary prevention of osteoarthritis - challenges and opportunities                                | 16:05 | 16:20 | Speaker | Ewa M.        | Roos      |
|           |  |  |  |                                                                                                                                                                                     |  | Closing                                                                                            | 16:55 | 17:00 | Speaker | Line Raunsbæk | Knudsen   |
|           |  |  |  |                                                                                                                                                                                     |  | Prevention of rheumatoid arthritis - preventive strategies in at-risk individuals. How far are we? | 16:00 | 16:05 | Speaker | Giulia        | Frazzei   |
|           |  |  |  |                                                                                                                                                                                     |  | Prevention of rheumatoid arthritis - preventive strategies in at-risk individuals. How far are we? | 15:45 | 16:00 | Speaker | Giulia        | Frazzei   |
|           |  |  |  |                                                                                                                                                                                     |  | The importance of a healthy lifestyle to prevent                                                   | 16:40 | 16:45 | Speaker | Maud          | Wieczorek |

|                                |            |                     |    |                                                                                                                                                                                                                                                                                      |                |                                                                      |       |       |         |               |                  |
|--------------------------------|------------|---------------------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|----------------------------------------------------------------------|-------|-------|---------|---------------|------------------|
|                                |            |                     |    |                                                                                                                                                                                                                                                                                      |                | progression of RMDs                                                  |       |       |         |               |                  |
|                                |            |                     |    |                                                                                                                                                                                                                                                                                      |                | The importance of a healthy lifestyle to prevent progression of RMDs | 16:25 | 16:40 | Speaker | Maud          | Wieczorek        |
|                                |            |                     |    |                                                                                                                                                                                                                                                                                      |                |                                                                      |       |       | Chair   | Wilfred       | Peter            |
|                                |            |                     |    |                                                                                                                                                                                                                                                                                      |                |                                                                      |       |       | Chair   | Line Raunsbæk | Knudsen          |
| Sustainability of Rheumatology | 12/06/2025 | 15:45:00 - 17:00:00 | A3 | 1. Identify upcoming challenges: Highlight potential challenges the rheumatology field is expected to face in the next few years.2. Evaluate sustainability measures: Assess current strategies and actions needed to maintain and increase sustainable care for people with RMDs 3. | EULAR Projects | Work trends in an ageing population                                  | 16:00 | 16:15 | Speaker | tbc           | tbc              |
|                                |            |                     |    |                                                                                                                                                                                                                                                                                      |                | Rheumatology workforce                                               | 16:30 | 16:45 | Speaker |               |                  |
|                                |            |                     |    |                                                                                                                                                                                                                                                                                      |                | Roundtable and Closing                                               | 16:45 | 17:00 | Speaker |               |                  |
|                                |            |                     |    |                                                                                                                                                                                                                                                                                      |                | Access and availability of medicines                                 | 16:15 | 16:30 | Speaker | César         | Hernández García |
|                                |            |                     |    |                                                                                                                                                                                                                                                                                      |                | Future trends in the incidence of RMDs                               | 15:45 | 16:00 | Speaker | Pedro         | Machado          |
|                                |            |                     |    |                                                                                                                                                                                                                                                                                      |                |                                                                      |       |       | Chair   | Loreto        | Carmona          |
|                                |            |                     |    |                                                                                                                                                                                                                                                                                      |                |                                                                      |       |       | Chair   | Margreet      | Kloppenburg      |

|           |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                            |                |                    |       |       |         |       |      |
|-----------|------------|---------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|--------------------|-------|-------|---------|-------|------|
|           |            |                     |    | Outline strategic responses to enhance patient care: Formulate and propose strategic actions to address challenges, including methods to improve care quality for people with RMDs.4. Foster collaboration: Discuss the importance of collaboration among stakeholders to enhance the effectiveness of rheumatology care systems. Keep up to date with EULAR Advocacy here |                |                    |       |       |         |       |      |
| Update on | 12/06/2025 | 15:45:00 - 17:00:00 | B4 | 1. To have an update on the                                                                                                                                                                                                                                                                                                                                                | EULAR Projects | PARE activities on | 16:55 | 17:00 | Speaker | Peter | Boyd |

|                                 |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |  |                                                                                                                                |       |       |             |           |        |
|---------------------------------|--|--|--|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------------|-----------|--------|
| EULAR<br>paediatric<br>projects |  |  |  | current status<br>of projects<br>fostering young<br>Paediatric<br>Rheumatologist<br>s in Europe;2.<br>To learn about<br>data<br>harmonization<br>approaches for<br>patient<br>registries in<br>Paediatric<br>Rheumatology;<br>3. To<br>understand<br>differences in<br>the<br>management of<br>Still's disease<br>and<br>macrophage<br>activation<br>syndrome; 4.<br>To have an<br>update on<br>activities from<br>People with<br>Arthritis/Rheum<br>atism in Europe<br>that focus on<br>Children.Keep<br>up to date with |  | paediatric<br>rheumatolog<br>y                                                                                                 |       |       |             |           |        |
|                                 |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |  | PARE<br>activities on<br>paediatric<br>rheumatolog<br>y                                                                        | 16:45 | 16:55 | Spea<br>ker | Peter     | Boyd   |
|                                 |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |  | Management<br>of Still's<br>disease and<br>macrophage<br>activation<br>syndrome:<br>Results from<br>the<br>Metaphor<br>project | 16:20 | 16:25 | Spea<br>ker | Francesca | Minoia |
|                                 |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |  | Harmonizing<br>registries:<br>Consequenc<br>es of the<br>metadata<br>registry for<br>rare disease<br>(MERITA)                  | 16:40 | 16:45 | Spea<br>ker | tbc       | tbc    |
|                                 |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |  | Harmonizing<br>registries:<br>Consequenc<br>es of the<br>metadata<br>registry for<br>rare disease<br>(MERITA)                  | 16:25 | 16:40 | Spea<br>ker | tbc       | tbc    |

|  |  |  |  |                    |  |                                                                                                                                |       |       |             |           |        |
|--|--|--|--|--------------------|--|--------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------------|-----------|--------|
|  |  |  |  | EULAR PAED<br>here |  | Management<br>of Still's<br>disease and<br>macrophage<br>activation<br>syndrome:<br>Results from<br>the<br>Metaphor<br>project | 16:05 | 16:20 | Spea<br>ker | Francesca | Minoia |
|  |  |  |  |                    |  | How are<br>EMErqing<br>paediatric<br>Rheumatolo<br>Gists in<br>Europe<br>supported:<br>Activities of<br>the<br>EMERGE<br>group | 15:45 | 16:00 | Spea<br>ker | Erdal     | Sag    |
|  |  |  |  |                    |  | How are<br>EMErqing<br>paediatric<br>Rheumatolo<br>Gists in<br>Europe<br>supported:<br>Activities of<br>the<br>EMERGE<br>group | 16:00 | 16:05 | Spea<br>ker | Erdal     | Sag    |
|  |  |  |  |                    |  |                                                                                                                                |       |       | Chair       | Tadej     | Avcin  |
|  |  |  |  |                    |  |                                                                                                                                |       |       | Chair       | Seza      | Ozen   |

|                                                                                             |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                                                                              |              |                                                                                                |       |       |         |          |        |
|---------------------------------------------------------------------------------------------|------------|---------------------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------------------------------------------------------------------------------------------|-------|-------|---------|----------|--------|
| What is the role of clinical composite scores in the management of PsA in routine practice? | 12/06/2025 | 15:45:00 - 17:00:00 | A1 | Several clinical composite scores have been published for PsA; the majority of them for research purposes, many of them are complex to calculate The objectives of this debate are:1. to learn about the clinical composite scores available for PsA and the scientific evidence behind their development2. to discuss the possible pearls and pitfalls of using these composite scores in routine practice3. to discuss the | EULAR Debate | Audience Voting                                                                                | 15:45 | 15:45 | Speaker |          |        |
|                                                                                             |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                                                                              |              | Clinical composite scores are fine for studies, but less helpful in clinical practice          | 16:05 | 16:25 | Speaker | Philipp  | Bosch  |
|                                                                                             |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                                                                              |              | Clinical composite scores are fine for studies, but less helpful in clinical practice          | 16:40 | 16:55 | Speaker | Philipp  | Bosch  |
|                                                                                             |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                                                                              |              | Audience Voting and Closing                                                                    | 16:55 | 17:00 | Speaker | Gizem    | Ayan   |
|                                                                                             |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                                                                              |              | Clinical composite scores are essential for the management of PsA patients in clinical routine | 15:45 | 16:05 | Speaker | Laura C. | Coates |
|                                                                                             |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                                                                              |              | Clinical composite scores are                                                                  | 16:25 | 16:40 | Speaker | Laura C. | Coates |

|                                                                               |            |                     |    |                                                                                                                                                                                                                                                                                                      |                                 |                                                                                                    |       |       |         |        |         |
|-------------------------------------------------------------------------------|------------|---------------------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|----------------------------------------------------------------------------------------------------|-------|-------|---------|--------|---------|
|                                                                               |            |                     |    | validity of these scores to reflect PsA related inflammation particularly in patients with comorbidities                                                                                                                                                                                             |                                 | essential for the management of PsA patients in clinical routine                                   |       |       |         |        |         |
|                                                                               |            |                     |    |                                                                                                                                                                                                                                                                                                      |                                 |                                                                                                    |       |       | Chair   | Gizem  | Ayan    |
|                                                                               |            |                     |    |                                                                                                                                                                                                                                                                                                      |                                 |                                                                                                    |       |       | Chair   | Fabian | Proft   |
| What makes "Difficult-to-treat RA" so difficult to treat? And what can we do? | 12/06/2025 | 15:45:00 - 17:00:00 | A2 | 1. Be aware of the definition of D2T-RA and understand the various reasons behind it2. Learn how to establish the causes of D2T-RA in the individual patient3. Be inspired to provide patients with D2T-RA the best possible care4. Understand the potential of new electro-immunological approaches | Challenges in Clinical Practice | Case presentation: Why are some patients "difficult to treat"?                                     | 15:50 | 16:00 | Speaker |        |         |
|                                                                               |            |                     |    |                                                                                                                                                                                                                                                                                                      |                                 | Case presentation: Options for patients with difficult-to-treat RA: neuro-immunological approaches | 16:15 | 16:25 | Speaker |        |         |
|                                                                               |            |                     |    |                                                                                                                                                                                                                                                                                                      |                                 | Discussion: Options for patients with difficult-to-treat RA: neuro-immunologic                     | 16:25 | 16:40 | Speaker | Frieda | Koopman |

|                                  |            |                     |         |                                                                                                                                                                                    |                    |                                                         |       |       |         |          |                 |
|----------------------------------|------------|---------------------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------------------------------------------------|-------|-------|---------|----------|-----------------|
|                                  |            |                     |         |                                                                                                                                                                                    |                    | al approaches                                           |       |       |         |          |                 |
|                                  |            |                     |         |                                                                                                                                                                                    |                    | Introduction                                            | 15:45 | 15:50 | Speaker | Katerina | Chatzidionysiou |
|                                  |            |                     |         |                                                                                                                                                                                    |                    | General Discussion and Q&A                              | 16:40 | 17:00 | Speaker | Katerina | Chatzidionysiou |
|                                  |            |                     |         |                                                                                                                                                                                    |                    | Discussion: Why are some patients "difficult to treat"? | 16:00 | 16:15 | Speaker | Paula    | David           |
|                                  |            |                     |         |                                                                                                                                                                                    |                    |                                                         |       |       | Chair   | Diane    | van der Woude   |
|                                  |            |                     |         |                                                                                                                                                                                    |                    |                                                         |       |       | Chair   | Katerina | Chatzidionysiou |
| Dermatomyositis and Polymyositis | 12/06/2025 | 16:30:00 - 17:15:00 | Plenary | 1. Review and analyse the latest pharmacological treatments for dermatomyositis and polymyositis including immunosuppressive and biologics drugs; 2. learn to develop personalised | How to Treat (HOT) | Dermatomyositis and Polymyositis                        | 16:30 | 17:15 | Speaker | Alain    | Meyer           |
| Dermatomyositis and Polymyositis |            |                     |         |                                                                                                                                                                                    |                    |                                                         |       |       | Chair   | Lorenzo  | Cavagna         |
| Dermatomyositis and Polymyositis |            |                     |         |                                                                                                                                                                                    |                    |                                                         |       |       | Chair   | Marzena  | Olesinska       |

|                                                    |            |                     |                   |                                                                                                                                                                                                                                               |                       |                                                    |       |       |         |        |        |
|----------------------------------------------------|------------|---------------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|----------------------------------------------------|-------|-------|---------|--------|--------|
|                                                    |            |                     |                   | treatment plans based on patient-specific factors; 3. explore the role of nonpharmacological interventions in inflammatory myopathies.                                                                                                        |                       |                                                    |       |       |         |        |        |
| Do you have “rheum” for a pharmacist in your team? | 13/06/2025 | 09:45:00 - 10:15:00 | Meet the Expert 2 | At the end of the session participants should:1. Have a better understanding of potential roles for clinical pharmacists in rheumatology;2 . Understand how pharmacists can be upskilled to fully participate in the multi-disciplinary team. | Meet the EULAR Expert | Do you have “rheum” for a pharmacist in your team? | 09:45 | 10:15 | Speaker | Hilary | McKnee |

|                                                                                  |            |                     |                   |                                                                                                                                                                                                                                                         |                       |                                                                                  |       |       |         |           |         |
|----------------------------------------------------------------------------------|------------|---------------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|----------------------------------------------------------------------------------|-------|-------|---------|-----------|---------|
| Polymyalgia rheumatica – when to use glucocorticoid sparing agents               | 13/06/2025 | 09:45:00 - 10:15:00 | Meet the Expert 3 | 1. To discuss the potential burden of long-term glucocorticoids in patients with PMR; 2. To discuss potential risk factors for relapses and glucocorticoid-related adverse events; 3. To discuss recent trials on glucocorticoid sparing agents in PMR. | Meet the EULAR Expert | Polymyalgia rheumatica – when to use glucocorticoid sparing agents               | 09:45 | 10:15 | Speaker | Elisabeth | Brouwer |
| Together on the Journey: Child and Family Involvement in Rheumatology Transition | 13/06/2025 | 09:45:00 - 10:15:00 | Meet the Expert 1 | 1. Delegates will learn best practice in supporting children with RMDs; 2. Delegates will learn how to support children as they transition to adult services; 3. Delegates will also be shown                                                           | Meet the EULAR Expert | Together on the Journey: Child and Family Involvement in Rheumatology Transition | 09:45 | 10:15 | Speaker | Klaire    | Connor  |

|                                                                                           |            |                     |                   |                                                                                                                                                                                                                                                                                                                                                    |                       |                                                                                           |       |       |         |      |         |
|-------------------------------------------------------------------------------------------|------------|---------------------|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|-------------------------------------------------------------------------------------------|-------|-------|---------|------|---------|
|                                                                                           |            |                     |                   | how families and siblings can be supported through the transition.                                                                                                                                                                                                                                                                                 |                       |                                                                                           |       |       |         |      |         |
| What are the new treatments for spondyloarthritis and psoriatic arthritis on the horizon? | 13/06/2025 | 09:45:00 - 10:15:00 | Meet the Expert 4 | 1. Identify emerging therapies and drug classes currently in development for the treatment of spondyloarthritis and psoriatic arthritis;2. Evaluate the mechanisms of action and potential benefits of these new treatments compared to existing therapies;3. Discuss the implications of these new treatments for patient management and clinical | Meet the EULAR Expert | What are the new treatments for spondyloarthritis and psoriatic arthritis on the horizon? | 09:45 | 10:15 | Speaker | Paul | Bowness |

|                                                   |            |                     |            |                                                                                                                                                                                                          |                   |                                                     |       |       |         |           |        |
|---------------------------------------------------|------------|---------------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-----------------------------------------------------|-------|-------|---------|-----------|--------|
|                                                   |            |                     |            | practice in spondyloarthritis and psoriatic arthritis.                                                                                                                                                   |                   |                                                     |       |       |         |           |        |
| How to evaluate larger joints: the ankle and knee | 13/06/2025 | 10:30:00 - 11:45:00 | Hands-On 1 | 1. Assessment of ankle and the knee joints by physical examination.2. Assessment of the ankle and the knee joints by ultrasound.3. How to integrate and correlate clinical and ultrasonography findings. | Hands-on Sessions | Discussion on presentations                         | 10:50 | 10:55 | Speaker |           |        |
|                                                   |            |                     |            |                                                                                                                                                                                                          |                   | How to access the knee: clinical examination        | 10:40 | 10:45 | Speaker | Rusmir    | Husic  |
|                                                   |            |                     |            |                                                                                                                                                                                                          |                   | How to access the ankle: clinical examination       | 10:30 | 10:35 | Speaker | Giasna    | Giokic |
|                                                   |            |                     |            |                                                                                                                                                                                                          |                   | Hands-on stations                                   | 10:55 | 11:45 | Speaker | Giasna    | Giokic |
|                                                   |            |                     |            |                                                                                                                                                                                                          |                   | How to access the knee: ultrasonography examination | 10:45 | 10:50 | Speaker | Daniela   | Fodor  |
| How to evaluate larger joints: the ankle and knee |            |                     |            |                                                                                                                                                                                                          |                   | How to access the ankle: ultrasonogra               | 10:35 | 10:40 | Speaker | Esperanza | Naredo |

|                                                                      |                |                        |                |                                                                                                                                                                                                                                                            |                      |                                                                                  |       |       |             |                 |            |
|----------------------------------------------------------------------|----------------|------------------------|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|----------------------------------------------------------------------------------|-------|-------|-------------|-----------------|------------|
|                                                                      |                |                        |                |                                                                                                                                                                                                                                                            |                      | phy<br>examination                                                               |       |       |             |                 |            |
|                                                                      |                |                        |                |                                                                                                                                                                                                                                                            |                      |                                                                                  |       |       | Chair       | Zunaid          | Karim      |
|                                                                      |                |                        |                |                                                                                                                                                                                                                                                            |                      |                                                                                  |       |       | Chair       | David<br>Andrew | Bong       |
| How to<br>evaluate<br>small<br>joints:<br>hand,<br>wrist and<br>foot | 13/06/<br>2025 | 10:30:00 -<br>11:45:00 | Hands-<br>On 2 | 1. Assessment<br>of hand, wrist<br>and foot joints<br>by physical<br>examination;2.<br>Assessment of<br>the hand, wrist<br>and foot joints<br>by<br>ultrasound;3.<br>How to<br>integrate and<br>correlate<br>clinical and<br>ultrasonograph<br>y findings. | Hands-on<br>Sessions | How to<br>access the<br>wrist and<br>hand:<br>ultrasonogra<br>phy<br>examination | 10:35 | 10:40 | Spea<br>ker | Sarah           | Ohrndorf   |
|                                                                      |                |                        |                |                                                                                                                                                                                                                                                            |                      | How to<br>access the<br>foot:<br>ultrasonogra<br>phy<br>examination              | 10:45 | 10:50 | Spea<br>ker | Emilio          | Filippucci |
|                                                                      |                |                        |                |                                                                                                                                                                                                                                                            |                      | How to<br>access the<br>foot: clinical<br>examination                            | 10:40 | 10:45 | Spea<br>ker | Carlo           | Perricone  |
|                                                                      |                |                        |                |                                                                                                                                                                                                                                                            |                      | How to<br>access the<br>wrist and<br>hand: clinical<br>examination               | 10:30 | 10:35 | Spea<br>ker | Luis            | Coronel    |
|                                                                      |                |                        |                |                                                                                                                                                                                                                                                            |                      | Hands-on<br>stations                                                             | 10:55 | 11:45 | Spea<br>ker | Luis            | Coronel    |
|                                                                      |                |                        |                |                                                                                                                                                                                                                                                            |                      | Discussion<br>on<br>presentation<br>s                                            | 10:50 | 10:55 | Spea<br>ker | Ingrid          | Möller     |
|                                                                      |                |                        |                |                                                                                                                                                                                                                                                            |                      |                                                                                  |       |       | Chair       | Miroslav        | Mayer      |
|                                                                      |                |                        |                |                                                                                                                                                                                                                                                            |                      |                                                                                  |       |       |             |                 |            |

|                                           |            |                     |         |                                                                                                                                                                                                                                                                                                 |                    |                                        |       |       |         |           |         |
|-------------------------------------------|------------|---------------------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------------------------|-------|-------|---------|-----------|---------|
|                                           |            |                     |         |                                                                                                                                                                                                                                                                                                 |                    |                                        |       |       | Chair   | Ingrid    | Möller  |
| Large Vessel Vasculitis                   | 13/06/2025 | 10:30:00 - 11:15:00 | Plenary | 1. To learn about recent publications on diagnostic and prognostic procedures in Large Vessel Vasculitis (LVV), particularly Giant cell arteritis (GCA) and Takayasu arteritis (TAK)2. To learn about recent management recommendations and update on novel treatment options in these diseases | What is New (WIN)  | What is new in large vessel vasculitis | 10:30 | 11:15 | Speaker | Sara      | Monti   |
|                                           |            |                     |         |                                                                                                                                                                                                                                                                                                 |                    |                                        |       |       | Chair   | Jens      | Thiel   |
|                                           |            |                     |         |                                                                                                                                                                                                                                                                                                 |                    |                                        |       |       | Chair   | Elisabeth | Brouwer |
| ANCA-associated vasculitis including EGPA | 13/06/2025 | 11:15:00 - 12:00:00 | Plenary | 1. To learn about current treatment recommendations in ANCA associated vasculitis including EGPA;2. To explore new                                                                                                                                                                              | How to Treat (HOT) | ANCA-vasculitis and EGPA               | 11:15 | 12:00 | Speaker | Benjamin  | Terrier |
|                                           |            |                     |         |                                                                                                                                                                                                                                                                                                 |                    |                                        |       |       | Chair   | Allyson   | Egan    |
|                                           |            |                     |         |                                                                                                                                                                                                                                                                                                 |                    |                                        |       |       | Chair   | Nils      | Venhoff |

|                                                                                                            |            |                     |                   |                                                                                                                                                                                                                                                          |                       |                                                                                                            |       |       |         |         |            |
|------------------------------------------------------------------------------------------------------------|------------|---------------------|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|------------------------------------------------------------------------------------------------------------|-------|-------|---------|---------|------------|
|                                                                                                            |            |                     |                   | treatment options in these diseases;3. To learn about prognostic factors and individualised treatment.                                                                                                                                                   |                       |                                                                                                            |       |       |         |         |            |
| Challenges associated with the management of interstitial lung disease in patients with systemic sclerosis | 13/06/2025 | 13:15:00 - 13:45:00 | Meet the Expert 3 | 1. To highlight the unmet needs regarding the management of systemic sclerosis-related interstitial lung disease.2. To learn about diagnosis, clinical relevance and definition of progression. 3. To know about the most modern therapeutic strategies. | Meet the EULAR Expert | Challenges associated with the management of interstitial lung disease in patients with systemic sclerosis | 13:15 | 13:45 | Speaker | Roberto | Giacomelli |
| Challenges associated with the management                                                                  | 13/06/2025 | 13:15:00 - 13:45:00 | Meet the Expert 1 | 1. To discuss the definition difficult to manage Lupus nephritis2. To                                                                                                                                                                                    | Meet the EULAR Expert | Challenges associated with the management                                                                  | 13:15 | 13:45 | Speaker | Anisur  | Rahman     |

|                                                                                                                                       |                |                        |                            |                                                                                                                                                                                                                                                                                                                                                  |                             |                                                                                                                       |       |       |             |     |       |
|---------------------------------------------------------------------------------------------------------------------------------------|----------------|------------------------|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------------------------------------------------------------------------------------------------|-------|-------|-------------|-----|-------|
| ment of<br>Lupus<br>Nephritis                                                                                                         |                |                        |                            | discuss the<br>optimal<br>treatment<br>selection in<br>different cases<br>with lupus<br>nephritis3. To<br>discuss the<br>relevance of<br>repeat biopsy<br>in patients with<br>lupus nephritis                                                                                                                                                    |                             | of Lupus<br>Nephritis                                                                                                 |       |       |             |     |       |
| Conventi<br>onal<br>DMARDs<br>in<br>Rheumat<br>oid<br>Arthritis:<br>rational<br>combinati<br>ons and<br>appropria<br>te follow-<br>up | 13/06/<br>2025 | 13:15:00 -<br>13:45:00 | Meet<br>the<br>Expert<br>4 | 1. To discuss<br>the evidence<br>behind<br>combinations of<br>conventional<br>DMARDs for<br>treatment of<br>RA2. To learn<br>about the<br>rationale<br>behind (the<br>frequency of)<br>follow-up<br>investigation in<br>patients treated<br>with<br>conventional<br>DMARDs3. To<br>discuss the<br>frequency and<br>severity of<br>adverse events | Meet the<br>EULAR<br>Expert | Conventional<br>DMARDs in<br>Rheumatoid<br>Arthritis:<br>rational<br>combination<br>s and<br>appropriate<br>follow-up | 13:15 | 13:45 | Spea<br>ker | Jon | Lampa |

|                                                          |            |                     |                   |                                                                                                                                                                                                                                                     |                       |                                                          |       |       |         |          |         |
|----------------------------------------------------------|------------|---------------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|----------------------------------------------------------|-------|-------|---------|----------|---------|
|                                                          |            |                     |                   | of conventional DMARDs when used as mono- or combination therapy                                                                                                                                                                                    |                       |                                                          |       |       |         |          |         |
| Vaccination in Rheumatic Diseases: anything new in 2025? | 13/06/2025 | 13:15:00 - 13:45:00 | Meet the Expert 2 | 1. What are the recommended vaccination in patients with autoimmune diseases;2. May vaccination induce autoimmune diseases or flare of autoimmune diseases;3. Can immunomodulators alter the vaccine response in patients with autoimmune diseases? | Meet the EULAR Expert | Vaccination in Rheumatic Diseases: anything new in 2025? | 13:15 | 13:45 | Speaker | Ori      | Elkayam |
| Adherence in the transition from                         | 13/06/2025 | 13:30:00 - 14:45:00 | B1                | 1. To identify the primary factors influencing                                                                                                                                                                                                      | Joint                 | Oral Abstract Presentation                               | 14:15 | 14:25 | Speaker |          |         |
|                                                          |            |                     |                   |                                                                                                                                                                                                                                                     |                       | Setting the scene:                                       | 13:30 | 13:45 | Speaker | Valentin | Ritschl |

|                         |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                          |  |                                                                                                                                                                  |       |       |         |         |           |
|-------------------------|--|--|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|---------|---------|-----------|
| pediatric to adult care |  |  |  | (non-)adherence to (non-)pharmacological treatments in children and adolescents and recognise the importance of addressing (non-)adherence early in the treatment process2. To understand the perspectives of children, adolescents, and their parents on adherence to treatment plans, especially in the transition from paediatric to adult rheumatology care3. To discuss the challenges and possible |  | understanding adherence in paediatric rheumatology care                                                                                                          |       |       |         |         |           |
|                         |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                          |  | Discussion and Closing                                                                                                                                           | 14:25 | 14:45 | Speaker | Loreto  | Carmona   |
|                         |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                          |  | From consultation to care: An HPR approach to enhancing adherence in paediatric rheumatology care and the transition from paediatric to adult rheumatology care. | 14:00 | 14:15 | Speaker | Polly   | Livermore |
|                         |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                          |  | Voices of experience: patient and family perspectives on adherence in paediatric rheumatology care                                                               | 13:45 | 14:00 | Speaker | Richard | Beesley   |

|                                                                  |            |                     |    |                                                                                                                                                                                                                                                                                                                  |                                            |                                                                                       |       |       |         |          |               |
|------------------------------------------------------------------|------------|---------------------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|---------------------------------------------------------------------------------------|-------|-------|---------|----------|---------------|
|                                                                  |            |                     |    | strategies for maintaining adherence in transitioning from paediatric to adult rheumatology care                                                                                                                                                                                                                 |                                            |                                                                                       |       |       | Chair   | Fernando | Estevez-Lopez |
|                                                                  |            |                     |    |                                                                                                                                                                                                                                                                                                                  |                                            |                                                                                       |       |       | Chair   | Loreto   | Carmona       |
| Empowering movement and sleep: Innovative digital tools for RMDs | 13/06/2025 | 13:30:00 - 14:45:00 | C1 | Delegates will be able to: 1. Identify challenges in balancing physical activity, rest and sleep and know about the components of a balanced 24-hour day;2. Apply consumer digital technologies to promote an active lifestyle and improve self-management capacity in people with RMDs;3. Discuss opportunities | Health Professionals in Rheumatology (HPR) | Discussion and Closing                                                                | 14:30 | 14:35 | Speaker | Tanja    | Stamm         |
|                                                                  |            |                     |    |                                                                                                                                                                                                                                                                                                                  |                                            | Using digital technology to support physical activity and sleep in people with RMDs   | 13:50 | 14:05 | Speaker | Linda    | Li            |
|                                                                  |            |                     |    |                                                                                                                                                                                                                                                                                                                  |                                            | Using digital technology to support physical activity and sleep in people with RMDs   | 14:05 | 14:10 | Speaker | Linda    | Li            |
|                                                                  |            |                     |    |                                                                                                                                                                                                                                                                                                                  |                                            | Leveraging digital rehabilitation tools for measuring movement in RMDs: opportunities | 14:25 | 14:30 | Speaker | tbc      | tbc           |

|  |  |  |  |                                                                                                                                                    |  |                                                                                                                                                       |       |       |         |         |        |
|--|--|--|--|----------------------------------------------------------------------------------------------------------------------------------------------------|--|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|---------|---------|--------|
|  |  |  |  | and challenges in using digital rehabilitation tools to measure and address physical activity, sedentary behaviour, and sleep in people with RMDs. |  | , challenges and implementation strategies in clinical practice.                                                                                      |       |       |         |         |        |
|  |  |  |  |                                                                                                                                                    |  | Leveraging digital rehabilitation tools for measuring movement in RMDs: opportunities, challenges and implementation strategies in clinical practice. | 14:10 | 14:25 | Speaker | tbc     | tbc    |
|  |  |  |  |                                                                                                                                                    |  | The whole day matters: understanding the 24-hour movement paradigm and relationships with health indicators across the lifespan                       | 13:45 | 13:50 | Speaker | Florian | Milatz |

|                                                       |            |                     |            |                                                                                                                                                                                                              |                   |                                                                                                                                 |       |       |         |                 |            |
|-------------------------------------------------------|------------|---------------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------|-------|-------|---------|-----------------|------------|
|                                                       |            |                     |            |                                                                                                                                                                                                              |                   | The whole day matters: understanding the 24-hour movement paradigm and relationships with health indicators across the lifespan | 13:30 | 13:45 | Speaker | Florian         | Milatz     |
|                                                       |            |                     |            |                                                                                                                                                                                                              |                   |                                                                                                                                 |       |       | Chair   | Tanja           | Stamm      |
|                                                       |            |                     |            |                                                                                                                                                                                                              |                   |                                                                                                                                 |       |       | Chair   | Devrim Can      | SARAÇ      |
| How to evaluate larger joints: the shoulder and elbow | 13/06/2025 | 13:30:00 - 14:45:00 | Hands-On 1 | 1. Assessment of the shoulder and elbow joints by physical examination;2. Assessment of the shoulder and elbow joints by ultrasound;3. How to integrate and correlate clinical and ultrasonography findings. | Hands-on Sessions | How to access the elbow: ultrasonography examination                                                                            | 13:35 | 13:40 | Speaker | Lene            | Terslev    |
|                                                       |            |                     |            |                                                                                                                                                                                                              |                   | Discussion on presentations                                                                                                     | 13:50 | 13:55 | Speaker | David           | Kane       |
|                                                       |            |                     |            |                                                                                                                                                                                                              |                   | How to access the shoulder: clinical examination                                                                                | 13:40 | 13:45 | Speaker | Edoardo         | Cipolletta |
|                                                       |            |                     |            |                                                                                                                                                                                                              |                   | How to access the elbow:                                                                                                        | 13:30 | 13:35 | Speaker | Florentin Ananu | Vreju      |

|                                                                             |            |                     |    |                                                                                                                                                                                                                                                                                                 |              |                                                                                           |       |       |         |                 |                        |
|-----------------------------------------------------------------------------|------------|---------------------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------------------------------------------------------------------------------------------|-------|-------|---------|-----------------|------------------------|
|                                                                             |            |                     |    |                                                                                                                                                                                                                                                                                                 |              | clinical examination                                                                      |       |       |         |                 |                        |
|                                                                             |            |                     |    |                                                                                                                                                                                                                                                                                                 |              | Hands-on stations                                                                         | 13:55 | 14:45 | Speaker | Florentin Ananu | Vreju                  |
|                                                                             |            |                     |    |                                                                                                                                                                                                                                                                                                 |              | How to access the shoulder: ultrasonography examination                                   | 13:45 | 13:50 | Speaker | Giorgio         | Tamborrini-Schütz      |
|                                                                             |            |                     |    |                                                                                                                                                                                                                                                                                                 |              |                                                                                           |       |       | Chair   | David           | Kane                   |
|                                                                             |            |                     |    |                                                                                                                                                                                                                                                                                                 |              |                                                                                           |       |       | Chair   | Petra           | Hanova                 |
| Individuals at high risk of rheumatoid arthritis: a new treatment frontier? | 13/06/2025 | 13:30:00 - 14:45:00 | B2 | 1. To discuss the most appropriate clinical management of the individuals at high risk for developing rheumatoid arthritis;2. To discuss how to best stratify individuals at high risk for developing rheumatoid arthritis;3. To discuss when and how to pharmacologically treat individuals at | EULAR Debate | Data in support of treatment efficacy of individuals at high risk of rheumatoid arthritis | 14:05 | 14:20 | Speaker | Jürgen          | Rech                   |
|                                                                             |            |                     |    |                                                                                                                                                                                                                                                                                                 |              | Data in support of treatment efficacy of individuals at high risk of rheumatoid arthritis | 13:35 | 13:50 | Speaker | Jürgen          | Rech                   |
|                                                                             |            |                     |    |                                                                                                                                                                                                                                                                                                 |              | Data NOT in support of treatment efficacy of individuals at high risk of                  | 14:20 | 14:35 | Speaker | Annette H.M.    | van der Helm – van Mil |

|                                        |            |                     |     |                                                                                                                                                              |              |                                                                                               |       |       |         |              |                        |
|----------------------------------------|------------|---------------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----------------------------------------------------------------------------------------------|-------|-------|---------|--------------|------------------------|
|                                        |            |                     |     | high risk for developing rheumatoid arthritis.                                                                                                               |              | rheumatoid arthritis                                                                          |       |       |         |              |                        |
|                                        |            |                     |     |                                                                                                                                                              |              | Data NOT in support of treatment efficacy of individuals at high risk of rheumatoid arthritis | 13:50 | 14:05 | Speaker | Annette H.M. | van der Helm – van Mil |
|                                        |            |                     |     |                                                                                                                                                              |              | Audience Voting and Closing                                                                   | 14:35 | 14:45 | Speaker | Andrea       | Rubbert-Roth           |
|                                        |            |                     |     |                                                                                                                                                              |              | Introduction & Audience Voting                                                                | 13:30 | 13:35 | Speaker | Mustafa      | Ekici                  |
|                                        |            |                     |     |                                                                                                                                                              |              |                                                                                               |       |       | Chair   | Andrea       | Rubbert-Roth           |
|                                        |            |                     |     |                                                                                                                                                              |              |                                                                                               |       |       | Chair   | Mustafa      | Ekici                  |
| Is fibromyalgia an autoimmune disease? | 13/06/2025 | 13:30:00 - 14:45:00 | 6.1 | 1. To discuss the evidence for a possible autoimmune vs. non-autoimmune origin of fibromyalgia. 2. To discuss the role of inflammation and antibodies in the | EULAR Debate | Audience Voting                                                                               | 14:30 | 14:30 | Speaker |              |                        |
|                                        |            |                     |     |                                                                                                                                                              |              | Fibromyalgia is an autoimmune disease                                                         | 13:40 | 13:55 | Speaker | Andreas      | Goebel                 |
|                                        |            |                     |     |                                                                                                                                                              |              | Audience Voting                                                                               | 13:40 | 13:40 | Speaker |              |                        |
|                                        |            |                     |     |                                                                                                                                                              |              | Oral Abstract Presentation                                                                    | 13:30 | 13:40 | Speaker |              |                        |
|                                        |            |                     |     |                                                                                                                                                              |              | Fibromyalgia is an autoimmune disease                                                         | 14:10 | 14:20 | Speaker | Andreas      | Goebel                 |

|                                                                      |            |                     |    |                                                                                                                                                                                                                                                          |                  |                                                          |       |       |         |                  |          |
|----------------------------------------------------------------------|------------|---------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|----------------------------------------------------------|-------|-------|---------|------------------|----------|
|                                                                      |            |                     |    | modification of pain perception                                                                                                                                                                                                                          |                  | Q&A and Closing                                          | 14:30 | 14:45 | Speaker | Victoria         | Konzett  |
|                                                                      |            |                     |    |                                                                                                                                                                                                                                                          |                  | Fibromyalgia is NOT an immune-mediated disease           | 14:20 | 14:30 | Speaker | Daniel           | Clauw    |
|                                                                      |            |                     |    |                                                                                                                                                                                                                                                          |                  | Fibromyalgia is NOT an immune-mediated disease           | 13:55 | 14:10 | Speaker | Daniel           | Clauw    |
|                                                                      |            |                     |    |                                                                                                                                                                                                                                                          |                  |                                                          |       |       | Chair   | Neil             | Basu     |
|                                                                      |            |                     |    |                                                                                                                                                                                                                                                          |                  |                                                          |       |       | Chair   | Victoria         | Konzett  |
| Management of extra-articular manifestations of rheumatoid arthritis | 13/06/2025 | 13:30:00 - 14:45:00 | F3 | Participants will - understand the latest approaches for managing extra-articular manifestations of rheumatoid arthritis; - identify effective diagnostic and treatment strategies for rheumatoid nodules, vasculitis, secondary Sjögren's syndrome, and | Clinical Science | Closing                                                  | 14:30 | 14:35 | Speaker | Ilenia           | Di Cola  |
|                                                                      |            |                     |    |                                                                                                                                                                                                                                                          |                  | Risk of Malignant Lymphoma: Is the Risk Still Increased? | 14:10 | 14:25 | Speaker | Karin            | Hellgren |
|                                                                      |            |                     |    |                                                                                                                                                                                                                                                          |                  | Risk of Malignant Lymphoma: Is the Risk Still Increased? | 14:25 | 14:30 | Speaker | Karin            | Hellgren |
|                                                                      |            |                     |    |                                                                                                                                                                                                                                                          |                  | Management of rheumatoid nodules                         | 13:30 | 13:45 | Speaker | Christopher John | Edwards  |
|                                                                      |            |                     |    |                                                                                                                                                                                                                                                          |                  | Management of                                            | 13:45 | 13:50 | Speaker | Christopher John | Edwards  |

|                                                       |            |                     |     |                                                                                                                                                                                                                                          |       |                                                                                                   |       |       |         |              |              |
|-------------------------------------------------------|------------|---------------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|---------------------------------------------------------------------------------------------------|-------|-------|---------|--------------|--------------|
|                                                       |            |                     |     | the risk of malignant lymphoma; - apply evidence-based practices to improve patient outcomes and reduce complications associated with these conditions.                                                                                  |       | rheumatoid nodules                                                                                |       |       |         |              |              |
|                                                       |            |                     |     |                                                                                                                                                                                                                                          |       | Rheumatoid vasculitis: still a threat?                                                            | 14:05 | 14:10 | Speaker | Ashima       | Makol        |
|                                                       |            |                     |     |                                                                                                                                                                                                                                          |       | Rheumatoid vasculitis: still a threat?                                                            | 13:50 | 14:05 | Speaker | Ashima       | Makol        |
|                                                       |            |                     |     |                                                                                                                                                                                                                                          |       |                                                                                                   |       |       | Chair   | Alejandro    | Balsa        |
|                                                       |            |                     |     |                                                                                                                                                                                                                                          |       |                                                                                                   |       |       | Chair   | Ilenia       | Di Cola      |
| Managing Sarcopenia and Frailty in patients with RMDs | 13/06/2025 | 13:30:00 - 14:45:00 | 6.2 | 1. Understand the assessments and diagnosis of sarcopenia and frailty2. Develop approach to manage sarcopenia and frailty and its consequences in inflammatory RMDs3. Recognise sarcopenic obesity as an important subtype of obesity in | Joint | Sarcopenia and Frailty: Assessment and Diagnosis                                                  | 13:30 | 13:50 | Speaker | Alfonso Jose | Cruz-Jentoft |
|                                                       |            |                     |     |                                                                                                                                                                                                                                          |       | Sarcopenia and Frailty: Assessment and Diagnosis                                                  | 13:50 | 13:55 | Speaker | Alfonso Jose | Cruz-Jentoft |
|                                                       |            |                     |     |                                                                                                                                                                                                                                          |       | Sarcopenic Obesity: Considerations for unique consequences of Weight Loss Drugs in Osteoarthritis | 14:40 | 14:45 | Speaker | Kristine     | Godziuk      |

|                                   |            |                     |            |                                                                                     |                   |                                                                                                   |       |       |         |          |            |
|-----------------------------------|------------|---------------------|------------|-------------------------------------------------------------------------------------|-------------------|---------------------------------------------------------------------------------------------------|-------|-------|---------|----------|------------|
|                                   |            |                     |            | osteoarthritis, and the differential impacts of weight loss drugs in osteoarthritis |                   | Management of frailty and its consequences in patients with inflammatory RMDs                     | 14:15 | 14:20 | Speaker | Lisa A.  | Mandl      |
|                                   |            |                     |            |                                                                                     |                   | Management of frailty and its consequences in patients with inflammatory RMDs                     | 13:55 | 14:15 | Speaker | Lisa A.  | Mandl      |
|                                   |            |                     |            |                                                                                     |                   | Sarcopenic Obesity: Considerations for unique consequences of Weight Loss Drugs in Osteoarthritis | 14:20 | 14:40 | Speaker | Kristine | Godziuk    |
|                                   |            |                     |            |                                                                                     |                   |                                                                                                   |       |       | Chair   | tbc      | tbc        |
|                                   |            |                     |            |                                                                                     |                   |                                                                                                   |       |       | Chair   | Elena    | Myasoedova |
| Musculoskeletal Ultrasound-guided | 13/06/2025 | 13:30:00 - 14:45:00 | Hands-On 2 | 1. How to perform ultrasound-guided synovial biopsies;2.                            | Hands-on Sessions | Ultrasound-guided joint aspirations and injections                                                | 13:44 | 13:51 | Speaker | Peter    | Mandl      |

|                                                                        |            |                     |    |                                                                                                                                                                                                                                                 |                         |                                                                              |       |       |         |         |          |
|------------------------------------------------------------------------|------------|---------------------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|------------------------------------------------------------------------------|-------|-------|---------|---------|----------|
| procedures                                                             |            |                     |    | How to perform ultrasound-guided peri-articular procedures;3. How to perform ultrasound-guided joint aspirations and injections;4. Preparation and aftercare, do's and don'ts of these rheumatology procedures;5. Supervised hands-on practice. |                         | Ultrasound-guided peri-articular procedures                                  | 13:37 | 13:44 | Speaker | Violeta | Vlad     |
|                                                                        |            |                     |    |                                                                                                                                                                                                                                                 |                         | Ultrasound-guided synovial biopsy                                            | 13:30 | 13:37 | Speaker | Aurelie | Najm     |
|                                                                        |            |                     |    |                                                                                                                                                                                                                                                 |                         | Hands-on stations                                                            | 13:56 | 14:45 | Speaker | Aurelie | Najm     |
|                                                                        |            |                     |    |                                                                                                                                                                                                                                                 |                         | Discussion on presentations                                                  | 13:51 | 13:56 | Speaker | Nemanja | Damjanov |
|                                                                        |            |                     |    |                                                                                                                                                                                                                                                 |                         |                                                                              |       |       | Chair   | Nemanja | Damjanov |
|                                                                        |            |                     |    |                                                                                                                                                                                                                                                 |                         |                                                                              |       |       | Chair   | PLAMEN  | TODOROV  |
| Neutrophil functions in non-infectious inflammatory rheumatic diseases | 13/06/2025 | 13:30:00 - 14:45:00 | A3 | 1. To learn how neutrophils contribute to tissue damage in autoinflammatory and autoimmune diseases; 2. To understand how gain-of-function mutations in myeloid kinases                                                                         | Basic and Translational | Neutrophils in autoimmune and autoinflammatory diseases: from mice to humans | 13:30 | 13:50 | Speaker | Attila  | Mocsai   |
|                                                                        |            |                     |    |                                                                                                                                                                                                                                                 |                         | Neutrophils in autoimmune and autoinflammatory                               | 13:50 | 13:55 | Speaker | Attila  | Mocsai   |

|                                    |            |                     |    |                                                                                                                                                                                                                                              |                  |                                                                        |       |       |         |         |                   |
|------------------------------------|------------|---------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|------------------------------------------------------------------------|-------|-------|---------|---------|-------------------|
|                                    |            |                     |    | contribute to inflammation;<br>3. To learn how Neutrophil extracellular trap (NET) formation and degradation could enhance the exposure of the immune system to modified autoantigens, promote vascular disease, and increase tissue damage. |                  | diseases: from mice to humans                                          |       |       |         |         |                   |
|                                    |            |                     |    |                                                                                                                                                                                                                                              |                  | NETosis in systemic autoimmune disorders                               | 14:40 | 14:45 | Speaker | Mariana | Kaplan            |
|                                    |            |                     |    |                                                                                                                                                                                                                                              |                  | Neutrophils in juvenile and adult patients with inflammatory arthritis | 14:15 | 14:20 | Speaker | Peter   | Nigrovic          |
|                                    |            |                     |    |                                                                                                                                                                                                                                              |                  | Neutrophils in juvenile and adult patients with inflammatory arthritis | 13:55 | 14:15 | Speaker | Peter   | Nigrovic          |
|                                    |            |                     |    |                                                                                                                                                                                                                                              |                  | NETosis in systemic autoimmune disorders                               | 14:20 | 14:40 | Speaker | Mariana | Kaplan            |
|                                    |            |                     |    |                                                                                                                                                                                                                                              |                  |                                                                        |       |       | Chair   | Ricardo | Grieshaber-Bouyer |
|                                    |            |                     |    |                                                                                                                                                                                                                                              |                  |                                                                        |       |       | Chair   | Tamás   | Németh            |
| Post-infectious rheumatic diseases | 13/06/2025 | 13:30:00 - 14:45:00 | A2 | 1. Learn how a viral infection can trigger rheumatic manifestations<br>2. Learn about musculoskeletal manifestations                                                                                                                         | Clinical Science | Bacteria-triggered Reactive Arthritis                                  | 14:20 | 14:40 | Speaker | tbc     | tbc               |
|                                    |            |                     |    |                                                                                                                                                                                                                                              |                  | Bacteria-triggered Reactive Arthritis                                  | 14:40 | 14:45 | Speaker | tbc     | tbc               |

|                                                    |            |                     |    |                                                                                             |                  |                                                                       |       |       |         |           |            |
|----------------------------------------------------|------------|---------------------|----|---------------------------------------------------------------------------------------------|------------------|-----------------------------------------------------------------------|-------|-------|---------|-----------|------------|
|                                                    |            |                     |    | in Lyme disease and post Lyme syndrome 3. Learn about Bacteria-triggered Reactive Arthritis |                  | Musculoskeletal manifestations in Lyme disease and post Lyme syndrome | 14:15 | 14:20 | Speaker | Volker    | Fingerle   |
|                                                    |            |                     |    |                                                                                             |                  | Musculoskeletal manifestations in Lyme disease and post Lyme syndrome | 13:55 | 14:15 | Speaker | Volker    | Fingerle   |
|                                                    |            |                     |    |                                                                                             |                  | Inflammatory rheumatic diseases following viral infections            | 13:50 | 13:55 | Speaker | Francesco | Ursini     |
|                                                    |            |                     |    |                                                                                             |                  | Inflammatory rheumatic diseases following viral infections            | 13:30 | 13:50 | Speaker | Francesco | Ursini     |
|                                                    |            |                     |    |                                                                                             |                  |                                                                       |       |       | Chair   | Dimitrios | Daoussis   |
| Rare vasculitis: update on diagnosis and treatment | 13/06/2025 | 13:30:00 - 14:45:00 | F1 | 1. To learn about the key clinical features of rare vasculitis;2. To learn about how to     | Clinical Science | Primary CNS vasculitis                                                | 13:50 | 13:55 | Speaker | Bernhard  | Hellmich   |
|                                                    |            |                     |    |                                                                                             |                  | Primary CNS vasculitis                                                | 13:30 | 13:50 | Speaker | Bernhard  | Hellmich   |
|                                                    |            |                     |    |                                                                                             |                  | Cryoglobulinemic vasculitis                                           | 14:40 | 14:45 | Speaker | Luca      | Quartuccio |

|                                                        |            |                     |     |                                                                                                                                |                                 |                                                                  |       |       |         |          |            |
|--------------------------------------------------------|------------|---------------------|-----|--------------------------------------------------------------------------------------------------------------------------------|---------------------------------|------------------------------------------------------------------|-------|-------|---------|----------|------------|
|                                                        |            |                     |     | diagnose these diseases and about the most relevant differential diagnoses;3. To learn about how to treat these diseases.      |                                 | Cryoglobulinemic vasculitis                                      | 14:20 | 14:40 | Speaker | Luca     | Quartuccio |
|                                                        |            |                     |     |                                                                                                                                |                                 | Polyarteritis nodosa                                             | 13:55 | 14:15 | Speaker | Katya    | Meridor    |
|                                                        |            |                     |     |                                                                                                                                |                                 | Polyarteritis nodosa                                             | 14:15 | 14:20 | Speaker | Katya    | Meridor    |
|                                                        |            |                     |     |                                                                                                                                |                                 |                                                                  |       |       | Chair   | Carlo    | Salvarani  |
|                                                        |            |                     |     |                                                                                                                                |                                 |                                                                  |       |       | Chair   | ALOJZIJA | HOCEVAR    |
| Sarcoidosis - challenges with diagnosis and management | 13/06/2025 | 13:30:00 - 14:45:00 | 6.3 | This session seeks to offer guidance on:1. diagnosing complex cases of sarcoidosis;2. managing difficult organ manifestations. | Challenges in Clinical Practice | Case by junior, chosen by senior                                 | 13:30 | 13:45 | Speaker |          |            |
|                                                        |            |                     |     |                                                                                                                                |                                 | Case by junior, chosen by senior                                 | 14:05 | 14:20 | Speaker | Matheus  | Vieira     |
|                                                        |            |                     |     |                                                                                                                                |                                 | Insights into CNS Sarcoidosis: A comprehensive case presentation | 14:20 | 14:40 | Speaker | Matheus  | Vieira     |
|                                                        |            |                     |     |                                                                                                                                |                                 | Q&A and Closing                                                  | 14:40 | 14:45 | Speaker | Jan      | Schirmer   |
|                                                        |            |                     |     |                                                                                                                                |                                 | Approach to a diagnosis of a complex case of Sarcoidosis         | 13:45 | 14:05 | Speaker | James    | Galloway   |
|                                                        |            |                     |     |                                                                                                                                |                                 |                                                                  |       |       | Chair   | Sara     | Monti      |
|                                                        |            |                     |     |                                                                                                                                |                                 |                                                                  |       |       | Chair   | Jan      | Schirmer   |

|                                     |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |                                                                          |       |       |         |              |               |
|-------------------------------------|------------|---------------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------------------------------------------------------------|-------|-------|---------|--------------|---------------|
| Spotlight Consultation: Scleroderma | 13/06/2025 | 13:30:00 - 14:45:00 | 6.4 | Difficult cases with several critical decisions will be discussed by three experts on the stage and the audience. The experts will not be aware of the cases and express their recommendations spontaneously based on evidence and clinical experience. Learning objectives: 1. To understand the scientific basis behind clinical decisions in patients with difficult to manage systemic sclerosis 2. To explore the (lack of) evidence and | Innovation | Discussions: Critical decisions in patients with Scleroderma             | 14:15 | 14:45 | Speaker | Yannick      | Allanore      |
|                                     |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                               |            | Spotlight Consultations: Critical decisions in patients with Scleroderma | 13:35 | 14:15 | Speaker | Latika       | Gupta         |
|                                     |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                               |            | Introduction                                                             | 13:30 | 13:35 | Speaker | Christophe r | Denton        |
|                                     |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |                                                                          |       |       | Chair   | Christophe r | Denton        |
|                                     |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |                                                                          |       |       | Chair   | Cristiana    | Sieiro Santos |

|                                     |            |                     |    |                                                                                                                                                                                                                                                                |      |                                                                                |       |       |         |          |            |
|-------------------------------------|------------|---------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|--------------------------------------------------------------------------------|-------|-------|---------|----------|------------|
|                                     |            |                     |    | clinical guidance in clinical practice of difficult cases                                                                                                                                                                                                      |      |                                                                                |       |       |         |          |            |
| Stop Eating Tomatoes and Move More! | 13/06/2025 | 13:30:00 - 14:45:00 | C3 | 1. This session will explore the wider impact of lifestyle factors on inflammation and symptoms. 2. Delegates will learn about the importance of nutrition and gut health. 3. Delegates will learn about importance of stress reduction and physical activity. | PARE | Oral Abstract Presentation                                                     | 14:15 | 14:25 | Speaker |          |            |
|                                     |            |                     |    |                                                                                                                                                                                                                                                                |      | Oral Abstract Presentation                                                     | 14:25 | 14:35 | Speaker |          |            |
|                                     |            |                     |    |                                                                                                                                                                                                                                                                |      | Nutrition and having an RMD - what to be aware of                              | 14:00 | 14:15 | Speaker | Connie   | Ziegler    |
|                                     |            |                     |    |                                                                                                                                                                                                                                                                |      | Closing                                                                        | 14:35 | 14:45 | Speaker | Shalaleh | Karkon     |
|                                     |            |                     |    |                                                                                                                                                                                                                                                                |      | Endotarget and the Relationship Between Gut, Microbiota and Rheumatic Diseases | 13:45 | 14:00 | Speaker | Rodolfo  | Gómez      |
|                                     |            |                     |    |                                                                                                                                                                                                                                                                |      | Self-management (physical activity and stress reduction) and gut health        | 13:30 | 13:45 | Speaker | Elena    | Nikiphorou |
|                                     |            |                     |    |                                                                                                                                                                                                                                                                |      |                                                                                |       |       | Chair   | Shalaleh | Karkon     |
|                                     |            |                     |    |                                                                                                                                                                                                                                                                |      |                                                                                |       |       | Chair   | Andri    | Phoka      |

|                                                                     |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                      |                |                                                                                                |       |       |         |               |         |
|---------------------------------------------------------------------|------------|---------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|------------------------------------------------------------------------------------------------|-------|-------|---------|---------------|---------|
| The Art of Inquiry: How, When, and Why in building a rheumatologist | 13/06/2025 | 13:30:00 - 14:45:00 | B4 | 1. To learn about the importance of finding a mentor for personal and professional development, 2. To understand the need of coaching and leadership for training and career, 3. To discuss how arts and humanities can make us better doctors by enhancing empathy and by improving observational and communication skillsKeep up to date with EULAR Education here | EULAR Projects | How arts and humanities can improve medical education in rheumatology: the two faces of Apollo | 14:20 | 14:40 | Speaker | Valderilio F  | Azevedo |
|                                                                     |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                      |                | How arts and humanities can improve medical education in rheumatology: the two faces of Apollo | 14:40 | 14:45 | Speaker | Valderilio F  | Azevedo |
|                                                                     |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                      |                | When minds meet, opportunities flourish: EULAR-EMEUNET Mentorship program                      | 13:50 | 13:55 | Speaker | Luis Fernando | Perez   |
|                                                                     |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                      |                | When minds meet, opportunities flourish: EULAR-EMEUNET                                         | 13:30 | 13:50 | Speaker | Luis Fernando | Perez   |

|                                              |            |                     |    |                                                                                                                                                                                                   |                  |                                                         |       |       |         |           |        |
|----------------------------------------------|------------|---------------------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|---------------------------------------------------------|-------|-------|---------|-----------|--------|
|                                              |            |                     |    |                                                                                                                                                                                                   |                  | Mentorship program                                      |       |       |         |           |        |
|                                              |            |                     |    |                                                                                                                                                                                                   |                  | Professional behavior changes: how could coaching help? | 13:55 | 14:15 | Speaker | Iulia     | Deac   |
|                                              |            |                     |    |                                                                                                                                                                                                   |                  | Professional behavior changes: how could coaching help? | 14:15 | 14:20 | Speaker | Iulia     | Deac   |
|                                              |            |                     |    |                                                                                                                                                                                                   |                  |                                                         |       |       | Chair   | Simona    | Rednic |
|                                              |            |                     |    |                                                                                                                                                                                                   |                  |                                                         |       |       | Chair   | Francisca | Sivera |
| Treating challenging manifestations in Lupus | 13/06/2025 | 13:30:00 - 14:45:00 | D1 | Understanding the importance of less common manifestations of SLE; Understanding how to diagnose and treat pericarditis in SLE; Understanding how to diagnose and treat GI manifestations in SLE. | Clinical Science | Management of gastrointestinal disease in SLE           | 14:10 | 14:30 | Speaker | tbc       | tbc    |
|                                              |            |                     |    |                                                                                                                                                                                                   |                  | Oral Abstract Presentation                              | 14:30 | 14:40 | Speaker |           |        |
|                                              |            |                     |    |                                                                                                                                                                                                   |                  | Management of pericarditis in SLE                       | 13:50 | 14:10 | Speaker | Eloisa    | Bonfa  |
|                                              |            |                     |    |                                                                                                                                                                                                   |                  | The taskforce on rare SLE manifestations                | 13:30 | 13:50 | Speaker | Laurent   | Arnaud |
|                                              |            |                     |    |                                                                                                                                                                                                   |                  | Q&A and Closing                                         | 14:40 | 14:45 | Speaker | Chris     | Wincup |

|                                                                                                                                                |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                                                          |                  |                                                                                                                |       |       |         |        |           |
|------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|----------------------------------------------------------------------------------------------------------------|-------|-------|---------|--------|-----------|
|                                                                                                                                                |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                                                          |                  |                                                                                                                |       |       | Chair   | Chris  | Wincup    |
|                                                                                                                                                |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                                                          |                  |                                                                                                                |       |       | Chair   | Chiara | Tani      |
| Unveiling the Hidden Rheumatologic Challenges in Migrant Populations: Navigating the Impact of Environmental, Dietary, and Infectious Factors" | 13/06/2025 | 13:30:00 - 14:45:00 | A1 | 1. Understand the Environmental Influence on Rheumatologic Health. Explore how sudden changes in climate, geography, and living conditions impact the presentation and progression of rheumatologic conditions such as sickle cell disease;2. Understand how Infections like malaria, tuberculosis, and dengue fever, prevalent in certain regions, may trigger or exacerbate rheumatologic disorders in | Clinical Science | Oral Abstract Presentation                                                                                     | 14:30 | 14:40 | Speaker |        |           |
|                                                                                                                                                |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                                                          |                  | Infectious causes of Rheumatic Diseases (Chikungunya, TB, Leprosy, HIV, Viral Haemorrhagic Fevers, Dengue etc) | 13:30 | 13:45 | Speaker | Amita  | Aggarwal  |
|                                                                                                                                                |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                                                          |                  | Infectious causes of Rheumatic Diseases (Chikungunya, TB, Leprosy, HIV, Viral Haemorrhagic Fevers, Dengue etc) | 13:45 | 13:50 | Speaker | Amita  | Aggarwal  |
|                                                                                                                                                |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                                                          |                  | Closing                                                                                                        | 14:40 | 14:45 | Speaker | Angela | Migowa    |
|                                                                                                                                                |            |                     |    |                                                                                                                                                                                                                                                                                                                                                                                                          |                  | Multidisciplinary Approach to Migrant Rheumatology Care                                                        | 14:10 | 14:25 | Speaker | Ihsane | Hmamouchi |

|                                   |            |                     |         |                                                                                                                                                                                      |                   |                                                         |       |       |         |          |                |
|-----------------------------------|------------|---------------------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|---------------------------------------------------------|-------|-------|---------|----------|----------------|
|                                   |            |                     |         | migrants;3. Discuss how dietary changes experienced by migrants, including nutrient deficiencies or excesses, influence the onset or management of rheumatologic symptoms.           |                   | Multidisciplinary Approach to Migrant Rheumatology Care | 14:25 | 14:30 | Speaker | Ihsane   | Hmamouchi      |
|                                   |            |                     |         |                                                                                                                                                                                      |                   | Musculoskeletal Manifestations in Sickle Cell Disease   | 13:50 | 14:05 | Speaker | Ayodele  | Faleye         |
|                                   |            |                     |         |                                                                                                                                                                                      |                   | Musculoskeletal Manifestations in Sickle Cell Disease   | 14:05 | 14:10 | Speaker | Ayodele  | Faleye         |
|                                   |            |                     |         |                                                                                                                                                                                      |                   |                                                         |       |       | Chair   | Angela   | Migowa         |
|                                   |            |                     |         |                                                                                                                                                                                      |                   |                                                         |       |       | Chair   | cathy    | Melong Pianta  |
| What is new in spondyloarthritis? | 13/06/2025 | 13:30:00 - 14:15:00 | Plenary | 1. Understand Recent Developments in Pathophysiology2. Review Advances in Diagnosis and Classification3. Review Recent Advances in Treatment Strategies4. Incorporate New Guidelines | What is New (WIN) | What is new in spondyloarthritis                        | 13:30 | 14:15 | Speaker | Helena   | Marzo-Ortega   |
|                                   |            |                     |         |                                                                                                                                                                                      |                   |                                                         |       |       | Chair   | Denis    | Poddubnyy      |
|                                   |            |                     |         |                                                                                                                                                                                      |                   |                                                         |       |       | Chair   | Victoria | Navarro-Compán |

|                     |            |                     |         |                                                                                                                                                                                                                                                                                                                                                           |                    |                                            |       |       |         |            |               |
|---------------------|------------|---------------------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|--------------------------------------------|-------|-------|---------|------------|---------------|
|                     |            |                     |         | into Clinical Practice5. Explore Emerging Research and Future Directions                                                                                                                                                                                                                                                                                  |                    |                                            |       |       |         |            |               |
| Psoriatic Arthritis | 13/06/2025 | 14:15:00 - 15:00:00 | Plenary | 1. To discuss the latest therapeutic advances in the context of psoriatic arthritis; 2. To identify the novelties in the clinical management of psoriatic arthritis; 3. To provide the most modern therapeutic algorithm in improving the outcome of psoriatic arthritis; 4. To know how to minimise the disease damage over time in psoriatic arthritis. | How to Treat (HOT) | The latest advances in psoriatic arthritis | 14:15 | 15:00 | Speaker | Laura C.   | Coates        |
|                     |            |                     |         |                                                                                                                                                                                                                                                                                                                                                           |                    |                                            |       |       | Chair   | Filip      | van den Bosch |
|                     |            |                     |         |                                                                                                                                                                                                                                                                                                                                                           |                    |                                            |       |       | Chair   | Clementina | López-Medina  |

|                                                                     |            |                     |                   |                                                                                                                                                                                                                                                                                                           |                       |                                                                     |       |       |         |          |          |
|---------------------------------------------------------------------|------------|---------------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|---------------------------------------------------------------------|-------|-------|---------|----------|----------|
| Burning questions in the management of systemic lupus erythematosus | 13/06/2025 | 15:00:00 - 15:30:00 | Meet the Expert 1 | This session will provide: 1. practical advice regarding the application of targeted therapies in SLE;2. the glucocorticoid dosing strategy and the chance of discontinuation will be shown through real life cases;3. the up-to-date diagnosis and therapy of lupus nephritis will be discussed as well. | Meet the EULAR Expert | Burning questions in the management of systemic lupus erythematosus | 15:00 | 15:30 | Speaker | László   | Kovács   |
| Communicating research to the public                                | 13/06/2025 | 15:00:00 - 15:30:00 | Meet the Expert 3 | 1. Understand importance of communicating research findings to the public and explore common strategies;2. Understand the role of                                                                                                                                                                         | Meet the EULAR Expert | Communicating research to the public                                | 15:00 | 15:30 | Speaker | Kathrine | Daniloff |

|                                                  |            |                     |                   |                                                                                                                                                                                                                                                     |                       |                                                  |       |       |         |       |                 |
|--------------------------------------------------|------------|---------------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|--------------------------------------------------|-------|-------|---------|-------|-----------------|
|                                                  |            |                     |                   | communication professionals and how to collaborate effectively.                                                                                                                                                                                     |                       |                                                  |       |       |         |       |                 |
| Management of vasculopathy in Systemic Sclerosis | 13/06/2025 | 15:00:00 - 15:30:00 | Meet the Expert 2 | 1. To describe the different clinical features of the vascular involvement in systemic sclerosis; 2. To provide clues and pearls for an early diagnosis; 3. To explain the treatment of the different vascular complications in systemic sclerosis. | Meet the EULAR Expert | Management of vasculopathy in systemic sclerosis | 15:00 | 15:30 | Speaker | Marco | Matucci-Cerinic |
| Single Organ Vasculitis                          | 13/06/2025 | 15:00:00 - 15:30:00 | Meet the Expert 4 | Learn about the interaction and overlap with rheumatological disease and what to expect (IBD, chronic hepatitis, autoimmune hepatitis) 1. what to                                                                                                   | Meet the EULAR Expert | Single Organ Vasculitis                          | 15:00 | 15:30 | Speaker | Carlo | Salvarani       |

|                                                                               |            |                     |     |                                                                                                                                                                                                                                       |                  |                                                           |       |       |         |         |        |
|-------------------------------------------------------------------------------|------------|---------------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|-----------------------------------------------------------|-------|-------|---------|---------|--------|
|                                                                               |            |                     |     | consider in pat with chronic liver disease and a newly diagnosed RMD;2. what to do if in a patient with RMD liver values start to rise;3. what to do as screening in patients with RMD.                                               |                  |                                                           |       |       |         |         |        |
| A tasty DISH: Diffuse idiopathic skeletal hyperostosis for the rheumatologist | 13/06/2025 | 15:45:00 - 17:01:00 | 6.1 | 1. Understand the pathophysiological mechanisms underlying DISH, including metabolic and systemic factors;2. Identify the key clinical and imaging manifestations characteristic of DISH;3. Explore current management strategies for | Clinical Science | Abstract Presentation                                     | 16:51 | 17:01 | Speaker |         |        |
|                                                                               |            |                     |     |                                                                                                                                                                                                                                       |                  | Why do people develop DISH? - Pathogenesis of the disease | 16:07 | 16:24 | Speaker | Cheryle | Séguin |
|                                                                               |            |                     |     |                                                                                                                                                                                                                                       |                  | Why do people develop DISH? - Pathogenesis of the disease | 16:24 | 16:29 | Speaker | tbc     | tbc    |
|                                                                               |            |                     |     |                                                                                                                                                                                                                                       |                  | Imaging of DISH: An Interactive                           | 15:45 | 16:02 | Speaker | Iris    | Eshed  |

|                   |            |                     |    |                                                                                                                                                                                          |                |                                                    |       |       |         |           |         |
|-------------------|------------|---------------------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|----------------------------------------------------|-------|-------|---------|-----------|---------|
|                   |            |                     |    | DISH, including pharmacological and non-pharmacological approaches.                                                                                                                      |                | Quiz with Case                                     |       |       |         |           |         |
|                   |            |                     |    |                                                                                                                                                                                          |                | Imaging of DISH: An Interactive Quiz with Case     | 16:02 | 16:07 | Speaker | Iris      | Eshed   |
|                   |            |                     |    |                                                                                                                                                                                          |                | How to deal with DISH? - Management of the disease | 16:46 | 16:51 | Speaker | Nelly     | Ziade   |
|                   |            |                     |    |                                                                                                                                                                                          |                | How to deal with DISH? - Management of the disease | 16:29 | 16:46 | Speaker | Nelly     | Ziade   |
|                   |            |                     |    |                                                                                                                                                                                          |                |                                                    |       |       | Chair   | Kay-Geert | Hermann |
|                   |            |                     |    |                                                                                                                                                                                          |                |                                                    |       |       | Chair   | Peter     | Balint  |
| A&R - ARD Session | 13/06/2025 | 15:45:00 - 17:00:00 | F3 | To learn more about the editorial selection process for Arthritis & Rheumatology and Annals of the Rheumatic Diseases. To appreciate the value and importance of the review and revision | EULAR Projects | ARD Paper 1                                        | 15:50 | 16:00 | Speaker |           |         |
|                   |            |                     |    |                                                                                                                                                                                          |                | Discussion on ARD Paper 1                          | 16:00 | 16:03 | Speaker |           |         |
|                   |            |                     |    |                                                                                                                                                                                          |                | A&R Paper 1                                        | 16:03 | 16:13 | Speaker |           |         |
|                   |            |                     |    |                                                                                                                                                                                          |                | Discussion on A&R Paper 1                          | 16:13 | 16:16 | Speaker |           |         |
|                   |            |                     |    |                                                                                                                                                                                          |                | ARD Paper 2                                        | 16:16 | 16:26 | Speaker |           |         |
|                   |            |                     |    |                                                                                                                                                                                          |                | Discussion on ARD Paper 2                          | 16:26 | 16:29 | Speaker |           |         |

|                                                                         |            |                     |     |                                                                                                                                                                                                                                 |                         |                                           |       |       |         |           |          |
|-------------------------------------------------------------------------|------------|---------------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|-------------------------------------------|-------|-------|---------|-----------|----------|
|                                                                         |            |                     |     | processes.To have an opportunity to hear from authors of selected, high-value papers recently accepted in these journals.To identify trends in rheumatology publishing.                                                         |                         | A&R Paper 2                               | 16:29 | 16:39 | Speaker |           |          |
|                                                                         |            |                     |     |                                                                                                                                                                                                                                 |                         | Discussion on A&R Paper 2                 | 16:39 | 16:42 | Speaker |           |          |
|                                                                         |            |                     |     |                                                                                                                                                                                                                                 |                         | General discussion on publication aspects | 16:42 | 16:52 | Speaker |           |          |
|                                                                         |            |                     |     |                                                                                                                                                                                                                                 |                         | Closing Remarks                           | 16:52 | 16:57 | Speaker | Josef S.  | Smolen   |
|                                                                         |            |                     |     |                                                                                                                                                                                                                                 |                         | Introduction                              | 15:45 | 15:50 | Speaker | Josef S.  | Smolen   |
|                                                                         |            |                     |     |                                                                                                                                                                                                                                 |                         |                                           |       |       | Chair   | Daniel H. | Solomon  |
|                                                                         |            |                     |     |                                                                                                                                                                                                                                 |                         |                                           |       |       | Chair   | Josef S.  | Smolen   |
| Autoimmune reactions protect against autoimmunity - how does that work? | 13/06/2025 | 15:45:00 - 17:05:00 | 6.3 | 1. To hear about different examples of immune activation and auto-antibodies that protect from autoimmune disease;2. To learn about the mechanisms that could lie behind these protective effects;3. To learn how this helps us | Basic and Translational | Protective auto-antibodies in vasculitis  | 16:04 | 16:19 | Speaker | Divi      | Cornec   |
|                                                                         |            |                     |     |                                                                                                                                                                                                                                 |                         | Protective auto-antibodies in vasculitis  | 16:19 | 16:22 | Speaker | Divi      | Cornec   |
|                                                                         |            |                     |     |                                                                                                                                                                                                                                 |                         | Are anti-DFS70 antibodies protective?     | 16:56 | 17:00 | Speaker | Torsten   | Witte    |
|                                                                         |            |                     |     |                                                                                                                                                                                                                                 |                         | Are anti-DFS70 antibodies protective?     | 16:41 | 16:56 | Speaker | Torsten   | Witte    |
|                                                                         |            |                     |     |                                                                                                                                                                                                                                 |                         | Protective auto-                          | 15:45 | 16:00 | Speaker | Rikard    | Holmdahl |

|                                    |            |                     |    |                                                                                                                                                                                    |                         |                                                            |       |       |         |           |          |
|------------------------------------|------------|---------------------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|------------------------------------------------------------|-------|-------|---------|-----------|----------|
|                                    |            |                     |    | understand natural control mechanisms of the immune system.                                                                                                                        |                         | antibodies in rheumatoid arthritis                         |       |       |         |           |          |
|                                    |            |                     |    |                                                                                                                                                                                    |                         | Protective auto-antibodies in rheumatoid arthritis         | 16:00 | 16:04 | Speaker | Rikard    | Holmdahl |
|                                    |            |                     |    |                                                                                                                                                                                    |                         | Healthy T cell reactivity in rheumatoid arthritis          | 16:22 | 16:37 | Speaker | John      | Isaacs   |
|                                    |            |                     |    |                                                                                                                                                                                    |                         | Healthy T cell reactivity in rheumatoid arthritis          | 16:37 | 16:41 | Speaker | John      | Isaacs   |
|                                    |            |                     |    |                                                                                                                                                                                    |                         |                                                            |       |       | Chair   | Rene E.M. | Toes     |
|                                    |            |                     |    |                                                                                                                                                                                    |                         |                                                            |       |       | Chair   | Leonie    | Taams    |
| Autoinflammation, state of the art | 13/06/2025 | 15:45:00 - 17:00:00 | B2 | 1. This session will provide an overview regarding the pathogenesis of autoinflammatory diseases.2. Overview will be provided regarding the role of immune and non-immune cells in | Basic and Translational | Autoinflammation driven by innate immune cells             | 16:30 | 16:35 | Speaker | Michael   | Ombrello |
|                                    |            |                     |    |                                                                                                                                                                                    |                         | Autoinflammation driven by innate immune cells             | 16:10 | 16:30 | Speaker | Michael   | Ombrello |
|                                    |            |                     |    |                                                                                                                                                                                    |                         | Autoinflammation driven by non-immune cells (Paneth cells, | 15:45 | 16:05 | Speaker | Ahmet     | Gül      |

|  |  |  |  |                                                                                                                         |  |                                                                                                                           |       |       |         |       |        |
|--|--|--|--|-------------------------------------------------------------------------------------------------------------------------|--|---------------------------------------------------------------------------------------------------------------------------|-------|-------|---------|-------|--------|
|  |  |  |  | autoinflammation.3. The role of exome sequencing in discriminating autoinflammation and autoimmunity will be discussed. |  | enterocytes, keratinocytes, stroma)                                                                                       |       |       |         |       |        |
|  |  |  |  |                                                                                                                         |  | Autoinflammation driven by non-immune cells (Paneth cells, enterocytes, keratinocytes, stroma)                            | 16:05 | 16:10 | Speaker | Ahmet | Gül    |
|  |  |  |  |                                                                                                                         |  | Autoinflammation or autoimmunity? - An approach when exome sequencing and whole-genome sequencing is not showing the way. | 16:35 | 16:55 | Speaker | Paul  | Brogan |
|  |  |  |  |                                                                                                                         |  | Autoinflammation or autoimmunity? - An approach when exome sequencing and whole-genome                                    | 16:55 | 17:00 | Speaker | Paul  | Brogan |

|                                                                                                 |                |                        |    |                                                                                                                                                                                                                                                                                                                                 |                             |                                                                                                                           |       |       |             |                 |                              |
|-------------------------------------------------------------------------------------------------|----------------|------------------------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------------------------------------------------------------------------------------------------------------|-------|-------|-------------|-----------------|------------------------------|
|                                                                                                 |                |                        |    |                                                                                                                                                                                                                                                                                                                                 |                             | sequencing i<br>s not<br>showing the<br>way.                                                                              |       |       |             |                 |                              |
|                                                                                                 |                |                        |    |                                                                                                                                                                                                                                                                                                                                 |                             |                                                                                                                           |       |       | Chair       | Dennis          | McGonagle                    |
|                                                                                                 |                |                        |    |                                                                                                                                                                                                                                                                                                                                 |                             |                                                                                                                           |       |       | Chair       | Gabriella       | Szűcs                        |
| Biomarke<br>r driven<br>clinical<br>trials in<br>rheumato<br>id arthritis<br>- where<br>are we? | 13/06/<br>2025 | 15:45:00 -<br>17:00:00 | B1 | 1. Learn new<br>ways of patient<br>stratification for<br>clinical trials<br>and innovated<br>clinical trial<br>design2. Learn<br>about the<br>current state of<br>prognostic<br>biomarkers for<br>planning<br>clinical trials in<br>early disease<br>stages3. Hear<br>how synovial<br>biopsies can<br>inform clinical<br>trials | From<br>Bench to<br>Bedside | Combining<br>molecular<br>biology and<br>artificial<br>intelligence<br>to stratify<br>rheumatoid<br>arthritis<br>patients | 15:45 | 16:05 | Spea<br>ker | Stefano         | Alivernini                   |
|                                                                                                 |                |                        |    |                                                                                                                                                                                                                                                                                                                                 |                             | Combining<br>molecular<br>biology and<br>artificial<br>intelligence<br>to stratify<br>rheumatoid<br>arthritis<br>patients | 16:05 | 16:10 | Spea<br>ker | Stefano         | Alivernini                   |
|                                                                                                 |                |                        |    |                                                                                                                                                                                                                                                                                                                                 |                             | Prognostic<br>biomarkers<br>for pre-<br>disease<br>treatment in<br>rheumatoid<br>arthritis                                | 16:30 | 16:35 | Spea<br>ker | Annette<br>H.M. | van der<br>Helm – van<br>Mil |
|                                                                                                 |                |                        |    |                                                                                                                                                                                                                                                                                                                                 |                             | Prognostic<br>biomarkers<br>for pre-                                                                                      | 16:10 | 16:30 | Spea<br>ker | Annette<br>H.M. | van der<br>Helm – van<br>Mil |

|                          |            |                     |    |                                                                                                                                                                |                |                                                                                       |       |       |         |            |          |
|--------------------------|------------|---------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|---------------------------------------------------------------------------------------|-------|-------|---------|------------|----------|
|                          |            |                     |    |                                                                                                                                                                |                | disease treatment in rheumatoid arthritis                                             |       |       |         |            |          |
|                          |            |                     |    |                                                                                                                                                                |                | Synovial biopsy driven treatment decisions in rheumatoid arthritis                    | 16:35 | 16:55 | Speaker | Costantino | Pitzalis |
|                          |            |                     |    |                                                                                                                                                                |                | Synovial biopsy driven treatment decisions in rheumatoid arthritis                    | 16:55 | 17:00 | Speaker | Costantino | Pitzalis |
|                          |            |                     |    |                                                                                                                                                                |                |                                                                                       |       |       | Chair   | Michael    | Bonelli  |
|                          |            |                     |    |                                                                                                                                                                |                |                                                                                       |       |       | Chair   | Maya       | Buch     |
| EULAR Projects: Research | 13/06/2025 | 15:45:00 - 17:00:00 | B4 | 1. To gain insight into the activities of EULAR Research Center; 2. To become familiarised with the main resources available for researchers through the EULAR | EULAR Projects | Oral Abstract Presentation                                                            | 16:30 | 16:40 | Speaker |            |          |
|                          |            |                     |    |                                                                                                                                                                |                | Oral Abstract Presentation                                                            | 16:40 | 16:50 | Speaker |            |          |
|                          |            |                     |    |                                                                                                                                                                |                | The EULAR Research Center Projects: Advanced Tissue Analysis; joining forces in using | 15:55 | 16:05 | Speaker | Rik        | Lories   |

|              |            |                     |    |                                                                                                                                                                                                      |                |                                                                                                                  |       |       |         |        |            |
|--------------|------------|---------------------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|------------------------------------------------------------------------------------------------------------------|-------|-------|---------|--------|------------|
|              |            |                     |    | Research Center;3. To understand how the individual researcher can contribute to the major projects currently underway at the EULAR Research Center.<br><br>Keep up to date with EULAR Research here |                | breakthrough technologies                                                                                        |       |       |         |        |            |
|              |            |                     |    |                                                                                                                                                                                                      |                | Q&A and Closing                                                                                                  | 16:50 | 17:00 | Speaker | Dirk   | Elewaut    |
|              |            |                     |    |                                                                                                                                                                                                      |                | Introduction                                                                                                     | 15:45 | 15:55 | Speaker | Anna   | Moltó      |
|              |            |                     |    |                                                                                                                                                                                                      |                | The EULAR Research Center Projects: RheumaFacts and Patient Survey, creating the "go-to" database for the future | 16:05 | 16:20 | Speaker | Anja   | Strangfeld |
|              |            |                     |    |                                                                                                                                                                                                      |                | The EULAR Research Center Projects: ENTRi; bringing centers together to do outstanding clinical trials           | 16:20 | 16:30 | Speaker | Andrew | Cope       |
|              |            |                     |    |                                                                                                                                                                                                      |                |                                                                                                                  |       |       | Chair   | Anna   | Moltó      |
|              |            |                     |    |                                                                                                                                                                                                      |                |                                                                                                                  |       |       | Chair   | Dirk   | Elewaut    |
| EULAR Recomm | 13/06/2025 | 15:45:00 - 17:00:00 | D1 |                                                                                                                                                                                                      | EULAR Projects |                                                                                                                  |       |       | Speaker |        |            |

|                                                                                    |                |                        |                |                                                                                                                                                                                                                                                                        |                      |                                                                                             |       |       |             |                 |             |
|------------------------------------------------------------------------------------|----------------|------------------------|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|---------------------------------------------------------------------------------------------|-------|-------|-------------|-----------------|-------------|
| endations<br>I                                                                     |                |                        |                |                                                                                                                                                                                                                                                                        |                      |                                                                                             |       |       |             |                 |             |
| Fast<br>ultrasoun<br>d<br>protocols<br>in<br>Rheumat<br>ology:<br>Point of<br>Care | 13/06/<br>2025 | 15:45:00 -<br>17:00:00 | Hands-<br>On 1 | 1. How to<br>perform fast<br>ultrasonograph<br>y scans in daily<br>clinical<br>practice;2.<br>Using handheld<br>portable<br>ultrasound<br>devices;3.<br>Examples in<br>different<br>anatomical<br>areas and<br>pathologies<br>using portable<br>ultrasound<br>devices. | Hands-on<br>Sessions | Point of Care<br>vessel scan<br>in suspected<br>vasculitis                                  | 16:00 | 16:05 | Spea<br>ker | Christina       | Duftner     |
|                                                                                    |                |                        |                |                                                                                                                                                                                                                                                                        |                      | Point of Care<br>salivary<br>gland scan<br>in suspected<br>sjögren's                        | 15:50 | 15:55 | Spea<br>ker | Baptiste        | Quere       |
|                                                                                    |                |                        |                |                                                                                                                                                                                                                                                                        |                      | Point of Care<br>joint scan in<br>suspected<br>arthritis                                    | 15:55 | 16:00 | Spea<br>ker | Marina          | Backhaus    |
|                                                                                    |                |                        |                |                                                                                                                                                                                                                                                                        |                      | Point of Care<br>lung scan in<br>patients with<br>suspected<br>interstitial<br>lung disease | 15:45 | 15:50 | Spea<br>ker | Andrea          | Delle Sedie |
|                                                                                    |                |                        |                |                                                                                                                                                                                                                                                                        |                      | Hands-on<br>stations                                                                        | 16:10 | 17:00 | Spea<br>ker | Andrea          | Delle Sedie |
|                                                                                    |                |                        |                |                                                                                                                                                                                                                                                                        |                      | Discussion<br>on<br>presentation<br>s                                                       | 16:05 | 16:10 | Spea<br>ker | Marion          | Kortekaas   |
|                                                                                    |                |                        |                |                                                                                                                                                                                                                                                                        |                      |                                                                                             |       |       | Chair       | Marion          | Kortekaas   |
|                                                                                    |                |                        |                |                                                                                                                                                                                                                                                                        |                      |                                                                                             |       |       | Chair       | Hilde<br>Berner | Hammer      |
| Musculos<br>keletal<br>Ultrasoun                                                   | 13/06/<br>2025 | 15:45:00 -<br>17:00:00 | Hands-<br>On 2 | 1. How to<br>perform<br>ultrasound-                                                                                                                                                                                                                                    | Hands-on<br>Sessions | Ultrasound-<br>guided joint<br>aspirations                                                  | 15:59 | 16:06 | Spea<br>ker | Peter           | Mandl       |

|                                                                                               |            |                     |    |                                                                                                                                                                                                                                                                        |              |                                                                                        |       |       |         |         |          |
|-----------------------------------------------------------------------------------------------|------------|---------------------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|----------------------------------------------------------------------------------------|-------|-------|---------|---------|----------|
| d-guided procedures                                                                           |            |                     |    | guided synovial biopsies2. How to perform ultrasound-guided peri-articular procedures3. How to perform ultrasound-guided joint aspirations and injections4. Preparation and aftercare, do's and don'ts of these rheumatology procedures5. Supervised hands-on practice |              | and injections                                                                         |       |       |         |         |          |
|                                                                                               |            |                     |    |                                                                                                                                                                                                                                                                        |              | Ultrasound-guided peri-articular procedures                                            | 15:52 | 15:59 | Speaker | Violeta | Vlad     |
|                                                                                               |            |                     |    |                                                                                                                                                                                                                                                                        |              | Ultrasound-guided synovial biopsy                                                      | 15:45 | 15:52 | Speaker | Aurelie | Najm     |
|                                                                                               |            |                     |    |                                                                                                                                                                                                                                                                        |              | Hands-on stations                                                                      | 16:11 | 17:00 | Speaker | Aurelie | Najm     |
|                                                                                               |            |                     |    |                                                                                                                                                                                                                                                                        |              | Discussion on presentations                                                            | 16:06 | 16:11 | Speaker | Nemanja | Damjanov |
|                                                                                               |            |                     |    |                                                                                                                                                                                                                                                                        |              |                                                                                        |       |       | Chair   | Nemanja | Damjanov |
|                                                                                               |            |                     |    |                                                                                                                                                                                                                                                                        |              |                                                                                        |       |       | Chair   | PLAMEN  | TODOROV  |
| Platelet enriched plasma (PRP) for treatment of OA: good for patients or for doctors' wallet? | 13/06/2025 | 15:45:00 - 17:00:00 | A1 | 1. to learn about the different applications and indications for Platelet enriched plasma (PRP) in the treatment of OA (Osteoarthritis)<br>2. to discuss the evidence                                                                                                  | EULAR Debate | PRP is a valid treatment option for patients with OA who fail first-line interventions | 15:48 | 16:08 | Speaker | tbc     | tbc      |
|                                                                                               |            |                     |    |                                                                                                                                                                                                                                                                        |              | PRP is a valid treatment option for patients with                                      | 16:28 | 16:43 | Speaker | tbc     | tbc      |

|                                                    |            |                     |    |                                                                                                                                           |                                            |                                                              |       |       |         |               |            |
|----------------------------------------------------|------------|---------------------|----|-------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|--------------------------------------------------------------|-------|-------|---------|---------------|------------|
|                                                    |            |                     |    | behind the use of PRP in OA3. to discuss the cost-effectiveness of PRP in the treatment of OA                                             |                                            | OA who fail first-line interventions                         |       |       |         |               |            |
|                                                    |            |                     |    |                                                                                                                                           |                                            | PRP cost an arm and a leg but are not much more than placebo | 16:43 | 16:58 | Speaker | David         | Hunter     |
|                                                    |            |                     |    |                                                                                                                                           |                                            | PRP cost an arm and a leg but are not much more than placebo | 16:08 | 16:28 | Speaker | David         | Hunter     |
|                                                    |            |                     |    |                                                                                                                                           |                                            | Introduction and Audience Voting                             | 15:45 | 15:48 | Speaker | Martin        | Englund    |
|                                                    |            |                     |    |                                                                                                                                           |                                            | Audience                                                     | 16:58 | 17:00 | Speaker | Zoran         | Veličković |
|                                                    |            |                     |    |                                                                                                                                           |                                            |                                                              |       |       | Chair   | Zoran         | Veličković |
|                                                    |            |                     |    |                                                                                                                                           |                                            |                                                              |       |       | Chair   | Martin        | Englund    |
| Proactive health: Preventing comorbidities in RMDs | 13/06/2025 | 15:45:00 - 17:00:00 | C1 | Delegates will be able:1. To understand the impact of living with multiple long term conditions;2. To understand the role of syndemics in | Health Professionals in Rheumatology (HPR) | Oral Abstract Presentation                                   | 16:45 | 16:55 | Speaker |               |            |
|                                                    |            |                     |    |                                                                                                                                           |                                            | Cardiovascular screening in people with rheumatoid arthritis | 16:40 | 16:45 | Speaker | Julie Katrine | Karstensen |
|                                                    |            |                     |    |                                                                                                                                           |                                            | Living with multiple long                                    | 16:00 | 16:05 | Speaker | Connie        | Ziegler    |

|                                                                  |            |                     |    |                                                                                                                                                                                        |                                 |                                                              |       |       |         |               |            |
|------------------------------------------------------------------|------------|---------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|--------------------------------------------------------------|-------|-------|---------|---------------|------------|
|                                                                  |            |                     |    | common co-morbidities in people with RMDs;3. To understand how to identify lifestyle factors contributing to common co-morbidities.                                                    |                                 | term conditions                                              |       |       |         |               |            |
|                                                                  |            |                     |    |                                                                                                                                                                                        |                                 | Cardiovascular screening in people with rheumatoid arthritis | 16:25 | 16:40 | Speaker | Julie Katrine | Karstensen |
|                                                                  |            |                     |    |                                                                                                                                                                                        |                                 | Living with multiple long term conditions                    | 15:45 | 16:00 | Speaker | Connie        | Ziegler    |
|                                                                  |            |                     |    |                                                                                                                                                                                        |                                 | Closing                                                      | 16:55 | 17:00 | Speaker | Catherine     | Beauvais   |
|                                                                  |            |                     |    |                                                                                                                                                                                        |                                 | Syndemics in RMDs                                            | 16:05 | 16:20 | Speaker | Elena         | Nikiphorou |
|                                                                  |            |                     |    |                                                                                                                                                                                        |                                 | Syndemics in RMDs                                            | 16:20 | 16:25 | Speaker | Elena         | Nikiphorou |
|                                                                  |            |                     |    |                                                                                                                                                                                        |                                 |                                                              |       |       | Chair   | tbc           | tbc        |
|                                                                  |            |                     |    |                                                                                                                                                                                        |                                 |                                                              |       |       | Chair   | Catherine     | Beauvais   |
| Rare and challenging: Whipple and Reticulohistiocytosis diseases | 13/06/2025 | 15:45:00 - 17:00:00 | A2 | 1. To better understand the pathophysiology of Whipple's disease and Multicentric Reticulohistiocytosis; 2. to learn about the diagnosis and differential diagnosis of these diseases; | Challenges in Clinical Practice | Case presentation: Whipple's disease                         | 15:45 | 15:55 | Speaker |               |            |
|                                                                  |            |                     |    |                                                                                                                                                                                        |                                 | Case presentation: Multicentric Reticulohistiocytosis        | 16:20 | 16:30 | Speaker |               |            |
|                                                                  |            |                     |    |                                                                                                                                                                                        |                                 | Whipple's disease                                            | 15:55 | 16:15 | Speaker | Xavier        | Puechal    |
|                                                                  |            |                     |    |                                                                                                                                                                                        |                                 | Whipple's disease                                            | 16:15 | 16:20 | Speaker | Xavier        | Puechal    |

|                              |            |                     |    |                                                                                                                                                                                                                                                                                                             |                  |                                                                        |       |       |         |           |            |
|------------------------------|------------|---------------------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|------------------------------------------------------------------------|-------|-------|---------|-----------|------------|
|                              |            |                     |    | 3. to discuss treatment options and prognosis.                                                                                                                                                                                                                                                              |                  | Multicentric Reticulohistiocytosis                                     | 16:50 | 16:55 | Speaker | Carlo     | Selmi      |
|                              |            |                     |    |                                                                                                                                                                                                                                                                                                             |                  | Multicentric Reticulohistiocytosis                                     | 16:30 | 16:50 | Speaker | Carlo     | Selmi      |
|                              |            |                     |    |                                                                                                                                                                                                                                                                                                             |                  |                                                                        |       |       | Chair   | Francesca | Crisafulli |
|                              |            |                     |    |                                                                                                                                                                                                                                                                                                             |                  |                                                                        |       |       | Chair   | György    | Nagy       |
| Rheumatology meets: Hormones | 13/06/2025 | 15:45:00 - 17:00:00 | F1 | 1. To learn about endocrine diseases mimicking RMDs2. To discuss the safety of long-term very low-dose glucocorticoid therapy3. To know the frequency of adrenal insufficiency in long-term glucocorticoid users and its possible clinical impact4. To understand the role of hormonal changes in menopause | Clinical Science | When endocrinological diseases mimic RMDs                              | 15:45 | 16:05 | Speaker |           |            |
|                              |            |                     |    |                                                                                                                                                                                                                                                                                                             |                  | RMDs and menopause – is there a place for hormone replacement therapy? | 16:35 | 16:55 | Speaker | tbc       | tbc        |
|                              |            |                     |    |                                                                                                                                                                                                                                                                                                             |                  | RMDs and menopause – is there a place for hormone replacement therapy? | 16:55 | 17:00 | Speaker | tbc       | tbc        |
|                              |            |                     |    |                                                                                                                                                                                                                                                                                                             |                  | When endocrinological diseases mimic RMDs                              | 16:05 | 16:10 | Speaker |           |            |
|                              |            |                     |    |                                                                                                                                                                                                                                                                                                             |                  | Long-Term low-dose Glucocorticoid Use: Safe                            | 16:30 | 16:35 | Speaker | Frank     | Buttgereit |

|                                 |            |                     |     |                                                                                                                                                                                         |                  |                                                                                                        |       |       |         |         |            |
|---------------------------------|------------|---------------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|--------------------------------------------------------------------------------------------------------|-------|-------|---------|---------|------------|
|                                 |            |                     |     | and their possible impact on pain and RMDs5. To discuss the value of hormone replacement therapy in patients with RMD for pain reduction                                                |                  | or a Risk for Adrenal Dysfunction and other complications?                                             |       |       |         |         |            |
|                                 |            |                     |     |                                                                                                                                                                                         |                  | Long-Term low-dose Glucocorticoid Use: Safe or a Risk for Adrenal Dysfunction and other complications? | 16:10 | 16:30 | Speaker | Frank   | Buttgereit |
|                                 |            |                     |     |                                                                                                                                                                                         |                  |                                                                                                        |       |       | Chair   | tbc     | tbc        |
|                                 |            |                     |     |                                                                                                                                                                                         |                  |                                                                                                        |       |       | Chair   | tbc     | tbc        |
| Rheumatology meets: Pulmonology | 13/06/2025 | 15:45:00 - 17:00:00 | 6.4 | This meeting between rheumatologists and pulmonologists is designed to help participants:1. Better understand the choice of treatments for patients with systemic autoimmune rheumatism | Clinical Science | Pulmonary Hypertension in Connective Tissue Diseases (Systemic Sclerosis and beyond)                   | 16:10 | 16:30 | Speaker | Olivier | Sitbon     |
|                                 |            |                     |     |                                                                                                                                                                                         |                  | Pulmonary Hypertension in Connective Tissue Diseases (Systemic                                         | 16:30 | 16:35 | Speaker | Olivier | Sitbon     |

|  |  |  |  |                                                                                                                                                                                                   |  |                                                                                                     |       |       |         |            |          |
|--|--|--|--|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|-----------------------------------------------------------------------------------------------------|-------|-------|---------|------------|----------|
|  |  |  |  | diseases and interstitial lung disease;2. Treat pulmonary hypertension in an inflammatory context;3. Understand the various pulmonary disorders associated with sarcoidosis and their management. |  | Sclerosis and beyond)                                                                               |       |       |         |            |          |
|  |  |  |  |                                                                                                                                                                                                   |  | Management of lung involvement in sarcoidosis: from Löfgren's syndrome to interstitial lung disease | 16:35 | 16:55 | Speaker | Jacobo     | Sellarés |
|  |  |  |  |                                                                                                                                                                                                   |  | Management of lung involvement in sarcoidosis: from Löfgren's syndrome to interstitial lung disease | 16:55 | 17:00 | Speaker | Jacobo     | Sellarés |
|  |  |  |  |                                                                                                                                                                                                   |  | Understanding (and criticising) the ACR/CHEST Guideline for the Treatment of ILD in patients with   | 16:05 | 16:10 | Speaker | Jeffrey A. | Sparks   |

|                                                     |            |                     |     |                                                                                                                                                                                 |       |                                                                                                                      |       |       |         |                |             |
|-----------------------------------------------------|------------|---------------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|----------------------------------------------------------------------------------------------------------------------|-------|-------|---------|----------------|-------------|
|                                                     |            |                     |     |                                                                                                                                                                                 |       | Rheumatic Diseases                                                                                                   |       |       |         |                |             |
|                                                     |            |                     |     |                                                                                                                                                                                 |       | Understanding (and criticising) the ACR/CHEST Guideline for the Treatment of ILD in patients with Rheumatic Diseases | 15:45 | 16:05 | Speaker | Jeffrey A.     | Sparks      |
|                                                     |            |                     |     |                                                                                                                                                                                 |       |                                                                                                                      |       |       | Chair   | Kastriot       | Kastrati    |
|                                                     |            |                     |     |                                                                                                                                                                                 |       |                                                                                                                      |       |       | Chair   | Pierre-Antoine | Juge        |
| Sport is medicine for inflammation and pain in RMDs | 13/06/2025 | 15:45:00 - 17:00:00 | 6.2 | 1. To identify the opportunities and challenges for sport in treating RMDs;2. To learn how patients with RMD could benefit most from sports;3. To review the evidence for sport | Joint | Q&A and Closing                                                                                                      | 16:45 | 17:00 | Speaker | Diederik       | De Cock     |
|                                                     |            |                     |     |                                                                                                                                                                                 |       | Introduction                                                                                                         | 15:45 | 15:50 | Speaker | Annette        | de Thurah   |
|                                                     |            |                     |     |                                                                                                                                                                                 |       | Sport - a DMARD and pain killer? The evidence behind                                                                 | 16:15 | 16:35 | Speaker | Daniel         | Neunhaeuser |
|                                                     |            |                     |     |                                                                                                                                                                                 |       | How sport can change the life of a patient with RMD                                                                  | 15:50 | 16:00 | Speaker | Mariana        | Carvalho    |

|                              |            |                     |         |                                                                                                                                                                             |                   |                                                                                         |       |       |         |              |                |
|------------------------------|------------|---------------------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-----------------------------------------------------------------------------------------|-------|-------|---------|--------------|----------------|
|                              |            |                     |         | interventions in the treatment of inflammation and pain;4. To share practical insights from implementing physical activity evidence-based guidelines.                       |                   | Beyond cycling and dancing - how does my patient benefit most from sports activities    | 16:00 | 16:15 | Speaker | Luis         | Coronel        |
|                              |            |                     |         |                                                                                                                                                                             |                   | Making Guidance Real: Lessons from Implementing EULAR Physical Activity Recommendations | 16:35 | 16:45 | Speaker | Anne-Kathrin | Rausch Osthoff |
|                              |            |                     |         |                                                                                                                                                                             |                   |                                                                                         |       |       | Chair   | Annette      | de Thurah      |
|                              |            |                     |         |                                                                                                                                                                             |                   |                                                                                         |       |       | Chair   | Diederik     | De Cock        |
| Systemic lupus erythematosus | 13/06/2025 | 15:45:00 - 16:30:00 | Plenary | In this session, we will: 1. explore the latest clinical and paraclinical tools for the diagnosis, disease mapping, and follow-up of patients with systemic lupus;2. review | What is New (WIN) | What is new in systemic lupus erythematosus?                                            | 15:45 | 16:30 | Speaker | Antonis      | Fanouriakis    |
|                              |            |                     |         |                                                                                                                                                                             |                   |                                                                                         |       |       | Chair   | Johanna      | Mucke          |
|                              |            |                     |         |                                                                                                                                                                             |                   |                                                                                         |       |       | Chair   | Ricard       | Cervera Segura |

|                       |            |                     |    |                                                                                                                                                                                                                                 |            |                                                 |       |       |         |                  |         |
|-----------------------|------------|---------------------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------------------------------------------|-------|-------|---------|------------------|---------|
|                       |            |                     |    | recent advancements in the optimal use of standard systemic lupus treatments and the introduction of new therapeutic classes;3. discuss the role of non-immune-targeting complementary treatments in systemic lupus management. |            |                                                 |       |       |         |                  |         |
| The Rheumatology Quiz | 13/06/2025 | 15:45:00 - 17:00:00 | A3 | The third edition of a popular quiz testing the knowledge of congress attendees on all facets of Rheumatology. 1. Test and reinforce knowledge of rheumatologic conditions through diverse, interactive quiz                    | Innovation | Introduction                                    | 15:45 | 15:50 | Speaker | Emre             | Bilgin  |
|                       |            |                     |    |                                                                                                                                                                                                                                 |            | Round 2 - Wheel of fortune                      | 16:10 | 16:30 | Speaker | Christopher John | Edwards |
|                       |            |                     |    |                                                                                                                                                                                                                                 |            | Finale - Questions with images                  | 16:30 | 17:00 | Speaker | Christopher John | Edwards |
|                       |            |                     |    |                                                                                                                                                                                                                                 |            | Round 1 - Via app available to all the audience | 15:50 | 16:10 | Speaker | Chris            | Wincup  |
|                       |            |                     |    |                                                                                                                                                                                                                                 |            |                                                 |       |       | Chair   | Kim              | Lauper  |
|                       |            |                     |    |                                                                                                                                                                                                                                 |            |                                                 |       |       | Chair   | Emre             | Bilgin  |

|                                                |            |                     |    |                                                                                                                                                                                                                                                                           |      |                                                                         |       |       |         |       |       |
|------------------------------------------------|------------|---------------------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-------------------------------------------------------------------------|-------|-------|---------|-------|-------|
|                                                |            |                     |    | questions.2. Apply clinical reasoning to challenging scenarios in rheumatology, improving the ability to differentiate between similar conditions.3. Enhance diagnostic skills by interpreting various clinical images and cases across different fields of rheumatology. |      |                                                                         |       |       |         |       |       |
| The Sleep Struggle: Navigating Fatigue in RMDs | 13/06/2025 | 15:45:00 - 17:01:00 | C3 | 1. This session aims to delve into the intricate relationship between sleep patterns and fatigue experienced by individuals with RMDs. 2. Experts will discuss lived experience,                                                                                          | PARE | Oral Abstract Presentation                                              | 16:50 | 17:00 | Speaker |       |       |
|                                                |            |                     |    |                                                                                                                                                                                                                                                                           |      | Tired but Resilient: Coping With Fatigue as a Person Living With an RMD | 16:05 | 16:15 | Speaker | Souzi | Makri |
|                                                |            |                     |    |                                                                                                                                                                                                                                                                           |      | Tired but Resilient: Coping With Fatigue as a Person                    | 16:15 | 16:20 | Speaker | Souzi | Makri |

|  |  |  |  |                                                                                                                                             |  |                                                                                                             |       |       |         |                 |          |
|--|--|--|--|---------------------------------------------------------------------------------------------------------------------------------------------|--|-------------------------------------------------------------------------------------------------------------|-------|-------|---------|-----------------|----------|
|  |  |  |  | underlying mechanisms, clinical implications, and strategies for managing fatigue to improve overall quality of life and clinical outcomes. |  | Living With an RMD                                                                                          |       |       |         |                 |          |
|  |  |  |  |                                                                                                                                             |  | Turning Knowledge Into Action: Practical Applications of the 2023 EULAR Recommendations for Fatigue in RMDs | 16:45 | 16:50 | Speaker | Rinie           | Geenen   |
|  |  |  |  |                                                                                                                                             |  | Turning Knowledge Into Action: Practical Applications of the 2023 EULAR Recommendations for Fatigue in RMDs | 16:35 | 16:45 | Speaker | Rinie           | Geenen   |
|  |  |  |  |                                                                                                                                             |  | Beyond Pain: Understanding the Clinical Significance of Fatigue in RMDs                                     | 16:30 | 16:35 | Speaker | José Antonio P. | da Silva |

|  |  |  |  |  |  |                                                                                              |       |       |         |                 |          |
|--|--|--|--|--|--|----------------------------------------------------------------------------------------------|-------|-------|---------|-----------------|----------|
|  |  |  |  |  |  | Sleep Hygiene 101: Understanding the Importance of Restorative Sleep on Health and Wellbeing | 16:00 | 16:05 | Speaker | Teresa          | Paiva    |
|  |  |  |  |  |  | Beyond Pain: Understanding the Clinical Significance of Fatigue in RMDs                      | 16:20 | 16:30 | Speaker | José Antonio P. | da Silva |
|  |  |  |  |  |  | Sleep Hygiene 101: Understanding the Importance of Restorative Sleep on Health and Wellbeing | 15:45 | 16:00 | Speaker | Teresa          | Paiva    |
|  |  |  |  |  |  |                                                                                              |       |       | Chair   | Mrinalini       | Dey      |
|  |  |  |  |  |  |                                                                                              |       |       | Chair   | Ilaria          | Bini     |

|                                                   |            |                     |         |                                                                                                                                                                                                                            |                    |                                                                                                      |       |       |         |         |               |
|---------------------------------------------------|------------|---------------------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------------------------------------------------------------------------------------------------|-------|-------|---------|---------|---------------|
| Osteoporosis                                      | 13/06/2025 | 16:30:00 - 17:15:00 | Plenary | 1. To understand treatment options in patients with osteoporosis;2. to evaluate individual fracture risk assessment;3. to discuss duration of treatment in patients according to their risk assessment.                    | How to Treat (HOT) | Fracture Risk Adapted Treatment Strategies - When to Start, What to Start with and How Long to Treat | 16:30 | 17:15 | Speaker | Bente   | Langdahl      |
|                                                   |            |                     |         |                                                                                                                                                                                                                            |                    |                                                                                                      |       |       | Chair   | Cécile  | Philippoteaux |
|                                                   |            |                     |         |                                                                                                                                                                                                                            |                    |                                                                                                      |       |       | Chair   | Bjoern  | Buehring      |
| AI in medicine: Your future doctor and researcher | 14/06/2025 | 09:00:00 - 10:15:00 | C3      | 1. To address challenges in developing Artificial Intelligence (AI)-based tools in research, diagnosis and prognosis of RMDs2. To discuss the pro's and con's for patients and health care3. To explore how to improve the | PARE               | Oral Abstract Presentation                                                                           | 09:45 | 09:55 | Speaker |         |               |
|                                                   |            |                     |         |                                                                                                                                                                                                                            |                    | Oral Abstract Presentation                                                                           | 09:55 | 10:05 | Speaker |         |               |
|                                                   |            |                     |         |                                                                                                                                                                                                                            |                    | Closing                                                                                              | 10:05 | 10:15 | Speaker | Michael | Poelzl        |
|                                                   |            |                     |         |                                                                                                                                                                                                                            |                    | AI for IA patients in flares – the researcher's perspective                                          | 09:15 | 09:30 | Speaker | Paul    | Studenic      |
|                                                   |            |                     |         |                                                                                                                                                                                                                            |                    | Innovations and Pitfalls: The Landscape of AI in RMDs                                                | 09:00 | 09:15 | Speaker | Norelee | Kennedy       |

|                                                          |            |                     |    |                                                                                                                                                                                                                                                                                                                          |                  |                                                                              |       |       |         |              |                 |
|----------------------------------------------------------|------------|---------------------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|------------------------------------------------------------------------------|-------|-------|---------|--------------|-----------------|
|                                                          |            |                     |    | implementation of AI-based tools                                                                                                                                                                                                                                                                                         |                  | AI for IA patients in flares – the patient's perspective                     | 09:30 | 09:45 | Speaker | Marieke      | Voshaar         |
|                                                          |            |                     |    |                                                                                                                                                                                                                                                                                                                          |                  |                                                                              |       |       | Chair   | Michael      | Poelzl          |
|                                                          |            |                     |    |                                                                                                                                                                                                                                                                                                                          |                  |                                                                              |       |       | Chair   | Corinna      | Elling-Audersch |
| Beyond CAR-T cells : B Cells targeting therapies in 2025 | 14/06/2025 | 09:00:00 - 10:15:00 | A2 | 1. To learn about new B-cell targeted therapies other than CAR-T cells and cellular therapies;2. New anti-CD20, anti-CD19 and T-cell engagers bispecific Ab may induce the same B-cell depletion as anti-CD19 CAR-T cells and could be simpler to use;3. Can they be as efficient as CAR-T cells in autoimmune diseases? | Clinical Science | Oral Abstract Presentation                                                   | 10:00 | 10:10 | Speaker |              |                 |
|                                                          |            |                     |    |                                                                                                                                                                                                                                                                                                                          |                  | Non-cellular B-Cell targeted therapy in systemic autoimmune diseases in 2025 | 09:20 | 09:35 | Speaker | Jacques-Eric | Gottenberg      |
|                                                          |            |                     |    |                                                                                                                                                                                                                                                                                                                          |                  | Non-cellular B-Cell targeted therapy in systemic autoimmune diseases in 2025 | 09:35 | 09:40 | Speaker | Jacques-Eric | Gottenberg      |
|                                                          |            |                     |    |                                                                                                                                                                                                                                                                                                                          |                  | T-cell engagers bispecific antibodies in systemic autoimmune diseases        | 09:55 | 10:00 | Speaker | Georg        | Schett          |

|                                                                      |            |                     |     |                                                                                                                                                     |                       |                                                                       |       |       |         |             |         |
|----------------------------------------------------------------------|------------|---------------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|-----------------------------------------------------------------------|-------|-------|---------|-------------|---------|
|                                                                      |            |                     |     |                                                                                                                                                     |                       | T-cell engagers bispecific antibodies in systemic autoimmune diseases | 09:40 | 09:55 | Speaker | Georg       | Schett  |
|                                                                      |            |                     |     |                                                                                                                                                     |                       | Non-cellular B-Cell targeted therapy in rheumatoid arthritis in 2025  | 09:15 | 09:20 | Speaker | Hans Ulrich | Scherer |
|                                                                      |            |                     |     |                                                                                                                                                     |                       | Non-cellular B-Cell targeted therapy in rheumatoid arthritis in 2025  | 09:00 | 09:15 | Speaker | Hans Ulrich | Scherer |
|                                                                      |            |                     |     |                                                                                                                                                     |                       |                                                                       |       |       | Chair   | Samuel      | Bitoun  |
|                                                                      |            |                     |     |                                                                                                                                                     |                       |                                                                       |       |       | Chair   | Alessia     | Alunno  |
| Calcium Pyrophosphate Deposition: Formation, Consequences, Treatment | 14/06/2025 | 09:00:00 - 10:15:00 | 6.1 | 1. Understand how CPPD (Calcium Pyrophosphate Deposition) crystals form<br>2. Appreciate the mechanisms by which calcium crystals can damage intra- | From Bench to Bedside | Oral Abstract Presentation                                            | 10:00 | 10:10 | Speaker |             |         |
|                                                                      |            |                     |     |                                                                                                                                                     |                       | CPPD: Current management and treatment options on the horizon         | 09:40 | 09:55 | Speaker | Tristan     | Pascart |
|                                                                      |            |                     |     |                                                                                                                                                     |                       | CPPD: Current                                                         | 09:55 | 10:00 | Speaker | Tristan     | Pascart |

|  |  |  |  |                                                                                      |  |                                                                    |       |       |         |           |          |
|--|--|--|--|--------------------------------------------------------------------------------------|--|--------------------------------------------------------------------|-------|-------|---------|-----------|----------|
|  |  |  |  | articular structures3. Recognise clinical consequences of CPPD and treatment options |  | management and treatment options on the horizon                    |       |       |         |           |          |
|  |  |  |  |                                                                                      |  | Discussion and Closing                                             | 10:10 | 10:15 | Speaker | Geraldine | McCarthy |
|  |  |  |  |                                                                                      |  | CPPD crystal formation and pathogenetic mechanisms of joint damage | 09:15 | 09:20 | Speaker | Sonia     | Nasi     |
|  |  |  |  |                                                                                      |  | CPPD crystal formation and pathogenetic mechanisms of joint damage | 09:00 | 09:15 | Speaker | Sonia     | Nasi     |
|  |  |  |  |                                                                                      |  | CPPD: Adverse clinical consequences in the joint and beyond        | 09:35 | 09:40 | Speaker | Sara K.   | Tedeschi |
|  |  |  |  |                                                                                      |  | CPPD: Adverse clinical consequences                                | 09:20 | 09:35 | Speaker | Sara K.   | Tedeschi |

|                                                                      |            |                     |    |                                                                                                                                                                                                                                                                                                                                                  |                         |                                                                                                           |       |       |         |             |             |
|----------------------------------------------------------------------|------------|---------------------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|-----------------------------------------------------------------------------------------------------------|-------|-------|---------|-------------|-------------|
|                                                                      |            |                     |    |                                                                                                                                                                                                                                                                                                                                                  |                         | es in the joint and beyond                                                                                |       |       |         |             |             |
|                                                                      |            |                     |    |                                                                                                                                                                                                                                                                                                                                                  |                         |                                                                                                           |       |       | Chair   | Geraldine   | McCarthy    |
|                                                                      |            |                     |    |                                                                                                                                                                                                                                                                                                                                                  |                         |                                                                                                           |       |       | Chair   | Hang Korng  | Ea          |
| Cardioimmunology - Effects of the immune system on the heart in iRMD | 14/06/2025 | 09:00:00 - 10:15:00 | F3 | The session presents the translational impact of heart immune homeostasis disorders in a clinical setting. 1. To learn the basic mechanisms underlying the arrhythmogenic effects of proinflammatory cytokine network in inflammatory arthritis. 2. To examine the autoantibody-mediated channelopathies underlying cardiac arrhythmias in iRMD. | Basic and Translational | Arrhythmogenic effects of the proinflammatory cytokine network in inflammatory arthritis                  | 09:20 | 09:35 | Speaker | Hafid       | Ait-Oufella |
|                                                                      |            |                     |    |                                                                                                                                                                                                                                                                                                                                                  |                         | Role of autoantibodies behind heart rhythm disturbances in iRMDs                                          | 09:35 | 09:50 | Speaker | Ágnes       | Szappanos   |
|                                                                      |            |                     |    |                                                                                                                                                                                                                                                                                                                                                  |                         | Cardioimmunology of arrhythmias: the emerging role of autoimmune and inflammatory cardiac channelopathies | 09:00 | 09:20 | Speaker | Pietro Enea | Lazzerini   |
|                                                                      |            |                     |    |                                                                                                                                                                                                                                                                                                                                                  |                         | Q&A and Closing                                                                                           | 09:50 | 10:10 | Speaker | Stephanie   | Ling        |
|                                                                      |            |                     |    |                                                                                                                                                                                                                                                                                                                                                  |                         |                                                                                                           |       |       | Chair   | Stephanie   | Ling        |

|                                                   |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                                                                 |                  |                                                                          |       |       |         |         |           |
|---------------------------------------------------|------------|---------------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|--------------------------------------------------------------------------|-------|-------|---------|---------|-----------|
|                                                   |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                                                                 |                  |                                                                          |       |       | Chair   | Gizem   | Ayan      |
| Diagnosis and monitoring SpA - is it all imaging? | 14/06/2025 | 09:00:00 - 10:15:00 | 6.3 | Discussion about the scientific evidence behind imaging for diagnosis, monitoring and imaging remission:1. Evaluate the scientific evidence supporting the use of imaging techniques in diagnosing and monitoring spondyloarthritis (SpA);2. Analyse the role of imaging in assessing disease remission and its impact on clinical decision-making;3. Discuss the integration of imaging findings with clinical | Clinical Science | Is imaging all-decisive in the diagnosis of axSpA?                       | 09:00 | 09:25 | Speaker | Augusta | Ortolan   |
|                                                   |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                                                                 |                  | The role of imaging in monitoring axSpA: added value over clinical exam? | 09:25 | 09:50 | Speaker | Robert  | Landewé   |
|                                                   |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                                                                 |                  | Should we target imaging or clinical remission in axSpA?                 | 09:50 | 10:15 | Speaker | Sofia   | Ramiro    |
|                                                   |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                                                                 |                  |                                                                          |       |       | Chair   | Murat   | Torgutalp |
|                                                   |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                                                                 |                  |                                                                          |       |       | Chair   | Liese   | de Bruin  |

|                                  |            |                     |    |                                                                                                                                                                                                                                                                                                                      |                                 |                                                                   |       |       |         |          |             |
|----------------------------------|------------|---------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|-------------------------------------------------------------------|-------|-------|---------|----------|-------------|
|                                  |            |                     |    | assessment and other diagnostic tools for a comprehensive approach to SpA management.                                                                                                                                                                                                                                |                                 |                                                                   |       |       |         |          |             |
| Difficult to manage osteoporosis | 14/06/2025 | 09:00:00 - 10:15:00 | B2 | 1. To learn about the management of osteoporosis in complex situations (e.g. chronic kidney disease, previous osteonecrosis of the jaw and severe osteoporosis); 2. To learn about the rationale for selection of anti-osteoporotic drug(s) in patients with inflammatory RMD; 3. To learn about long-term treatment | Challenges in Clinical Practice | Case presentation                                                 | 09:35 | 09:45 | Speaker |          |             |
|                                  |            |                     |    |                                                                                                                                                                                                                                                                                                                      |                                 | Case presentation                                                 | 09:00 | 09:10 | Speaker |          |             |
|                                  |            |                     |    |                                                                                                                                                                                                                                                                                                                      |                                 | Difficult to treat osteoporosis in patients with inflammatory RMD | 10:05 | 10:10 | Speaker | Frank    | Buttgereit  |
|                                  |            |                     |    |                                                                                                                                                                                                                                                                                                                      |                                 | Difficult to treat osteoporosis in patients with inflammatory RMD | 09:45 | 10:05 | Speaker | Frank    | Buttgereit  |
|                                  |            |                     |    |                                                                                                                                                                                                                                                                                                                      |                                 | Closing                                                           | 10:10 | 10:15 | Speaker | Maria    | Yavropoulou |
|                                  |            |                     |    |                                                                                                                                                                                                                                                                                                                      |                                 | Challenges in the long-term management of anti                    | 09:30 | 09:35 | Speaker | Giovanni | Adami       |
|                                  |            |                     |    |                                                                                                                                                                                                                                                                                                                      |                                 |                                                                   |       |       |         |          |             |

|                                                                                               |            |                     |    |                                                                                                                                                                                                                                                                                               |                         |                                                                  |       |       |         |              |             |
|-----------------------------------------------------------------------------------------------|------------|---------------------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|------------------------------------------------------------------|-------|-------|---------|--------------|-------------|
|                                                                                               |            |                     |    | strategies including drug holiday and treatment termination in case of adverse events.                                                                                                                                                                                                        |                         | resorptive agents                                                |       |       |         |              |             |
|                                                                                               |            |                     |    |                                                                                                                                                                                                                                                                                               |                         | Challenges in the long-term management of anti resorptive agents | 09:10 | 09:30 | Speaker | Giovanni     | Adami       |
|                                                                                               |            |                     |    |                                                                                                                                                                                                                                                                                               |                         |                                                                  |       |       | Chair   | Maria        | Yavropoulou |
|                                                                                               |            |                     |    |                                                                                                                                                                                                                                                                                               |                         |                                                                  |       |       | Chair   | Radmila      | Matijevic   |
| Epi-Transcriptomics in rheumatic diseases: role in inflammation and therapeutic opportunities | 14/06/2025 | 09:00:00 - 10:15:00 | B4 | 1. Learn about the various post-transcriptional modifications of RNA and how they can be measured reliably<br>2. Hear about studies exploring the role of RNA modifications in regulating inflammation<br>3. Learn about the potential of RNA methyltransferases as novel therapeutic targets | Basic and Translational | Epitranscriptomic changes in rheumatoid arthritis and beyond     | 09:45 | 09:50 | Speaker | Konstantinos | Stellos     |
|                                                                                               |            |                     |    |                                                                                                                                                                                                                                                                                               |                         | Epitranscriptomic changes in rheumatoid arthritis and beyond     | 09:25 | 09:45 | Speaker | Konstantinos | Stellos     |
|                                                                                               |            |                     |    |                                                                                                                                                                                                                                                                                               |                         | What is the epitranscriptome and how it can be measured?         | 09:00 | 09:20 | Speaker | Eva Maria    | Novoa       |
|                                                                                               |            |                     |    |                                                                                                                                                                                                                                                                                               |                         | What is the epitranscriptome and how it can                      | 09:20 | 09:25 | Speaker | Eva Maria    | Novoa       |

|                                                |            |                     |    |                                                                                                            |                                            |                                                                                          |       |       |         |              |          |
|------------------------------------------------|------------|---------------------|----|------------------------------------------------------------------------------------------------------------|--------------------------------------------|------------------------------------------------------------------------------------------|-------|-------|---------|--------------|----------|
|                                                |            |                     |    |                                                                                                            |                                            | be measured?                                                                             |       |       |         |              |          |
|                                                |            |                     |    |                                                                                                            |                                            | Therapeutic opportunities exploiting the epitranscriptome - lessons from cancer research | 09:50 | 10:10 | Speaker | Konstantinos | Tzelepis |
|                                                |            |                     |    |                                                                                                            |                                            | Therapeutic opportunities exploiting the epitranscriptome - lessons from cancer research | 10:10 | 10:15 | Speaker | Konstantinos | Tzelepis |
|                                                |            |                     |    |                                                                                                            |                                            |                                                                                          |       |       | Chair   | Rami         | Bechara  |
|                                                |            |                     |    |                                                                                                            |                                            |                                                                                          |       |       | Chair   | Gunnel       | Nordmark |
| EULAR Recommendations II                       | 14/06/2025 | 09:00:00 - 10:15:00 | D1 | Keep up to date with EULAR Quality of Care here                                                            | EULAR Projects                             |                                                                                          |       |       | Speaker |              |          |
| Health literacy and challenges in Rheumatology | 14/06/2025 | 09:00:00 - 10:15:00 | C1 | Delegates will be able to: 1. Understand what health literacy is;2. How health literacy relates to health, | Health Professionals in Rheumatology (HPR) | Health literacy, patient engagement and outcomes                                         | 09:00 | 09:15 | Speaker | tbc          | tbc      |
|                                                |            |                     |    |                                                                                                            |                                            | Oral Abstract Presentation                                                               | 10:00 | 10:10 | Speaker |              |          |

|  |  |  |  |                                                                                                                            |  |                                                                                    |       |       |         |               |           |
|--|--|--|--|----------------------------------------------------------------------------------------------------------------------------|--|------------------------------------------------------------------------------------|-------|-------|---------|---------------|-----------|
|  |  |  |  | disease activity and disease impact in Rheumatology;<br>3. Get an idea of how we can improve our patients health literacy. |  | Health literacy, patient engagement and outcomes                                   | 09:15 | 09:20 | Speaker | tbc           | tbc       |
|  |  |  |  |                                                                                                                            |  | How can we as professionals assess and help improve our patients' health literacy? | 09:35 | 09:40 | Speaker | Mark Matthijs | Bakker    |
|  |  |  |  |                                                                                                                            |  | How can we as professionals assess and help improve our patients' health literacy? | 09:20 | 09:35 | Speaker | Mark Matthijs | Bakker    |
|  |  |  |  |                                                                                                                            |  | Health literacy and health promotion in patients with knee pain                    | 09:40 | 09:55 | Speaker | Charlotte     | Sylwander |
|  |  |  |  |                                                                                                                            |  | Health literacy and health promotion in patients with knee pain                    | 09:55 | 10:00 | Speaker | Charlotte     | Sylwander |

|                                                                       |            |                     |     |                                                                                                                                                                                                                                                                                                                                                 |                          |                                                                    |       |       | Chair   | Heidi         | Zangi     |
|-----------------------------------------------------------------------|------------|---------------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|--------------------------------------------------------------------|-------|-------|---------|---------------|-----------|
|                                                                       |            |                     |     |                                                                                                                                                                                                                                                                                                                                                 |                          |                                                                    |       |       | Chair   | Line Raunsbæk | Knudsen   |
| Novelties in laboratory parameters and clinical practice implications | 14/06/2025 | 09:00:00 - 10:15:00 | 6.2 | 1. To discuss novel developments of commonly used laboratory parameters and their implications in clinical practice. 2. To provide insights about the specificity of ACPA and its clinical implication 3. To interpret ANA tests in daily clinical practice 4. To learn new developments about complement and their daily practice implications | Practical Skills Lecture | New developments about complement system and clinical implications | 09:50 | 10:10 | Speaker | Dimitrios C   | Mastellos |
|                                                                       |            |                     |     |                                                                                                                                                                                                                                                                                                                                                 |                          | New developments about complement system and clinical implications | 10:10 | 10:15 | Speaker | Dimitrios C   | Mastellos |
|                                                                       |            |                     |     |                                                                                                                                                                                                                                                                                                                                                 |                          | Interpreting ANA tests, beyond the basics                          | 09:45 | 09:50 | Speaker | Maria Orietta | Borghi    |
|                                                                       |            |                     |     |                                                                                                                                                                                                                                                                                                                                                 |                          | Interpreting ANA tests, beyond the basics                          | 09:25 | 09:45 | Speaker | Maria Orietta | Borghi    |
|                                                                       |            |                     |     |                                                                                                                                                                                                                                                                                                                                                 |                          | The clinical implications of understanding the ACPA specificity    | 09:00 | 09:20 | Speaker | Caroline      | Grönwall  |
|                                                                       |            |                     |     |                                                                                                                                                                                                                                                                                                                                                 |                          | The clinical implications of                                       | 09:20 | 09:25 | Speaker | Caroline      | Grönwall  |

|                                                            |                |                        |    |                                                                                                                                                                                                                                                                                                                                           |                     |                                                                                    |       |       |             |        |                    |
|------------------------------------------------------------|----------------|------------------------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------------------------------------------------------------|-------|-------|-------------|--------|--------------------|
|                                                            |                |                        |    |                                                                                                                                                                                                                                                                                                                                           |                     | understandin<br>g the ACPA<br>specificity                                          |       |       |             |        |                    |
|                                                            |                |                        |    |                                                                                                                                                                                                                                                                                                                                           |                     |                                                                                    |       |       | Chair       | Xavier | Bossuyt            |
|                                                            |                |                        |    |                                                                                                                                                                                                                                                                                                                                           |                     |                                                                                    |       |       | Chair       | tbc    | tbc                |
| Preventio<br>n and<br>manage<br>ment of<br>chronic<br>pain | 14/06/<br>2025 | 09:00:00 -<br>10:15:00 | A1 | 1. To learn how<br>to prevent<br>transition of<br>acute to<br>chronic pain; 2.<br>To learn about<br>the unmet<br>needs of<br>patients with<br>chronic<br>musculoskeleta<br>l pain<br>syndrome;3. To<br>learn about<br>current<br>pharmacologic<br>al and non-<br>pharmacologic<br>al treatment<br>options of<br>chronic pain<br>syndrome. | Joint               | How can we<br>prevent the<br>transition of<br>acute pain to<br>chronic pain        | 09:15 | 09:30 | Spea<br>ker | tbc    | tbc                |
|                                                            |                |                        |    |                                                                                                                                                                                                                                                                                                                                           |                     | Non-<br>pharmacolog<br>ical<br>treatment of<br>chronic<br>musculoskel<br>etal pain | 09:45 | 10:00 | Spea<br>ker | Thomas | Graven-<br>Nielsen |
|                                                            |                |                        |    |                                                                                                                                                                                                                                                                                                                                           |                     | Pharmacolo<br>gical<br>treatment of<br>chronic<br>musculoskel<br>etal pain         | 09:30 | 09:45 | Spea<br>ker | Lars   | Arendt-<br>Nielsen |
|                                                            |                |                        |    |                                                                                                                                                                                                                                                                                                                                           |                     | How to live<br>with chronic<br>pain - a<br>patients<br>perspective                 | 09:00 | 09:15 | Spea<br>ker | NADIA  | MALLIOU            |
|                                                            |                |                        |    |                                                                                                                                                                                                                                                                                                                                           |                     | Discussion<br>and Closing                                                          | 10:00 | 10:15 | Spea<br>ker | Elena  | Rezus              |
|                                                            |                |                        |    |                                                                                                                                                                                                                                                                                                                                           |                     |                                                                                    |       |       | Chair       | Elena  | Rezus              |
|                                                            |                |                        |    |                                                                                                                                                                                                                                                                                                                                           |                     |                                                                                    |       |       | Chair       | Souzi  | Makri              |
| Rheumat<br>ology                                           | 14/06/<br>2025 | 09:00:00 -<br>10:15:00 | F1 | 1. To review the<br>new insights of                                                                                                                                                                                                                                                                                                       | Clinical<br>Science | Oral Abstract<br>Presentation                                                      | 10:00 | 10:10 | Spea<br>ker |        |                    |

|                                                                                       |  |  |  |                                                                                                                                                                                                                                                                                                                                                                           |  |                                                                           |       |       |         |         |              |
|---------------------------------------------------------------------------------------|--|--|--|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|---------------------------------------------------------------------------|-------|-------|---------|---------|--------------|
| meets<br>Ophthalmology:<br>uveitis,<br>retinal<br>vasculitis<br>and sicca<br>syndrome |  |  |  | the most common ocular diseases in rheumatology, such as uveitis, retinal vasculitis and dry eye disease;2. To explore the main causes of uveitis, beyond spondylarthritis; 3. Approach to ocular anatomy and how this is important for diagnostic purposes;4. Therapeutic perspectives of inflammatory ocular disease;5. Approach to sicca syndrome and dry eye disease. |  | Ophthalmology pattern recognition, can our eye doctor make the diagnosis? | 09:35 | 09:40 | Speaker | Luca    | Cimino       |
|                                                                                       |  |  |  |                                                                                                                                                                                                                                                                                                                                                                           |  | Ophthalmology pattern recognition, can our eye doctor make the diagnosis? | 09:20 | 09:35 | Speaker | Luca    | Cimino       |
|                                                                                       |  |  |  |                                                                                                                                                                                                                                                                                                                                                                           |  | Perspectives in the management of dry eye disease                         | 09:40 | 09:55 | Speaker | Manuel  | Ramos-Casals |
|                                                                                       |  |  |  |                                                                                                                                                                                                                                                                                                                                                                           |  | Uveitis in rheumatology, it is not all about spondyloarthritis!           | 09:00 | 09:15 | Speaker | Alfredo | Adan         |
|                                                                                       |  |  |  |                                                                                                                                                                                                                                                                                                                                                                           |  | Perspectives in the management of dry eye disease                         | 09:55 | 10:00 | Speaker | Manuel  | Ramos-Casals |
|                                                                                       |  |  |  |                                                                                                                                                                                                                                                                                                                                                                           |  | Uveitis in rheumatology, it is not all about                              | 09:15 | 09:20 | Speaker | Alfredo | Adan         |

|                                |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                                      |                  |                                                                                                              |       |       |         |              |                    |
|--------------------------------|------------|---------------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|--------------------------------------------------------------------------------------------------------------|-------|-------|---------|--------------|--------------------|
|                                |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                                      |                  | spondyloarthritis!                                                                                           |       |       |         |              |                    |
|                                |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                                      |                  |                                                                                                              |       |       | Chair   | Vanessa      | Ocampo             |
|                                |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                                      |                  |                                                                                                              |       |       | Chair   | Valerie      | Devauchelle-Pensec |
| Rheumatology meets: Nephrology | 14/06/2025 | 09:00:00 - 10:15:00 | 6.4 | 1. To illustrate the integration of nephrologic expertise in the management of patients with systemic rheumatic diseases; 2. To learn about renal disease in primary Sjögren's syndrome; 3. To look critically at the latest guidelines and recommendations (ACR, EULAR, KDIGO) for the management of ANCA-associated vasculitis; 4. To learn about recent advancement and potential | Clinical Science | Chronic kidney disease (CKD) therapy in renal involvement from immune mediated diseases                      | 09:30 | 09:50 | Speaker | Hans Joachim | Anders             |
|                                |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                                      |                  | The kidney in Sjögren Syndrome: rare, but not insignificant                                                  | 09:00 | 09:15 | Speaker | tbc          | tbc                |
|                                |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                                      |                  | Debate and Closing                                                                                           | 09:50 | 10:05 | Speaker | Gabriella    | Moroni             |
|                                |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                                      |                  | Renal involvement in ANCA-associated vasculitis: navigating between different guidelines and recommendations | 09:15 | 09:30 | Speaker | David R. W.  | Jayne              |

|                                     |            |                     |         |                                                                                                                                                                                                                                                                              |                          |                                              |       |       |         |                |           |
|-------------------------------------|------------|---------------------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|----------------------------------------------|-------|-------|---------|----------------|-----------|
|                                     |            |                     |         | future therapies and management of chronic kidney disease in rheumatic diseases.                                                                                                                                                                                             |                          |                                              |       |       | Chair   | Gabriella      | Moroni    |
|                                     |            |                     |         |                                                                                                                                                                                                                                                                              |                          |                                              |       |       | Chair   | Ioannis        | Parodis   |
| Start building your own 3D cultures | 14/06/2025 | 09:00:00 - 10:15:00 | B1      | 1. To get informed about the standard 3D models of synovium and skin; 2. To go step-by-step through the protocols and learn about critical points and pitfalls; 3. To get some tips from experts and discuss the problems you might encounter in your 3D cultures with them. | Practical Skills Lecture | Creating vascularised human skin equivalents | 10:00 | 10:10 | Speaker | Alexandru-Emil | Matei     |
|                                     |            |                     |         |                                                                                                                                                                                                                                                                              |                          | Creating vascularised human skin equivalents | 09:35 | 10:00 | Speaker | Alexandru-Emil | Matei     |
|                                     |            |                     |         |                                                                                                                                                                                                                                                                              |                          | 3D synovial tissue cultures                  | 09:00 | 09:25 | Speaker | Aziza          | Elmesmari |
|                                     |            |                     |         |                                                                                                                                                                                                                                                                              |                          | 3D synovial tissue cultures                  | 09:25 | 09:35 | Speaker | Aziza          | Elmesmari |
|                                     |            |                     |         |                                                                                                                                                                                                                                                                              |                          |                                              |       |       | Chair   | Gabriela       | Kania     |
|                                     |            |                     |         |                                                                                                                                                                                                                                                                              |                          |                                              |       |       | Chair   | Sander W.      | Tas       |
| Systemic Sclerosis                  | 14/06/2025 | 09:00:00 - 09:45:00 | Plenary | 1. Learn about novel drug targets in SSc. 2. Hear                                                                                                                                                                                                                            | What is New (WIN)        | What is New in Systemic Sclerosis            | 09:00 | 09:45 | Speaker | Dinesh         | Khanna    |
|                                     |            |                     |         |                                                                                                                                                                                                                                                                              |                          |                                              |       |       | Chair   | Marie-Elise    | Truchetet |

|                                                      |            |                     |    |                                                                                                                                                                                                                                                                                                                      |                         |                                                                          |       |       |         |              |           |
|------------------------------------------------------|------------|---------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|--------------------------------------------------------------------------|-------|-------|---------|--------------|-----------|
|                                                      |            |                     |    | how innovative trial design can be applied in SSc3. Learn about relevant patient stratification and outcome measures in SSc                                                                                                                                                                                          |                         |                                                                          |       |       | Chair   | Christophe r | Denton    |
| T cells in RA - could they be the key to tolerance ? | 14/06/2025 | 09:00:00 - 10:15:00 | A3 | Rheumatoid arthritis arises when the adaptive immune system targets self-antigens. Identifying autoantigens is crucial to restore immune tolerance. This session will summarise the potential of autoantigen discovery for clinical translation with a focus on tolerogenic therapies for rheumatoid arthritis. This | Basic and Translational | And if it's the innate side?                                             | 09:40 | 09:55 | Speaker | tbc          | tbc       |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                                                                                      |                         | Oral Abstract Presentation                                               | 10:00 | 10:10 | Speaker |              |           |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                                                                                      |                         | And if it's the innate side?                                             | 09:55 | 10:00 | Speaker | tbc          | tbc       |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                                                                                      |                         | The role of microbiota-specific T cells in chronic inflammatory diseases | 09:15 | 09:20 | Speaker | Petra        | Bacher    |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                                                                                      |                         | The role of microbiota-specific T cells in chronic inflammatory diseases | 09:00 | 09:15 | Speaker | Petra        | Bacher    |
|                                                      |            |                     |    |                                                                                                                                                                                                                                                                                                                      |                         | T cell repertoire and clonal expansion in                                | 09:20 | 09:35 | Speaker | Vivianne     | Malmström |

|                          |            |                     |         |                                                                                                                                                                                                                                |                    |                                                        |       |       |         |           |           |
|--------------------------|------------|---------------------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|--------------------------------------------------------|-------|-------|---------|-----------|-----------|
|                          |            |                     |         | session will help delegates:<br>1. understand the role of autoreactive T cells in RA;2. understand the role of T cells in synovial pathophysiology;3. understand the role of interaction with the innate side of autoimmunity. |                    | the synovium                                           |       |       |         |           |           |
|                          |            |                     |         |                                                                                                                                                                                                                                |                    | T cell repertoire and clonal expansion in the synovium | 09:35 | 09:40 | Speaker | Vivianne  | Malmström |
|                          |            |                     |         |                                                                                                                                                                                                                                |                    | Closing                                                | 10:10 | 10:15 | Speaker | Sebastien | Viatte    |
|                          |            |                     |         |                                                                                                                                                                                                                                |                    |                                                        |       |       | Chair   | Ufuk      | Ilgen     |
|                          |            |                     |         |                                                                                                                                                                                                                                |                    |                                                        |       |       | Chair   | Sebastien | Viatte    |
| Relapsing Polychondritis | 14/06/2025 | 09:45:00 - 10:30:00 | Plenary | 1. Review the current evidence based treatment options for Relapsing Polychondritis; 2. Review recent advances in research and emerging therapies; 3. Develop personalised treatment plans based on patients                   | How to Treat (HOT) | Relapsing Polychondritiss                              | 09:45 | 10:30 | Speaker | Laurent   | Arnaud    |
|                          |            |                     |         |                                                                                                                                                                                                                                |                    |                                                        |       |       | Chair   | Raquel    | Faria     |
|                          |            |                     |         |                                                                                                                                                                                                                                |                    |                                                        |       |       | Chair   | Oliver    | Sander    |

|                                                          |            |                     |            |                                                                                                                                                                                                                                                                   |                   |                                                          |       |       |         |           |             |
|----------------------------------------------------------|------------|---------------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|----------------------------------------------------------|-------|-------|---------|-----------|-------------|
|                                                          |            |                     |            | specific factors, such as organ involvement, disease severity and comorbidities;<br>4. Recognise and treat emergencies in Relapsing Polychondritis; highlight the importance of interdisciplinary care with pulmonologists, otolaryngologist , thoracic surgeons. |                   |                                                          |       |       |         |           |             |
| Fast ultrasound protocols in Rheumatology: Point of Care | 14/06/2025 | 10:15:00 - 11:30:00 | Hands-On 1 | 1. How to perform fast ultrasonography scans in daily clinical practice;2. Using handheld portable ultrasound devices;3. Examples in different anatomical areas and pathologies                                                                                   | Hands-on Sessions | Point of Care vessel scan in suspected vasculitis        | 10:30 | 10:35 | Speaker | Christina | Duftner     |
|                                                          |            |                     |            |                                                                                                                                                                                                                                                                   |                   | Point of Care salivary gland scan in suspected sjögren's | 10:20 | 10:25 | Speaker | Baptiste  | Quere       |
|                                                          |            |                     |            |                                                                                                                                                                                                                                                                   |                   | Point of Care joint scan in suspected arthritis          | 10:25 | 10:30 | Speaker | Marina    | Backhaus    |
|                                                          |            |                     |            |                                                                                                                                                                                                                                                                   |                   | Point of Care lung scan in                               | 10:15 | 10:20 | Speaker | Andrea    | Delle Sedie |

|                                  |            |                     |            |                                                                                                                                                                                                                                                                 |                   |                                                                                                              |       |       |         |              |             |
|----------------------------------|------------|---------------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|--------------------------------------------------------------------------------------------------------------|-------|-------|---------|--------------|-------------|
|                                  |            |                     |            | using portable ultrasound devices.                                                                                                                                                                                                                              |                   | patients with suspected interstitial lung disease                                                            |       |       |         |              |             |
|                                  |            |                     |            |                                                                                                                                                                                                                                                                 |                   | Hands-on stations                                                                                            | 10:40 | 11:30 | Speaker | Andrea       | Delle Sedie |
|                                  |            |                     |            |                                                                                                                                                                                                                                                                 |                   | Discussion on presentations                                                                                  | 10:35 | 10:40 | Speaker | Marion       | Kortekaas   |
|                                  |            |                     |            |                                                                                                                                                                                                                                                                 |                   |                                                                                                              |       |       | Chair   | Marion       | Kortekaas   |
|                                  |            |                     |            |                                                                                                                                                                                                                                                                 |                   |                                                                                                              |       |       | Chair   | Hilde Berner | Hammer      |
| How to assess the foot and ankle | 14/06/2025 | 10:15:00 - 11:30:00 | Hands-On 2 | 1. Identify core anatomical structures within the foot and ankle which are frequently affected in Rheumatic and musculoskeletal diseases (RMDs);2. Apply anatomical knowledge to conduct a basic examination of the musculoskeletal, neurological, and vascular | Hands-on Sessions | Hands-on stations: Assessment of Musculoskeletal system, Neurovascular systems and Footwear, skin, and nails | 10:35 | 11:25 | Speaker | Aimie        | Patience    |
|                                  |            |                     |            |                                                                                                                                                                                                                                                                 |                   | Introduction and anatomy refresher: Key structures in the foot and ankle                                     | 10:15 | 10:35 | Speaker | Christophe r | Joyce       |
|                                  |            |                     |            |                                                                                                                                                                                                                                                                 |                   | Questions on                                                                                                 | 11:25 | 11:30 | Speaker | Christophe r | Joyce       |

|                                                                     |            |                     |                   |                                                                                                                                                                                                                                                                                            |                       |                                                                     |       |       |         |             |                |
|---------------------------------------------------------------------|------------|---------------------|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|---------------------------------------------------------------------|-------|-------|---------|-------------|----------------|
|                                                                     |            |                     |                   | systems within the foot and ankle;3. Identify common pathologies that affect the foot and ankle in RMDs.                                                                                                                                                                                   |                       | presentations and practice                                          |       |       |         |             |                |
|                                                                     |            |                     |                   |                                                                                                                                                                                                                                                                                            |                       |                                                                     |       |       | Chair   | Laura       | Ramos Petersen |
|                                                                     |            |                     |                   |                                                                                                                                                                                                                                                                                            |                       |                                                                     |       |       | Chair   | Christopher | Joyce          |
| Burning questions in the management of systemic lupus erythematosus | 14/06/2025 | 11:00:00 - 11:30:00 | Meet the Expert 1 | <p>This session will provide: 1. practical advice regarding the application of targeted therapies in SLE;2. the glucocorticoid dosing strategy and the chance of discontinuation will be shown through real life cases;3. the up-to-date diagnosis and therapy of lupus nephritis will</p> | Meet the EULAR Expert | Burning questions in the management of systemic lupus erythematosus | 11:00 | 11:30 | Speaker | László      | Kovács         |

|                                                          |            |                     |                   |                                                                                                                                                                                                                                                                                                           |                       |                                                          |       |       |         |         |         |
|----------------------------------------------------------|------------|---------------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|----------------------------------------------------------|-------|-------|---------|---------|---------|
|                                                          |            |                     |                   | be discussed as well.                                                                                                                                                                                                                                                                                     |                       |                                                          |       |       |         |         |         |
| Case discussion: Difficult to treat Rheumatoid Arthritis | 14/06/2025 | 11:00:00 - 11:30:00 | Meet the Expert 3 | <p>Several factors may make Rheumatoid arthritis (RA) difficult to treat (D2T). This session will</p> <p>provide a state-of-the art overview of D2T RA, including: 1. contributing factors2. burden of the disease and management options. Practical guidance will be provided for the classification</p> | Meet the EULAR Expert | Case discussion: Difficult to treat Rheumatoid Arthritis | 11:00 | 11:30 | Speaker | Iain B. | McInnes |

|                                                                                               |                |                        |                            |                                                                                                                                                                                                                                                                                                                                                                                                    |                             |                                                                                         |       |       |             |       |    |
|-----------------------------------------------------------------------------------------------|----------------|------------------------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------------------------------------------------------------------|-------|-------|-------------|-------|----|
|                                                                                               |                |                        |                            | and<br>management<br><br>of D2T RA.                                                                                                                                                                                                                                                                                                                                                                |                             |                                                                                         |       |       |             |       |    |
| Citizen<br>Science:<br>A web<br>portal for<br>patients<br>to<br>transform<br>pain<br>research | 14/06/<br>2025 | 11:00:00 -<br>11:30:00 | Meet<br>the<br>Expert<br>2 | Delegates<br>will:1. Learn<br>about a social<br>movement that<br>gets the public<br>to join forces<br>with health<br>scientists to<br>learn more<br>about pain;2.<br>Understand the<br>value of first-<br>hand<br>experience of a<br>disease,<br>condition, or<br>symptoms for<br>research<br>activities;3.<br>Discuss<br>opportunities<br>for setting up a<br>similar web<br>portal in<br>Europe. | Meet the<br>EULAR<br>Expert | Citizen<br>Science: A<br>web portal<br>for patients<br>to transform<br>pain<br>research | 11:00 | 11:30 | Spea<br>ker | Linda | Li |

|                                                          |            |                     |                   |                                                                                                                                                                                                                                                      |                       |                                                          |       |       |         |         |               |
|----------------------------------------------------------|------------|---------------------|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|----------------------------------------------------------|-------|-------|---------|---------|---------------|
| Vaccination in Rheumatic Diseases: anything new in 2025? | 14/06/2025 | 11:00:00 - 11:30:00 | Meet the Expert 4 | 1. What are the recommended vaccinations in patients with autoimmune diseases;2. May vaccination induce autoimmune diseases or flare of autoimmune diseases;3. Can immunomodulators alter the vaccine response in patients with autoimmune diseases? | Meet the EULAR Expert | Vaccination in Rheumatic Diseases: anything new in 2025? | 11:00 | 11:30 | Speaker | Ori     | Elkayam       |
| Rheumatoid Arthritis                                     | 14/06/2025 | 11:45:00 - 12:30:00 | Plenary           | 1. To discuss new findings in the pathogenesis of rheumatoid arthritis allowing to distinguish between different clinical subsets;3. to understand                                                                                                   | What is New (WIN)     | Rheumatoid Arthritis                                     | 11:45 | 12:30 | Speaker | Diane   | van der Woude |
|                                                          |            |                     |                   |                                                                                                                                                                                                                                                      |                       |                                                          |       |       | Chair   | Maria V | Sokolova      |
|                                                          |            |                     |                   |                                                                                                                                                                                                                                                      |                       |                                                          |       |       | Chair   | tbc     | tbc           |

|                                                                            |             |                     |    |                                                                                                                                                                                                                                                                                         |                   |                                                                                    |       |       |         |       |        |
|----------------------------------------------------------------------------|-------------|---------------------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|------------------------------------------------------------------------------------|-------|-------|---------|-------|--------|
|                                                                            |             |                     |    | how B cell populations and autoantibodies could be indicative of RA subsets;4. to understand how differentiating between RA subsets can impact on treatment decisions;5. to understand how treatment responses to specific and targeted therapies can help differentiate clear subsets. |                   |                                                                                    |       |       |         |       |        |
| Building Your Research Future: Funding Networks , EULAR Opportunities, and | 14/06/ 2025 | 12:00:00 - 13:15:00 | B4 | A session guiding young researchers and rheumatologists in research.1. Develop skills to transform research ideas                                                                                                                                                                       | EMEUNE T Presents | My project got funded, now what? Effective Project Management and Collaboration in | 12:30 | 12:45 | Speaker | Sofia | Ramiro |

|                           |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                |  |                                                                    |       |       |         |        |           |
|---------------------------|--|--|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--------------------------------------------------------------------|-------|-------|---------|--------|-----------|
| Clinical Study Initiation |  |  |  | into well-structured study proposals, with practical tips for success;2. Explore funding opportunities for research projects, including EULAR's options and how to effectively apply for them;3. Gain insights on managing funded projects, from securing funding to achieving meaningful research results;4. Understand the importance of interdisciplinary collaboration in research and how to successfully |  | Rheumatology Research                                              |       |       |         |        |           |
|                           |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                |  | Interdisciplinary Approaches in Rheumatology Research              | 12:45 | 13:00 | Speaker | Axel   | Finckh    |
|                           |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                |  | Q&A and Closing                                                    | 13:00 | 13:15 | Speaker | Deniz  | Bayraktar |
|                           |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                |  | Creating a good study proposal                                     | 12:00 | 12:15 | Speaker | Andrew | Cope      |
|                           |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                |  | Navigating Research Funding and Grant Applications in Rheumatology | 12:15 | 12:30 | Speaker | Felice | Rivellese |
|                           |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                |  |                                                                    |       |       | Chair   | Madga  | Osipyan   |
|                           |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                |  |                                                                    |       |       | Chair   | Deniz  | Bayraktar |

|                                                                                                                         |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                           |                          |                                                                                                         |       |       |         |     |     |
|-------------------------------------------------------------------------------------------------------------------------|------------|---------------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|---------------------------------------------------------------------------------------------------------|-------|-------|---------|-----|-----|
|                                                                                                                         |            |                     |     | integrate multiple disciplines into your study.                                                                                                                                                                                                                                                                                                                           |                          |                                                                                                         |       |       |         |     |     |
| Chest High Resolution Computed Tomography (HRCT) in detecting, staging and follow up of interstitial lung disease (ILD) | 14/06/2025 | 12:00:00 - 13:15:00 | 6.3 | 1. How to diagnose connective tissue disease - interstitial lung disease (CTD-ILD) using chest High Resolution Computed Tomography (HRCT)2. How to avoid misdiagnosing3. How to identify different subtypes of ILD4. How to assess severity of CTD-ILD on chest HRCT After short introductory presentations, the audience will learn from cases prepared by the speakers. | Practical Skills Lecture | Introductory lesson: Interpretation of HRCT findings in interstitial lung disease (pearls and pitfalls) | 12:00 | 12:10 | Speaker | tbc | tbc |
|                                                                                                                         |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                           |                          | Case presentations: Interpretation of HRCT findings in interstitial lung disease (pearls and pitfalls)  | 12:10 | 12:35 | Speaker | tbc | tbc |
|                                                                                                                         |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                           |                          | Introductory lesson: Differentiating subtypes of CTD-ILD using HRCT, staging and follow up              | 12:35 | 12:45 | Speaker | tbc | tbc |
|                                                                                                                         |            |                     |     |                                                                                                                                                                                                                                                                                                                                                                           |                          | Case presentations:                                                                                     | 12:45 | 13:10 | Speaker | tbc | tbc |

|                                                          |            |                     |    |                                                                                                                                                                                                                                                                                      |              |                                                                                        |       |       |         |            |               |
|----------------------------------------------------------|------------|---------------------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|----------------------------------------------------------------------------------------|-------|-------|---------|------------|---------------|
|                                                          |            |                     |    |                                                                                                                                                                                                                                                                                      |              | Differentiating subtypes of CTD-ILD using HRCT, staging and follow up                  |       |       |         |            |               |
|                                                          |            |                     |    |                                                                                                                                                                                                                                                                                      |              | Q&As and Closing                                                                       | 13:10 | 13:15 | Speaker | Vladimira  | Boyadzhieva   |
|                                                          |            |                     |    |                                                                                                                                                                                                                                                                                      |              |                                                                                        |       |       | Chair   | Vladimira  | Boyadzhieva   |
|                                                          |            |                     |    |                                                                                                                                                                                                                                                                                      |              |                                                                                        |       |       | Chair   | Aleksandra | Opinc-Rosiak  |
| Combination therapy for fibrosis in systemic sclerosis ? | 14/06/2025 | 12:00:00 - 13:15:00 | B2 | 1. To discuss the possible benefits and risks of an upfront combination therapy of anti-inflammatory and anti-fibrotic drugs;2. To learn how to best stratify patients at risk for rapid progression;3. To discuss a research agenda in the management of systemic sclerosis related | EULAR Debate | Audience Voting                                                                        | 13:10 | 13:10 | Speaker |            |               |
|                                                          |            |                     |    |                                                                                                                                                                                                                                                                                      |              | Audience Voting                                                                        | 12:00 | 12:00 | Speaker |            |               |
|                                                          |            |                     |    |                                                                                                                                                                                                                                                                                      |              | Rebuttal Pro: Upfront combination therapy of anti-inflammatory and anti-fibrotic drugs | 12:50 | 13:00 | Speaker | Anna-Maria | Hoffmann-Vold |
|                                                          |            |                     |    |                                                                                                                                                                                                                                                                                      |              | Pro: Upfront combination therapy of anti-inflammatory and anti-fibrotic drugs          | 12:00 | 12:25 | Speaker | Anna-Maria | Hoffmann-Vold |
|                                                          |            |                     |    |                                                                                                                                                                                                                                                                                      |              | Rebuttal Contra: Upfront                                                               | 13:00 | 13:10 | Speaker | Oliver     | Distler       |

|                                                                  |            |                     |    |                                                                                                                                                                                                                              |                                 |                                                                                          |       |       |         |           |               |
|------------------------------------------------------------------|------------|---------------------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|------------------------------------------------------------------------------------------|-------|-------|---------|-----------|---------------|
|                                                                  |            |                     |    | interstitial lung disease.                                                                                                                                                                                                   |                                 | combination therapy of anti-inflammatory and anti-fibrotic drugs                         |       |       |         |           |               |
|                                                                  |            |                     |    |                                                                                                                                                                                                                              |                                 | Contra: Upfront combination therapy of anti-inflammatory and anti-fibrotic drugs         | 12:25 | 12:50 | Speaker | Oliver    | Distler       |
|                                                                  |            |                     |    |                                                                                                                                                                                                                              |                                 |                                                                                          |       |       | Chair   | Alexandra | Balbir-Gurman |
|                                                                  |            |                     |    |                                                                                                                                                                                                                              |                                 |                                                                                          |       |       | Chair   | Mislav    | Radic         |
| Complicated pregnancies in SLE, to save the mother and the child | 14/06/2025 | 12:00:00 - 13:15:00 | A2 | 1. Gain insight into the challenges of managing pregnancies in women with SLE with or without APS;2. Understand the therapeutic options for SLE and APS during pregnancy; 3. Be updated on the best practice recommendations | Challenges in Clinical Practice | Case presentation: The pitfalls of treating SLE during pregnancy, with or without APS    | 12:30 | 12:40 | Speaker |           |               |
|                                                                  |            |                     |    |                                                                                                                                                                                                                              |                                 | Case presentation: Complications in lupus pregnancies - how to monitor, what to look for | 12:05 | 12:15 | Speaker |           |               |

|                                                                          |            |                     |    |                                                                                                                            |                  |                                                                                          |       |       |         |           |              |
|--------------------------------------------------------------------------|------------|---------------------|----|----------------------------------------------------------------------------------------------------------------------------|------------------|------------------------------------------------------------------------------------------|-------|-------|---------|-----------|--------------|
|                                                                          |            |                     |    | ns for pregnancies complicated by SLE.                                                                                     |                  | Q&A and Closing                                                                          | 12:55 | 13:15 | Speaker | Johanna   | Mucke        |
|                                                                          |            |                     |    |                                                                                                                            |                  | Introduction                                                                             | 12:00 | 12:05 | Speaker | Johanna   | Mucke        |
|                                                                          |            |                     |    |                                                                                                                            |                  | Case presentation: Complications in lupus pregnancies - how to monitor, what to look for | 12:15 | 12:30 | Speaker | Rebecca   | Fischer-Betz |
|                                                                          |            |                     |    |                                                                                                                            |                  | Case presentation: The pitfalls of treating SLE during pregnancy, with or without APS    | 12:40 | 12:55 | Speaker | Irene     | Bultink      |
|                                                                          |            |                     |    |                                                                                                                            |                  |                                                                                          |       |       | Chair   | Johanna   | Mucke        |
|                                                                          |            |                     |    |                                                                                                                            |                  |                                                                                          |       |       | Chair   | George K. | Bertsias     |
| Disaster Medicine - Impact of climate change, heat and global insecurity | 14/06/2025 | 12:00:00 - 13:15:00 | F1 | To understand the impact of global factors such as climate change, war, global insecurity and social disparities in highly | Clinical Science | Oral Abstract Presentation                                                               | 13:00 | 13:10 | Speaker |           |              |
|                                                                          |            |                     |    |                                                                                                                            |                  | Will climate change impact rheumatological care taking?                                  | 12:00 | 12:20 | Speaker | Oliver    | Sander       |
|                                                                          |            |                     |    |                                                                                                                            |                  | Social disparities                                                                       | 12:40 | 13:00 | Speaker | Kate      | Webb         |

|  |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                                  |  |                                                                                         |       |       |         |         |       |
|--|--|--|--|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|-----------------------------------------------------------------------------------------|-------|-------|---------|---------|-------|
|  |  |  |  | developed countries on rheumatology1. impact of critical weather events on medical care taking as well as global heating and its impact on rheumatic diseases; 2. impact of regional insecurity i.e. War on medical care taking (psychological burden, insecure working situation, constant threads, migrants,...); 3. understand the difficulties in medical care taking in African countries within those countries as well as |  | and impact on outcome                                                                   |       |       |         |         |       |
|  |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                                  |  | Q&A and Closing                                                                         | 13:10 | 13:15 | Speaker | Mustafa | Ekici |
|  |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                                  |  | How is global and regional insecurity impacting on medical care taking in rheumatology? | 12:20 | 12:40 | Speaker | Marta   | Dzhus |
|  |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                                  |  |                                                                                         |       |       | Chair   | tbc     | tbc   |
|  |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                                                  |  |                                                                                         |       |       | Chair   | Mustafa | Ekici |

|                                                     |            |                     |    |                                                                                                                                                                                                                                                                                                                       |                         |                                                                                |       |       |         |              |        |
|-----------------------------------------------------|------------|---------------------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|--------------------------------------------------------------------------------|-------|-------|---------|--------------|--------|
|                                                     |            |                     |    | compared to European health care systems.                                                                                                                                                                                                                                                                             |                         |                                                                                |       |       |         |              |        |
| How does sex and gender predispose to autoimmunity? | 14/06/2025 | 12:00:00 - 13:15:00 | A1 | Hormonal status is probably not the culprit explaining the higher prevalence of autoimmunity in women. In this session, you will learn 1. about defect X chromosome inactivation that could favor autoimmunity in women, 2. the role of Xist, a long non-coding RNA and its implication for aberrant immune responses | Basic and Translational | Reduced X chromosome inactivation skewing in autoimmunity                      | 12:20 | 12:35 | Speaker | Amy          | Robers |
|                                                     |            |                     |    |                                                                                                                                                                                                                                                                                                                       |                         | Oral Abstract Presentation                                                     | 13:00 | 13:10 | Speaker |              |        |
|                                                     |            |                     |    |                                                                                                                                                                                                                                                                                                                       |                         | Reduced X chromosome inactivation skewing in autoimmunity                      | 12:35 | 12:40 | Speaker | Amy          | Robers |
|                                                     |            |                     |    |                                                                                                                                                                                                                                                                                                                       |                         | Defect of X inactivation increases TLR7 expression and may induce autoimmunity | 12:00 | 12:15 | Speaker | Jean-Charles | Guéry  |
|                                                     |            |                     |    |                                                                                                                                                                                                                                                                                                                       |                         | Defect of X inactivation increases TLR7 expression and may induce              | 12:15 | 12:20 | Speaker | Jean-Charles | Guéry  |

|                                                      |                |                        |    |                                                                                                                                                                                                                |       |                                                                                                   |       |       |             |        |          |
|------------------------------------------------------|----------------|------------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|---------------------------------------------------------------------------------------------------|-------|-------|-------------|--------|----------|
|                                                      |                |                        |    |                                                                                                                                                                                                                |       | autoimmunit<br>y                                                                                  |       |       |             |        |          |
|                                                      |                |                        |    |                                                                                                                                                                                                                |       | Xist<br>ribonucleopr<br>oteins<br>promote<br>female sex-<br>biased<br>autoimmunit<br>y            | 12:55 | 13:00 | Spea<br>ker | Rami   | Bechara  |
|                                                      |                |                        |    |                                                                                                                                                                                                                |       | Xist<br>ribonucleopr<br>oteins<br>promote<br>female sex-<br>biased<br>autoimmunit<br>y            | 12:40 | 12:55 | Spea<br>ker | Rami   | Bechara  |
|                                                      |                |                        |    |                                                                                                                                                                                                                |       |                                                                                                   |       |       | Chair       | Rami   | Bechara  |
|                                                      |                |                        |    |                                                                                                                                                                                                                |       |                                                                                                   |       |       | Chair       | Jelena | Colic    |
| How to<br>involve<br>patients<br>in your<br>research | 14/06/<br>2025 | 12:00:00 -<br>13:15:00 | B1 | 1. Overview of<br>the updated<br>EULAR<br>recommendatio<br>ns for involving<br>Patient<br>Research<br>Partners<br>(PRPs) in<br>rheumatology<br>research<br>focusing on the<br>importance of<br>its application | Joint | How to<br>motivate and<br>involve<br>Patient<br>Research<br>Partners' in a<br>Research<br>Project | 12:15 | 12:30 | Spea<br>ker | Paul   | Studenic |
|                                                      |                |                        |    |                                                                                                                                                                                                                |       | How to<br>motivate and<br>involve<br>Patient<br>Research<br>Partners' in a                        | 12:30 | 12:35 | Spea<br>ker | Paul   | Studenic |

|  |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                             |  |                                                                                      |       |       |         |        |             |
|--|--|--|--|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--------------------------------------------------------------------------------------|-------|-------|---------|--------|-------------|
|  |  |  |  | in research studies2. Discuss strategies to enhance PRP involvement for successful partnerships. 3. Learn practical strategies for recruiting and training PRPs to optimize their involvement.4. Explore the role of a PRP coordinator in facilitating effective collaboration in research projects.5. Develop skills for effective training of both PRPs and researchers to ensure meaningful involvement. |  | Research Project                                                                     |       |       |         |        |             |
|  |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                             |  | How to Train PRPs and Researchers to Optimise Patient Research Partners' Involvement | 12:50 | 12:55 | Speaker | Heidi  | Bertheussen |
|  |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                             |  | How to Train PRPs and Researchers to Optimise Patient Research Partners' Involvement | 12:35 | 12:50 | Speaker | Heidi  | Bertheussen |
|  |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                             |  | The Role of a Patient Research Partner Coordinator in a Research Project             | 13:10 | 13:15 | Speaker | Muriel | Elhai       |
|  |  |  |  |                                                                                                                                                                                                                                                                                                                                                                                                             |  | The updated EULAR recommendations on Patient Research Partners'                      | 12:10 | 12:15 | Speaker | Ana    | Vieira      |

|                                                                      |            |                     |    |                                                                                                                                                                                    |      |                                                                                         |       |       |         |         |              |
|----------------------------------------------------------------------|------------|---------------------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------------------------------------------------------------------------------------|-------|-------|---------|---------|--------------|
|                                                                      |            |                     |    |                                                                                                                                                                                    |      | involvement in research                                                                 |       |       |         |         |              |
|                                                                      |            |                     |    |                                                                                                                                                                                    |      | The Role of a Patient Research Partner Coordinator in a Research Project                | 12:55 | 13:10 | Speaker | Muriel  | Elhai        |
|                                                                      |            |                     |    |                                                                                                                                                                                    |      | The updated EULAR recommendations on Patient Research Partners' involvement in research | 12:00 | 12:10 | Speaker | Ana     | Vieira       |
|                                                                      |            |                     |    |                                                                                                                                                                                    |      |                                                                                         |       |       | Chair   | Krystel | Aouad        |
|                                                                      |            |                     |    |                                                                                                                                                                                    |      |                                                                                         |       |       | Chair   | Jette   | Primdahl     |
| I Can't Afford to Have a Rheumatic and Musculoskeletal Disease (RMD) | 14/06/2025 | 12:00:00 - 13:15:00 | C3 | 1.Delegates will learn about the various hidden costs to the individual and society of living with a RMD, 2.Delegates will learn about the additional costs of living with an RMD, | PARE | Abstract Presentation                                                                   | 12:45 | 12:55 | Speaker |         |              |
|                                                                      |            |                     |    |                                                                                                                                                                                    |      | Abstract Presentation                                                                   | 12:55 | 13:05 | Speaker |         |              |
|                                                                      |            |                     |    |                                                                                                                                                                                    |      | Debate and Closing                                                                      | 13:05 | 13:15 | Speaker | Sladana | Rumpl Tunjić |
|                                                                      |            |                     |    |                                                                                                                                                                                    |      | The Hidden Costs of Living with an RMD: A Personal Perspective                          | 12:30 | 12:45 | Speaker | Kyriaki | Spanidou     |

|                                    |            |                     |     |                                                                                                                                                                                                                                                                                                      |                          |                                                               |       |       |         |           |               |
|------------------------------------|------------|---------------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|---------------------------------------------------------------|-------|-------|---------|-----------|---------------|
|                                    |            |                     |     | 3.Delegates will learn about the impact of a RMD on earnings and financial security                                                                                                                                                                                                                  |                          | Individual Cost of Arthritis                                  | 12:15 | 12:30 | Speaker | Grainne   | O Leary       |
|                                    |            |                     |     |                                                                                                                                                                                                                                                                                                      |                          | Costs related to RMDs in comparison to cancer                 | 12:00 | 12:15 | Speaker | Stine     | Wasenius Dahl |
|                                    |            |                     |     |                                                                                                                                                                                                                                                                                                      |                          |                                                               |       |       | Chair   | Andri     | Phoka         |
|                                    |            |                     |     |                                                                                                                                                                                                                                                                                                      |                          |                                                               |       |       | Chair   | Slađana   | Rumpl Tunjić  |
| Imaging in axial spondyloarthritis | 14/06/2025 | 12:00:00 - 13:15:00 | 6.4 | 1. Learn a systematic approach for assessing imaging abnormalities typical for spondyloarthritis on both radiographs and MRI, with an emphasis on structured evaluation of the axial skeleton.2. Understand the role of MRI sequences in diagnosing spondyloarthritis including how to interpret key | Practical Skills Lecture | Structured radiographic assessment of the axial skeleton      | 12:00 | 12:25 | Speaker | Lennart   | Jans          |
|                                    |            |                     |     |                                                                                                                                                                                                                                                                                                      |                          | MR imaging of the spine and SI joints, how to properly do it! | 12:25 | 12:50 | Speaker | Kay-Geert | Hermann       |
|                                    |            |                     |     |                                                                                                                                                                                                                                                                                                      |                          | Case discussions on differential diagnosis                    | 12:50 | 13:15 | Speaker | Iris      | Eshed         |
|                                    |            |                     |     |                                                                                                                                                                                                                                                                                                      |                          |                                                               |       |       | Chair   | Bayram    | Farisogullari |
|                                    |            |                     |     |                                                                                                                                                                                                                                                                                                      |                          |                                                               |       |       | Chair   | tbc       | tbc           |

|                                                          |            |                     |     |                                                                                                                                                                                                                                                                                                     |       |                                                                |       |       |         |           |             |
|----------------------------------------------------------|------------|---------------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|----------------------------------------------------------------|-------|-------|---------|-----------|-------------|
|                                                          |            |                     |     | sequences and distinguish between pathological and normal findings.3. Apply differential diagnosis techniques by reviewing X-ray and MRI case studies, identifying imaging features of SpA, and differentiating them from other conditionsAll using the Berlin Case Viewer for interactive feedback |       |                                                                |       |       |         |           |             |
| Multidisciplinary approach to patients with inflammatory | 14/06/2025 | 12:00:00 - 13:15:00 | 6.1 | 1. How to make a full assessment of the myositis patient, including manual muscle test 8;2.                                                                                                                                                                                                         | Joint | Roundtable and Closing                                         | 13:00 | 13:15 | Speaker | Eleonora  | Camerone    |
|                                                          |            |                     |     |                                                                                                                                                                                                                                                                                                     |       | How to make a full assessment the myositis patient - including | 12:00 | 12:20 | Speaker | Antonella | Notarnicola |

|                                                  |            |                     |     |                                                                                                                                                                                                           |                  |                                                                          |       |       |         |            |               |
|--------------------------------------------------|------------|---------------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|--------------------------------------------------------------------------|-------|-------|---------|------------|---------------|
| myopathies                                       |            |                     |     | Importance of physiotherapy in the management of inflammatory myositis;3. How mental health and quality of life is affected by inflammatory myositis, and how this can be reduced.                        |                  | demonstration of MMT-8                                                   |       |       |         |            |               |
|                                                  |            |                     |     |                                                                                                                                                                                                           |                  | Importance of physiotherapy in the management of inflammatory myopathies | 12:20 | 12:40 | Speaker | Helene     | Alexandersson |
|                                                  |            |                     |     |                                                                                                                                                                                                           |                  | Mental health and quality of life in inflammatory myopathies             | 12:40 | 13:00 | Speaker | Lesley Ann | Saketkoo      |
|                                                  |            |                     |     |                                                                                                                                                                                                           |                  |                                                                          |       |       | Chair   | Alain      | Meyer         |
|                                                  |            |                     |     |                                                                                                                                                                                                           |                  |                                                                          |       |       | Chair   | Eleonora   | Camerone      |
| New Potential Targets for Pain in Osteoarthritis | 14/06/2025 | 12:00:00 - 13:15:00 | 6.2 | 1. understand the evidence regarding genicular artery embolization and radiofrequency ablation in knee OA (osteoarthritis);<br>2. examine how tVNS (transcutaneous vagus nerve stimulation) may alleviate | Clinical Science | Oral Abstract Presentation                                               | 13:00 | 13:10 | Speaker |            |               |
|                                                  |            |                     |     |                                                                                                                                                                                                           |                  | Harnessing the autonomic nervous system: tVNS for osteoarthritis         | 12:35 | 12:40 | Speaker | Zsuzsa     | Jenei-Lanzl   |
|                                                  |            |                     |     |                                                                                                                                                                                                           |                  | Harnessing the autonomic nervous system: tVNS for osteoarthritis         | 12:20 | 12:35 | Speaker | Zsuzsa     | Jenei-Lanzl   |

|  |  |  |  |                                                                                                       |  |                                                                                                                                              |       |       |         |          |       |
|--|--|--|--|-------------------------------------------------------------------------------------------------------|--|----------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|---------|----------|-------|
|  |  |  |  | pain in OA; 3. recognise TrkA (Tropomyosin receptor kinase A) as a potential novel target for OA pain |  | Genicular artery embolization and Radiofrequency ablation for knee osteoarthritis : promise or sham?                                         | 12:15 | 12:20 | Speaker | Edwin    | Oei   |
|  |  |  |  |                                                                                                       |  | Genicular artery embolization and Radiofrequency ablation for knee osteoarthritis : promise or sham?                                         | 12:00 | 12:15 | Speaker | Edwin    | Oei   |
|  |  |  |  |                                                                                                       |  | Targeting nociceptors in the post-NGF (nerve growth factor) era -- hope or hype for TrkA (Tropomyosin receptor kinase A) in osteoarthritis ? | 12:40 | 12:55 | Speaker | David A. | Walsh |

|                                          |            |                     |    |                                                                                                                                                                                                 |                       |                                                                                                                                             |       |       |         |          |        |
|------------------------------------------|------------|---------------------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|---------|----------|--------|
|                                          |            |                     |    |                                                                                                                                                                                                 |                       | Targeting nociceptors in the post-NGF (nerve growth factor) era -- hope or hype for TrkA (Tropomyosin receptor kinase A) in osteoarthritis? | 12:55 | 13:00 | Speaker | David A. | Walsh  |
|                                          |            |                     |    |                                                                                                                                                                                                 |                       | Discussion and Closing                                                                                                                      | 13:10 | 13:15 | Speaker | Michel   | Crema  |
|                                          |            |                     |    |                                                                                                                                                                                                 |                       |                                                                                                                                             |       |       | Chair   | tbc      | tbc    |
|                                          |            |                     |    |                                                                                                                                                                                                 |                       |                                                                                                                                             |       |       | Chair   | tbc      | tbc    |
| Osteoporosis in men: pearls and pitfalls | 14/06/2025 | 12:00:00 - 13:15:00 | F3 | This session will assist clinicians in:1. understanding the pathophysiology and etiology of male osteoporosis;2. recognising potential diagnostic pitfalls;3. effectively treating the disease. | From Bench to Bedside | Causes and pathophysiology of osteoporosis in men                                                                                           | 12:00 | 12:20 | Speaker | Bernard  | Cortet |
|                                          |            |                     |    |                                                                                                                                                                                                 |                       | Causes and pathophysiology of osteoporosis in men                                                                                           | 12:20 | 12:25 | Speaker | Bernard  | Cortet |
|                                          |            |                     |    |                                                                                                                                                                                                 |                       | Treatment of osteoporosis in men                                                                                                            | 12:50 | 13:10 | Speaker | Nicholas | Fuggle |
|                                          |            |                     |    |                                                                                                                                                                                                 |                       | Treatment of osteoporosis in men                                                                                                            | 13:10 | 13:15 | Speaker | Nicholas | Fuggle |

|                                                                             |            |                     |    |                                                                                                                                                                                                                                                                           |                  |                                                                                            |       |       |         |         |           |
|-----------------------------------------------------------------------------|------------|---------------------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|--------------------------------------------------------------------------------------------|-------|-------|---------|---------|-----------|
|                                                                             |            |                     |    |                                                                                                                                                                                                                                                                           |                  | How and when to diagnose osteoporosis in men                                               | 12:25 | 12:45 | Speaker | Radmila | Matijevic |
|                                                                             |            |                     |    |                                                                                                                                                                                                                                                                           |                  | How and when to diagnose osteoporosis in men                                               | 12:45 | 12:50 | Speaker | Radmila | Matijevic |
|                                                                             |            |                     |    |                                                                                                                                                                                                                                                                           |                  |                                                                                            |       |       | Chair   | Piet    | Geusens   |
|                                                                             |            |                     |    |                                                                                                                                                                                                                                                                           |                  |                                                                                            |       |       | Chair   | Karine  | Briot     |
| Rheumatology meets Dermatology: Febrile dermatoses in rheumatologic context | 14/06/2025 | 12:00:00 - 13:15:00 | D1 | 1. To provide the dermatologic point of view in describing the elementary lesions of febrile dermatoses of interest in rheumatologic context; 2. To discuss the autoinflammatory and autoimmune diseases which could manifest with febrile dermatoses using the models of | Clinical Science | The elementary skin lesions of febrile dermatoses of interest in the rheumatologic context | 12:00 | 12:20 | Speaker | tbc     | tbc       |
|                                                                             |            |                     |    |                                                                                                                                                                                                                                                                           |                  | The elementary skin lesions of febrile dermatoses of interest in the rheumatologic context | 12:20 | 12:25 | Speaker | tbc     | tbc       |
|                                                                             |            |                     |    |                                                                                                                                                                                                                                                                           |                  | The autoimmune side in febrile                                                             | 13:10 | 13:15 | Speaker | Miriam  | Wittmann  |

|  |  |  |  |                                                                                                                                                                                                                                                                                                           |  |                                                                                                           |       |       |         |        |                 |
|--|--|--|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|-----------------------------------------------------------------------------------------------------------|-------|-------|---------|--------|-----------------|
|  |  |  |  | Schnitzler syndrome and cutaneous systemic lupus erythematosus;<br>3. To know how the presence of mucocutaneous manifestations together with fever may have a clinical significance as a part of the initial presentation or activation stage of both autoimmune and autoinflammatory rheumatic diseases. |  | dermatoses, the model of cutaneous lesions in systemic lupus erythematosus                                |       |       |         |        |                 |
|  |  |  |  |                                                                                                                                                                                                                                                                                                           |  | The autoimmune side in febrile dermatoses, the model of cutaneous lesions in systemic lupus erythematosus | 12:50 | 13:10 | Speaker | Miriam | Wittmann        |
|  |  |  |  |                                                                                                                                                                                                                                                                                                           |  | The autoinflammatory side in febrile dermatoses; the model of Schnitzler syndrome                         | 12:25 | 12:45 | Speaker | Ewa    | Więsik-Szewczyk |
|  |  |  |  |                                                                                                                                                                                                                                                                                                           |  | The autoinflammatory side in febrile dermatoses; the model of                                             | 12:45 | 12:50 | Speaker | Ewa    | Więsik-Szewczyk |

|                                                                                            |            |                     |    |                                                                                                                                                                                                                                                                                                                               |                                            |                                                                                                              |       |       |         |                |               |
|--------------------------------------------------------------------------------------------|------------|---------------------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|--------------------------------------------------------------------------------------------------------------|-------|-------|---------|----------------|---------------|
|                                                                                            |            |                     |    |                                                                                                                                                                                                                                                                                                                               |                                            | Schnitzler syndrome                                                                                          |       |       |         |                |               |
|                                                                                            |            |                     |    |                                                                                                                                                                                                                                                                                                                               |                                            |                                                                                                              |       |       | Chair   | John           | Reynolds      |
|                                                                                            |            |                     |    |                                                                                                                                                                                                                                                                                                                               |                                            |                                                                                                              |       |       | Chair   | Maria Concetta | Fagnoli       |
| The prevalence and impact of health inequalities in rheumatic and musculoskeletal diseases | 14/06/2025 | 12:00:00 - 13:15:00 | C1 | Delegates will be able to: 1. Discuss key concepts in health inequalities and know where to find data related to health inequalities in Rheumatic and Musculoskeletal Diseases (RMDs);2. Understand the prevalence and impact of health inequalities relating to RMDs;3. Discuss evidence-based approaches to reducing health | Health Professionals in Rheumatology (HPR) | Discussion and Closing                                                                                       | 13:00 | 13:15 | Speaker | Ricardo J. O.  | Ferreira      |
|                                                                                            |            |                     |    |                                                                                                                                                                                                                                                                                                                               |                                            | The impact of social determinants of health in inflammatory arthritis outcomes in Spain                      | 12:20 | 12:40 | Speaker | Loreto         | Carmona       |
|                                                                                            |            |                     |    |                                                                                                                                                                                                                                                                                                                               |                                            | Equity in digital health: the role of co-creative development                                                | 12:40 | 13:00 | Speaker | Rafael         | Prieto Moreno |
|                                                                                            |            |                     |    |                                                                                                                                                                                                                                                                                                                               |                                            | What can we learn from the prevalence and impact of health inequalities in the UK: a focus on osteoarthritis | 12:00 | 12:20 | Speaker | CHRISTOPHER    | MARTEY        |
|                                                                                            |            |                     |    |                                                                                                                                                                                                                                                                                                                               |                                            |                                                                                                              |       |       | Chair   | Ricardo J. O.  | Ferreira      |
|                                                                                            |            |                     |    |                                                                                                                                                                                                                                                                                                                               |                                            |                                                                                                              |       |       |         |                |               |

|                                                                                            |            |                     |    |                                                                                                                                                                                                                                       |                         |                                                                      |       |       |         |          |             |
|--------------------------------------------------------------------------------------------|------------|---------------------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|----------------------------------------------------------------------|-------|-------|---------|----------|-------------|
|                                                                                            |            |                     |    | inequalities in RMDs.                                                                                                                                                                                                                 |                         |                                                                      |       |       | Chair   | Hana     | Smucrova    |
| When environmental health goes molecular - environmental influences on disease development | 14/06/2025 | 12:00:00 - 13:15:00 | A3 | 1. Hear how environmental influences shape the metabolome2. Learn what the DOHaD hypothesis is and how early life exposures influence health in later life3. Learn what the exposome is and how chemicals influence the immune system | Basic and Translational | The influence of environment on blood cell activation and metabolism | 12:05 | 12:20 | Speaker | tbc      | tbc         |
|                                                                                            |            |                     |    |                                                                                                                                                                                                                                       |                         | Early life exposures and their influence on disease development      | 12:25 | 12:40 | Speaker | tbc      | tbc         |
|                                                                                            |            |                     |    |                                                                                                                                                                                                                                       |                         | Abstract Presentation                                                | 13:05 | 13:15 | Speaker |          |             |
|                                                                                            |            |                     |    |                                                                                                                                                                                                                                       |                         | The influence of environment on blood cell activation and metabolism | 12:20 | 12:25 | Speaker | tbc      | tbc         |
|                                                                                            |            |                     |    |                                                                                                                                                                                                                                       |                         | Early life exposures and their influence on disease development      | 12:40 | 12:45 | Speaker | tbc      | tbc         |
|                                                                                            |            |                     |    |                                                                                                                                                                                                                                       |                         | Introduction                                                         | 12:00 | 12:05 | Speaker | Johanna  | Sigaux      |
|                                                                                            |            |                     |    |                                                                                                                                                                                                                                       |                         | The role of the                                                      | 13:00 | 13:05 | Speaker | Karen H. | Costenbader |

|                         |            |                     |         |                                                                                                                                                                                    |                    |                                                        |       |       |         |          |             |
|-------------------------|------------|---------------------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|--------------------------------------------------------|-------|-------|---------|----------|-------------|
|                         |            |                     |         |                                                                                                                                                                                    |                    | environmental exposome in autoimmunity                 |       |       |         |          |             |
|                         |            |                     |         |                                                                                                                                                                                    |                    | The role of the environmental exposome in autoimmunity | 12:45 | 13:00 | Speaker | Karen H. | Costenbader |
|                         |            |                     |         |                                                                                                                                                                                    |                    |                                                        |       |       | Chair   | Johanna  | Sigaux      |
|                         |            |                     |         |                                                                                                                                                                                    |                    |                                                        |       |       | Chair   | tbc      | tbc         |
| Chronic tophaceous gout | 14/06/2025 | 12:30:00 - 13:15:00 | Plenary | 1. Treatment options in patients with chronic tophaceous gout;2. Evaluate individual risk factors for not achieving target serum uric acid levels;3. Discuss combination strategy. | How to Treat (HOT) | Chronic tophaceous gout                                | 12:30 | 13:15 | Speaker | Fernando | Perez-Ruiz  |
|                         |            |                     |         |                                                                                                                                                                                    |                    |                                                        |       |       | Chair   | Jakub    | Závada      |
|                         |            |                     |         |                                                                                                                                                                                    |                    |                                                        |       |       | Chair   | Pascal   | Richette    |
| EULAR 2025 Highlights   | 14/06/2025 | 13:15:00 - 14:45:00 | Plenary |                                                                                                                                                                                    | EULAR Projects     |                                                        |       |       | Speaker |          |             |